Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

Aalders, K. C., Postma, E. L., Strobbe, L. J., van der Heiden-van der Loo, M., Sonke, G. S., Boersma, L. J., . . . van Dalen, T. (2016). Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. J Clin Oncol, 34(18), 2107-2114. doi:10.1200/jco.2015.64.3536

Aalders, K. C., van Bommel, A. C., van Dalen, T., Sonke, G. S., van Diest, P. J., Boersma, L. J., & van der Heiden-van der Loo, M. (2016). Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer, 63, 118-126. doi:10.1016/j.ejca.2016.05.010

Aapro, M., Bernard-Marty, C., Brain, E. G., Batist, G., Erdkamp, F., Krzemieniecki, K., . . . Wedding, U. (2011). Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol, 22(2), 257-267. doi:10.1093/annonc/mdq609

Abusief, M. E., Missmer, S. A., Ginsburg, E. S., Weeks, J. C., & Partridge, A. H. (2010). The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer, 116(4), 791-798. doi:10.1002/cncr.24835

Abusief, M. E., Missmer, S. A., Ginsburg, E. S., Weeks, J. C., & Partridge, A. H. (2012). Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer. Fertil Steril, 97(1), 154-159. doi:10.1016/j.fertnstert.2011.10.005

Adam, H., Bygdeson, M., & de Boniface, J. (2014). The oncological safety of nipple-sparing mastectomy - a Swedish matched cohort study. Eur J Surg Oncol, 40(10), 1209-1215. doi:10.1016/j.ejso.2014.07.037

Adam, H., Docherty Skogh, A. C., Edsander Nord, A., Schultz, I., Gahm, J., Hall, P., . . . de Boniface, J. (2018). Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction. Br J Surg, 105(11), 1435-1445. doi:10.1002/bjs.10866

Adank, M. A., Jonker, M. A., Kluijt, I., van Mil, S. E., Oldenburg, R. A., Mooi, W. J., . . . Waisfisz, Q. (2011). CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet, 48(12), 860-863. doi:10.1136/jmedgenet-2011-100380

Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., . . . Sellmeyer, D. E. (2016). Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res, 31(1), 16-35. doi:10.1002/jbmr.2708

Aebi, S., Gelber, S., Láng, I., Anderson, S.J., Robidoux, A., Martin, M., Nortier, J.W.R., Mamounas, E.P., Geyer, C.E., Maibach, R. Jr., Gelber, R.D., Wolmark, N., Wapnir, I. (2012). Chemotherapy prolongs survival for isolated local or regional recurrence of breast cncer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Cancer Research, 72(24). doi:10.1158/0008-5472.SABCS12-S3-2

Agarwal, S., Pappas, L., Neumayer, L., Kokeny, K., & Agarwal, J. (2014). Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg, 149(3), 267-274. doi:10.1001/jamasurg.2013.3049

Ahmed, M., Baker, R., & Rubio, I. T. (2016). Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer. Br J Surg, 103(12), 1579-1588. doi:10.1002/bjs.10289

Ahn, B. Y., Kim, H. H., Moon, W. K., Pisano, E. D., Kim, H. S., Cha, E. S., . . . Park, S. H. (2003). Pregnancy- and lactation-associated breast cancer: mammographic and sonographic findings. J Ultrasound Med, 22(5), 491-497; quiz 498-499. 

AJCC Cancer Staging Manual (Edge, Ajcc Cancer Staging Manual) 7th Edition. Chicago: Springer.

Akbari, M. R., Wallis, C. J., Toi, A., Trachtenberg, J., Sun, P., Narod, S. A., & Nam, R. K. (2014). The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer, 111(6), 1238-1240. doi:10.1038/bjc.2014.428

Akrivis, C., Varras, M., Thodos, A., Hadjopoulos, G., Bellou, A., & Antoniou, N. (2003). Action of 25 microg 17beta-oestradiol vaginal tablets in the treatment of vaginal atrophy in Greek postmenopausal women; clinical study. Clin Exp Obstet Gynecol, 30(4), 229-234. 

Al-Ghazal, S. K., Sully, L., Fallowfield, L., & Blamey, R. W. (2000). The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol, 26(1), 17-19. 

Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart, A. C., Pluzanska, A., . . . O'Shaughnessy, J. (2008). Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol, 26(24), 3950-3957. doi:10.1200/JCO.2007.11.9362

Albertini, J. J., Lyman, G. H., Cox, C., Yeatman, T., Balducci, L., Ku, N., . . . Reintgen, D. S. (1996). Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. Jama, 276(22), 1818-1822. 

Alderman, A. K., Wilkins, E. G., Kim, H. M., & Lowery, J. C. (2002). Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg, 109(7), 2265-2274. 

Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., . . . Wolmark, N. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol, 30(12), 1268-1273. doi:10.1200/jco.2010.34.0141

Allweis, T. M., Boisvert, M. E., Otero, S. E., Perry, D. J., Dubin, N. H., & Priebat, D. A. (2002). Immediate reconstruction after mastectomy for breast cancer does not prolong the time to starting adjuvant chemotherapy. Am J Surg, 183(3), 218-221. 

Alpert, T. E., Kuerer, H. M., Arthur, D. W., Lannin, D. R., & Haffty, B. G. (2005). Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys, 63(3), 845-851. doi:10.1016/j.ijrobp.2005.02.035

Amadori, D., Aglietta, M., Alessi, B., Gianni, L., Ibrahim, T., Farina, G., . . . Ripamonti, C. I. (2013). Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol, 14(7), 663-670. doi:10.1016/s1470-2045(13)70174-8

Amant, F., Deckers, S., Van Calsteren, K., Loibl, S., Halaska, M., Brepoels, L., . . . Du Bois, A. (2010). Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer, 46(18), 3158-3168. doi:10.1016/j.ejca.2010.09.010

Amant, F., Van Calsteren, K., Halaska, M. J., Gziri, M. M., Hui, W., Lagae, L., . . . Ottevanger, P. B. (2012). Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol, 13(3), 256-264. doi:10.1016/s1470-2045(11)70363-1

Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., . . . Van Calsteren, K. (2015). Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med, 373(19), 1824-1834. doi:10.1056/NEJMoa1508913

Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., . . . Loibl, S. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol, 31(20), 2532-2539. doi:10.1200/jco.2012.45.6335

Amendola, B. E., Wolf, A. L., Coy, S. R., Amendola, M., & Bloch, L. (2000). Gamma knife radiosurgery in the treatment of patients with single and multiple brain metastases from carcinoma of the breast. Cancer J, 6(2), 88-92. 

Amir, E., Clemons, M., Purdie, C. A., Miller, N., Quinlan, P., Geddie, W., . . . Thompson, A. M. (2012). Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev, 38(6), 708-714. doi:10.1016/j.ctrv.2011.11.006

Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocana, A. (2011). Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst, 103(17), 1299-1309. doi:10.1093/jnci/djr242

Amir, Z., Neary, D., & Luker, K. (2008). Cancer survivors' views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs, 12(3), 190-197. doi:10.1016/j.ejon.2008.01.006

Anastasilakis, A. D., Polyzos, S. A., Makras, P., Aubry-Rozier, B., Kaouri, S., & Lamy, O. (2017). Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res, 32(6), 1291-1296. doi:10.1002/jbmr.3110

Anderson, G. L., Chlebowski, R. T., Aragaki, A. K., Kuller, L. H., Manson, J. E., Gass, M., . . . Wactawski-Wende, J. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol, 13(5), 476-486. doi:10.1016/s1470-2045(12)70075-x

Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., . . . Langkjer, S. T. (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol, 29(3), 264-271. doi:10.1200/JCO.2010.30.8213

Andersson, T. M., Johansson, A. L., Fredriksson, I., & Lambe, M. (2015). Cancer during pregnancy and the postpartum period: A population-based study. Cancer, 121(12), 2072-2077. doi:10.1002/cncr.29325

Andersson, T. M., Johansson, A. L., Hsieh, C. C., Cnattingius, S., & Lambe, M. (2009). Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol, 114(3), 568-572. doi:10.1097/AOG.0b013e3181b19154

Andersson, Y., Frisell, J., Sylvan, M., de Boniface, J., & Bergkvist, L. (2010). Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol, 28(17), 2868-2873. doi:10.1200/jco.2009.24.5001

Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., . . . Juric, D. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med, 380(20), 1929-1940. doi:10.1056/NEJMoa1813904

Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., . . . Spielmann, M. (2004). Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol, 22(16), 3302-3308. doi:10.1200/JCO.2004.08.095

Anothaisintawee, T., Wiratkapun, C., Lerdsitthichai, P., Kasamesup, V., Wongwaisayawan, S., Srinakarin, J., . . . Thakkinstian, A. (2013). Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health, 25(5), 368-387. doi:10.1177/1010539513488795

Antman, K. H., Rowlings, P. A., Vaughan, W. P., Pelz, C. J., Fay, J. W., Fields, K. K., . . . Horowitz, M. M. (1997). High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol, 15(5), 1870-1879. 

Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkas, K., Roberts, J., . . . Tischkowitz, M. (2014). Breast-cancer risk in families with mutations in PALB2. N Engl J Med, 371(6), 497-506. doi:10.1056/NEJMoa1400382

Antoniou, A. C., Pharoah, P. P., Smith, P., & Easton, D. F. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer, 91(8), 1580-1590. doi:10.1038/sj.bjc.6602175

Arnez, Z. M., Khan, U., Pogorelec, D., & Planinsek, F. (1999). Breast reconstruction using the free superficial inferior epigastric artery (SIEA) flap. Br J Plast Surg, 52(4), 276-279. doi:10.1054/bjps.1999.3100

Arthur, D. W., Winter, K. A., Kuerer, H. M., Haffty, B., Cuttino, L., Todor, D. A., . . . White, J. R. (2019). Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA Oncol. doi:10.1001/jamaoncol.2019.4320

Arthur, D. W., Winter, K. A., Kuerer, H. M., Haffty, B. G., Cuttino, L. W., Todor, D. A., . . . White, J. (2017). NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. Int J Radiat Oncol Biol Phys, 98(5), 1028-1035. doi:10.1016/j.ijrobp.2017.03.016

Asgeirsson, K. S., McCulley, S. J., Pinder, S. E., & Macmillan, R. D. (2003). Size of invasive breast cancer and risk of local recurrence after breast-conservation therapy. Eur J Cancer, 39(17), 2462-2469. 

Ashikaga, T., Krag, D. N., Land, S. R., Julian, T. B., Anderson, S. J., Brown, A. M., . . . Wolmark, N. (2010). Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol, 102(2), 111-118. doi:10.1002/jso.21535

Asken, M. J. (1975). Psychoemotional aspects of mastectomy: a review of recent literature. Am J Psychiatry, 132(1), 56-59. 

Aspegren, K., Holmberg, L., & Adami, H. O. (1988). Standardization of the surgical technique in breast-conserving treatment of mammary cancer. Br J Surg, 75(8), 807-810. 

Assessment report. Perjeta. International non-proprietary name: PERTUZUMAB. (2013). Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002547/WC500141004.pdf

Atisha, D. M., Rushing, C. N., Samsa, G. P., Locklear, T. D., Cox, C. E., Shelley Hwang, E., . . . Abernethy, A. P. (2015). A national snapshot of satisfaction with breast cancer procedures. Ann Surg Oncol, 22(2), 361-369. doi:10.1245/s10434-014-4246-9

Autier, P., Boniol, M., Gavin, A., & Vatten, L. J. (2011). Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Bmj, 343, d4411. doi:10.1136/bmj.d4411

Axelsson, C. K., Mouridsen, H. T., & Zedeler, K. (1992). Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer, 28a(8-9), 1415-1418. 

Azim, H. A., Jr., Kroman, N., Paesmans, M., Gelber, S., Rotmensz, N., Ameye, L., . . . Peccatori, F. A. (2013). Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol, 31(1), 73-79. doi:10.1200/JCO.2012.44.2285

Azim, H. A., Jr., Metzger-Filho, O., de Azambuja, E., Loibl, S., Focant, F., Gresko, E., . . . Piccart-Gebhart, M. (2012). Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat, 133(1), 387-391. doi:10.1007/s10549-012-1996-6

Azim, H. A., Jr., Santoro, L., Pavlidis, N., Gelber, S., Kroman, N., Azim, H., & Peccatori, F. A. (2011). Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer, 47(1), 74-83. doi:10.1016/j.ejca.2010.09.007

Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J. M., Freyer, G., . . . Pujade-Lauraine, E. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol, 30(22), 2718-2724. doi:10.1200/JCO.2011.39.0708

Bachelot, T., Romieu, G., Campone, M., Dieras, V., Cropet, C., Dalenc, F., . . . Labbe-Devilliers, C. (2013). Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol, 14(1), 64-71. doi:10.1016/s1470-2045(12)70432-1

Badiyan, S. N., Shah, C., Arthur, D., Khan, A. J., Freedman, G., Poppe, M. M., & Vicini, F. A. (2014). Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiother Oncol, 110(1), 39-44. doi:10.1016/j.radonc.2013.12.006

Badwe, R., Hawaldar, R., Nair, N., Kaushik, R., Parmar, V., Siddique, S., . . . Gupta, S. (2015). Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol, 16(13), 1380-1388. doi:10.1016/s1470-2045(15)00135-7

Bafford, A. C., Burstein, H. J., Barkley, C. R., Smith, B. L., Lipsitz, S., Iglehart, J. D., . . . Golshan, M. (2009). Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat, 115(1), 7-12. doi:10.1007/s10549-008-0101-7

Bagaria, S. P., Wasif, N., Rawal, B., McLaughlin, S. A., & Giuliano, A. E. (2015). Is mastectomy undertreatment for low-risk breast cancers eligible for breast-conserving therapy? Cancer, 121(16), 2705-2712. doi:10.1002/cncr.29416

Balducci, L., & Corcoran, M. B. (2000). Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am, 14(1), 193-212, x-xi. 

Bancroft, E. K., Page, E. C., Castro, E., Lilja, H., Vickers, A., Sjoberg, D., . . . Eeles, R. A. (2014). Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol, 66(3), 489-499. doi:10.1016/j.eururo.2014.01.003

Barlow, L., Westergren, K., Holmberg, L., & Talback, M. (2009). The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol, 48(1), 27-33. doi:10.1080/02841860802247664

Barreau-Pouhaer, L., Le, M. G., Rietjens, M., Arriagada, R., Contesso, G., Martins, R., & Petit, J. Y. (1992). Risk factors for failure of immediate breast reconstruction with prosthesis after total mastectomy for breast cancer. Cancer, 70(5), 1145-1151. 

Barrett, T., Bowden, D. J., Greenberg, D. C., Brown, C. H., Wishart, G. C., & Britton, P. D. (2009). Radiological staging in breast cancer: which asymptomatic patients to image and how. Br J Cancer, 101(9), 1522-1528. doi:10.1038/sj.bjc.6605323

Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., . . . Collette, L. (2015). Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol, 16(1), 47-56. doi:10.1016/s1470-2045(14)71156-8

Barthelmes, L., & Gateley, C. A. (2004). Tamoxifen and pregnancy. Breast, 13(6), 446-451. doi:S0960-9776(04)00130-4 [pii]

10.1016/j.breast.2004.08.007

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., . . . Piccart-Gebhart, M. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379(9816), 633-640. doi:10.1016/s0140-6736(11)61847-3

Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahmoud, T., . . . Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 366(6), 520-529. doi:10.1056/NEJMoa1109653

Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., . . . Group, C. S. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366(2), 109-119. doi:10.1056/NEJMoa1113216

Baselga, J., Dent, S. F., Cortés, J., Im, Y.-H., Diéras, V., Harbeck, N., . . . Jacot, W. (2018). Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. 36(18_suppl), LBA1006-LBA1006. doi:10.1200/JCO.2018.36.18_suppl.LBA1006

Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., . . . Norton, L. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 14(3), 737-744. 

Bastiaannet, E., Liefers, G. J., de Craen, A. J., Kuppen, P. J., van de Water, W., Portielje, J. E., . . . Westendorp, R. G. (2010). Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat, 124(3), 801-807. doi:10.1007/s10549-010-0898-8

Basu, N. N., Ross, G. L., Evans, D. G., & Barr, L. (2015). The Manchester guidelines for contralateral risk-reducing mastectomy. World J Surg Oncol, 13, 237. doi:10.1186/s12957-015-0638-y

Baum, M., Budzar, A. U., Cuzick, J., Forbes, J., Houghton, J. H., Klijn, J. G., & Sahmoud, T. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359(9324), 2131-2139. 

Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., . . . Bowel Project Protocol, B. (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21(22), 4165-4174. doi:10.1200/JCO.2003.12.005

Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Jr., Mamounas, E. P., Fisher, B., . . . Wolmark, N. (2006). Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 24(13), 2019-2027. doi:10.1200/JCO.2005.04.1665

Beaver, K., Tysver-Robinson, D., Campbell, M., Twomey, M., Williamson, S., Hindley, A., . . . Luker, K. (2009). Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. Bmj, 338, a3147. doi:10.1136/bmj.a3147

Beaver, K., Williamson, S., & Chalmers, K. (2010). Telephone follow-up after treatment for breast cancer: views and experiences of patients and specialist breast care nurses. J Clin Nurs, 19(19-20), 2916-2924. doi:10.1111/j.1365-2702.2010.03197.x

Bennett, C. L., Silver, S. M., Djulbegovic, B., Samaras, A. T., Blau, C. A., Gleason, K. J., . . . Henke, M. (2008). Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Jama, 299(8), 914-924. doi:10.1001/jama.299.8.914

Bense, R. D., Sotiriou, C., Piccart-Gebhart, M. J., Haanen, J. B., van Vugt, M. A., de Vries, E. G., . . . Fehrmann, R. S. (2017). Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst, 109(1). doi:10.1093/jnci/djw192

Beral, V., Doll, R., Hermon, C., Peto, R., & Reeves, G. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371(9609), 303-314. doi:10.1016/s0140-6736(08)60167-1

Beral, V., Peto, R., Pirie, K., & Reeves, G. (2019). Menopausal hormone therapy and 20-year breast cancer mortality. Lancet. doi:10.1016/s0140-6736(19)32033-1

Berber, B., Ibarra, R., Snyder, L., Yao, M., Fabien, J., Milano, M. T., . . . Sanabria, J. (2013). Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB (Oxford). doi:10.1111/hpb.12044

Beresford, M. J., Ravichandran, D., & Makris, A. (2007). Neoadjuvant endocrine therapy in breast cancer. Cancer Treat Rev, 33(1), 48-57. doi:10.1016/j.ctrv.2006.10.003

Bergenfeldt, M., Jensen, B. V., Skjoldbye, B., & Nielsen, D. (2011). Liver resection and local ablation of breast cancer liver metastases--a systematic review. Eur J Surg Oncol, 37(7), 549-557. doi:10.1016/j.ejso.2011.04.013

Bergenthal, N., Will, A., Streckmann, F., Wolkewitz, K. D., Monsef, I., Engert, A., . . . Skoetz, N. (2014). Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev(11), Cd009075. doi:10.1002/14651858.CD009075.pub2

Bergh, J. (2000). Where next with stem-cell-supported high-dose therapy for breast cancer? Lancet, 355(9208), 944-945. doi:10.1016/S0140-6736(00)90007-2

Bergh, J., Jonsson, P. E., Glimelius, B., Nygren, P., & Care, S. B.-g. S. C. o. T. A. i. H. (2001). A systematic overview of chemotherapy effects in breast cancer. Acta Oncol, 40(2-3), 253-281. 

Bergh, J., Jonsson, P. E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattstrom, D., . . . Henriksson, R. (2012). FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol, 30(16), 1919-1925. doi:10.1200/JCO.2011.38.1095

Bergh, J., Pritchard, K. I., & Cameron, D. (2016). Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. J Clin Oncol, 34(9), 895-897. doi:10.1200/jco.2015.65.2255

Bergh, J. C. S., Andersson, A., Bjohle, J., Bosch, A., Carlsson, L., Dreifaldt, A. C., . . . Hatschek, T. (2019). Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard? , 37(15_suppl), 501-501. doi:10.1200/JCO.2019.37.15_suppl.501

Bergkvist, L., & Frisell, J. (2005). Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br J Surg, 92(10), 1221-1224. doi:10.1002/bjs.5052

Bergkvist, L., Frisell, J., Liljegren, G., Celebioglu, F., Damm, S., & Thorn, M. (2001). Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg, 88(12), 1644-1648. doi:10.1046/j.0007-1323.2001.01948.x

Berliere, M., Dalenc, F., Malingret, N., Vindevogel, A., Piette, P., Roche, H., . . . Machiels, J. P. (2008). Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer, 8, 56. doi:10.1186/1471-2407-8-56

Berlin, N. L., Tandon, V. J., Qi, J., Kim, H. M., Hamill, J. B., Momoh, A. O., . . . Wilkins, E. G. (2019). Hospital Variations in Clinical Complications and Patient-reported Outcomes at 2 Years After Immediate Breast Reconstruction. Ann Surg, 269(5), 959-965. doi:10.1097/sla.0000000000002711

Berrino, P., Campora, E., & Santi, P. (1987). Postquadrantectomy breast deformities: classification and techniques of surgical correction. Plast Reconstr Surg, 79(4), 567-572. 

Berruti, A., Amoroso, V., Gallo, F., Bertaglia, V., Simoncini, E., Pedersini, R., . . . Sormani, M. P. (2014). Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol, 32(34), 3883-3891. doi:10.1200/jco.2014.55.2836

Berry, D. A., Ueno, N. T., Johnson, M. M., Lei, X., Caputo, J., Rodenhuis, S., . . . Demirer, T. (2011). High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol, 29(24), 3214-3223. doi:10.1200/jco.2010.32.5910

Bertram, L. A., Stefanick, M. L., Saquib, N., Natarajan, L., Patterson, R. E., Bardwell, W., . . . Pierce, J. P. (2011). Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study. Cancer Causes Control, 22(3), 427-435. doi:10.1007/s10552-010-9714-3

Beugels, J., Bod, L., van Kuijk, S. M. J., Qiu, S. S., Tuinder, S. M. H., Heuts, E. M., . . . van der Hulst, R. (2018). Complications following immediate compared to delayed deep inferior epigastric artery perforator flap breast reconstructions. Breast Cancer Res Treat, 169(2), 349-357. doi:10.1007/s10549-018-4695-0

Biagi, J. J., Raphael, M., King, W. D., Kong, W., Booth, C. M., Mackillop, W. J. (2011). The effecto of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): A systematic review and meta-analysis (Vol. 29): Journal of Clinical Oncology.

Biazus, J. V., Stumpf, C. C., Melo, M. P., Zucatto, A. E., Cericatto, R., Cavalheiro, J. A., & Damin, A. P. (2018). Breast-Conserving Surgery with Immediate Autologous Fat Grafting Reconstruction: Oncologic Outcomes. Aesthetic Plast Surg, 42(5), 1195-1201. doi:10.1007/s00266-018-1155-5

Biganzoli, L., Cufer, T., Bruning, P., Coleman, R., Duchateau, L., Calvert, A. H., . . . Piccart, M. J. (2002). Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol, 20(14), 3114-3121. 

Bines, J., Earl, H., Buzaid, A. C., & Saad, E. D. (2014). Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol, 25(6), 1079-1085. doi:10.1093/annonc/mdu007

Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H., Olver, I. N., . . . Canetta, R. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol, 17(8), 2355-2364. 

Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., . . . O'Shaughnessy, J. (2010). Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol, 28(7), 1124-1130. doi:10.1200/JCO.2008.21.4437

Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., . . . O'Shaughnessy, J. (2012). Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol, 30(21), 2585-2592. doi:10.1200/JCO.2011.35.6725

Blamey, R. W., Bates, T., Chetty, U., Duffy, S. W., Ellis, I. O., George, D., . . . Pinder, S. E. (2013). Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer, 49(10), 2294-2302. doi:10.1016/j.ejca.2013.02.031

Bleicher, R. J., Abrahamse, P., Hawley, S. T., Katz, S. J., & Morrow, M. (2008). The influence of age on the breast surgery decision-making process. Ann Surg Oncol, 15(3), 854-862. doi:10.1245/s10434-007-9708-x

Bleicher, R. J., Ruth, K., Sigurdson, E. R., Daly, J. M., Boraas, M., Anderson, P. R., & Egleston, B. L. (2016). Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients. Cancer, 122(1), 42-49. doi:10.1002/cncr.29726

Bliss, J. M., Kilburn, L. S., Coleman, R. E., Forbes, J. F., Coates, A. S., Jones, S. E., . . . Coombes, R. C. (2012). Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol, 30(7), 709-717. doi:10.1200/jco.2010.33.7899

Blok, E. J., Bastiaannet, E., van den Hout, W. B., Liefers, G. J., Smit, V., Kroep, J. R., & van de Velde, C. J. H. (2018). Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev, 62, 74-90. doi:10.1016/j.ctrv.2017.10.012

Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., . . . van de Velde, C. J. H. (2018). Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst, 110(1). doi:10.1093/jnci/djx134

Blom Goldman, U., Svane, G., Anderson, M., Wennberg, B., & Lind, P. (2014). Long-term functional and radiological pulmonary changes after radiation therapy for breast cancer. Acta Oncol, 53(10), 1373-1379. doi:10.3109/0284186x.2014.934967

Blondeel, P. N. (1999). One hundred free DIEP flap breast reconstructions: a personal experience. Br J Plast Surg, 52(2), 104-111. doi:10.1054/bjps.1998.3033

Blumenfeld, Z. (2012). Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol, 26(3), 379-390. doi:10.1016/j.bpobgyn.2011.11.008

Boda-Heggemann, J., Knopf, A. C., Simeonova-Chergou, A., Wertz, H., Stieler, F., Jahnke, A., . . . Lohr, F. (2016). Deep Inspiration Breath Hold-Based Radiation Therapy: A Clinical Review. Int J Radiat Oncol Biol Phys, 94(3), 478-492. doi:10.1016/j.ijrobp.2015.11.049

Boekel, N. B., Schaapveld, M., Gietema, J. A., Russell, N. S., Poortmans, P., Theuws, J. C., . . . van Leeuwen, F. E. (2016). Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors. Int J Radiat Oncol Biol Phys, 94(5), 1061-1072. doi:10.1016/j.ijrobp.2015.11.040

Boekel, N. B., Schaapveld, M., Gietema, J. A., Rutgers, E. J., Versteegh, M. I., Visser, O., . . . van Leeuwen, F. E. (2014). Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. J Natl Cancer Inst, 106(8). doi:10.1093/jnci/dju156

Boekhout, A. H., Vincent, A. D., Dalesio, O. B., van den Bosch, J., Foekema-Tons, J. H., Adriaansz, S., . . . Schellens, J. H. (2011). Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 29(29), 3862-3868. doi:10.1200/jco.2010.33.1298

Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., . . . Papapoulos, S. (2017). 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol, 5(7), 513-523. doi:10.1016/s2213-8587(17)30138-9

Bonilla, L., Ben-Aharon, I., Vidal, L., Gafter-Gvili, A., Leibovici, L., & Stemmer, S. M. (2010). Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst, 102(24), 1845-1854. doi:10.1093/jnci/djq409

Bonnefoi, H., Piccart, M., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E., . . . Iggo, R. (2011). TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol, 12(6), 527-539. doi:10.1016/s1470-2045(11)70094-8

Bonneterre, J., Dieras, V., Tubiana-Hulin, M., Bougnoux, P., Bonneterre, M. E., Delozier, T., . . . Bendahmane, B. (2004). Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer, 91(8), 1466-1471. doi:10.1038/sj.bjc.6602179

Bonneterre, J., Thurlimann, B., Robertson, J. F., Krzakowski, M., Mauriac, L., Koralewski, P., . . . von Euler, M. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 18(22), 3748-3757. 

Bonomi, R., Betal, D., Rapisarda, I. F., Kalra, L., Sajid, M. S., & Johri, A. (2013). Role of lipomodelling in improving aesthetic outcomes in patients undergoing immediate and delayed reconstructive breast surgery. Eur J Surg Oncol, 39(10), 1039-1045. doi:10.1016/j.ejso.2013.07.001

Bonotto, M., Gerratana, L., Di Maio, M., De Angelis, C., Cinausero, M., Moroso, S., . . . Puglisi, F. (2017). Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Breast, 31, 114-120. doi:10.1016/j.breast.2016.10.021

Bonotto, M., Gerratana, L., Iacono, D., Minisini, A. M., Rihawi, K., Fasola, G., & Puglisi, F. (2015). Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? Oncologist, 20(7), 719-724. doi:10.1634/theoncologist.2015-0002

Bontenbal, M., Creemers, G. J., Braun, H. J., de Boer, A. C., Janssen, J. T., Leys, R. B., . . . Dutch Community Setting Trial for the Clinical Trial, G. (2005). Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol, 23(28), 7081-7088. doi:10.1200/JCO.2005.06.236

Bordeleau, L., Pritchard, K. I., Loprinzi, C. L., Ennis, M., Jugovic, O., Warr, D., . . . Goodwin, P. J. (2010). Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol, 28(35), 5147-5152. doi:10.1200/jco.2010.29.9230

Borg, Å. (2009). Cell- och tumörbiologi. Retrieved from Södertälje: 

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., . . . Ellis, M. J. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov, 3(2), 224-237. doi:10.1158/2159-8290.Cd-12-0349

Bostwick, J., 3rd, & Scheflan, M. (1980). The latissimus dorsi musculocutaneous flap: a one-stage breast reconstruction. Clin Plast Surg, 7(1), 71-78. 

Bouchardy, C., Rapiti, E., Fioretta, G., Laissue, P., Neyroud-Caspar, I., Schafer, P., . . . Vlastos, G. (2003). Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol, 21(19), 3580-3587. doi:10.1200/jco.2003.02.046

Boughey, J. C., Haffty, B. G., Habermann, E. B., Hoskin, T. L., & Goetz, M. P. (2017). Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer? Ann Surg Oncol, 24(3), 614-617. doi:10.1245/s10434-016-5740-z

Bourgier, C., Kerns, S., Gourgou, S., Lemanski, C., Gutowski, M., Fenoglietto, P., . . . Azria, D. (2016). Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. Ann Oncol, 27(3), 474-480. doi:10.1093/annonc/mdv602

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Braems, G., Denys, H., De Wever, O., Cocquyt, V., & Van den Broecke, R. (2011). Use of tamoxifen before and during pregnancy. Oncologist, 16(11), 1547-1551. doi:10.1634/theoncologist.2011-0121

Braithwaite, D., Izano, M., Moore, D. H., Kwan, M. L., Tammemagi, M. C., Hiatt, R. A., . . . Caan, B. (2012). Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat, 136(2), 521-533. doi:10.1007/s10549-012-2276-1

Brandberg, Y., Malm, M., & Blomqvist, L. (2000). A prospective and randomized study, "SVEA," comparing effects of three methods for delayed breast reconstruction on quality of life, patient-defined problem areas of life, and cosmetic result. Plast Reconstr Surg, 105(1), 66-74; discussion 75-66. 

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394-424. doi:10.3322/caac.21492

Bray, F. N., Simmons, B. J., Wolfson, A. H., & Nouri, K. (2016). Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb), 6(2), 185-206. doi:10.1007/s13555-016-0120-y

Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. (2002). Lancet, 360(9328), 187-195. doi:10.1016/s0140-6736(02)09454-0

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. (1996). Lancet, 347(9017), 1713-1727. 

Brennan, M. E., & Houssami, N. (2012). Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast, 21(2), 112-123. doi:10.1016/j.breast.2011.10.005

Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., . . . Group, E. W. (2012). The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen, 19 Suppl 1, 14-25. doi:10.1258/jms.2012.012078

Brogi, E., Torres-Matundan, E., Tan, L. K., & Cody, H. S., 3rd. (2005). The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol, 12(2), 173-180. doi:10.1245/aso.2005.03.067

Broglio, K. R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S. M., . . . Berry, D. A. (2016). Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol, 2(6), 751-760. doi:10.1001/jamaoncol.2015.6113

Brollo, J., Curigliano, G., Disalvatore, D., Marrone, B. F., Criscitiello, C., Bagnardi, V., . . . Goldhirsch, A. (2013). Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev, 39(1), 44-50. doi:10.1016/j.ctrv.2012.03.009

Brorson, H. (2010). From lymph to fat: complete reduction of lymphoedema. Phlebology, 25 Suppl 1, 52-63. doi:10.1258/phleb.2010.010s08

Brothers, J. M., Kidwell, K. M., Brown, R. K., & Henry, N. L. (2016). Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence. Breast Cancer Res Treat, 155(2), 395-403. doi:10.1007/s10549-016-3687-1

Brown JP FS, G. N., Beck Jensen JE, Pannacciulli N, Roux C, Smith S, Törring O, Valter I, Wagman RB, Wang AT, Cummings SR. (2016). Discontinuation of Denosumab and associated vertebral fracture incidence: Analysis from FREEDOM and its extension. ASBMR; Atlanta GA, USA, 2016.

Brown, P. D., Ballman, K. V., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Whitton, A. C., . . . Roberge, D. (2017). Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 18(8), 1049-1060. doi:10.1016/s1470-2045(17)30441-2

Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., . . . Asher, A. L. (2016). Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. Jama, 316(4), 401-409. doi:10.1001/jama.2016.9839

Buchanan, C. L., Dorn, P. L., Fey, J., Giron, G., Naik, A., Mendez, J., . . . Sclafani, L. M. (2006). Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg, 203(4), 469-474. doi:10.1016/j.jamcollsurg.2006.06.015

Buchholz, T. A., Mittendorf, E. A., & Hunt, K. K. (2015). Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. J Natl Cancer Inst Monogr, 2015(51), 11-14. doi:10.1093/jncimonographs/lgv020

Budach, W., Bolke, E., Kammers, K., Gerber, P. A., Nestle-Kramling, C., & Matuschek, C. (2015). Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol, 10, 258. doi:10.1186/s13014-015-0568-4

Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., . . . Brady, C. (2001). Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol, 19(14), 3357-3366. 

Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., . . . Lee, D. (1998). Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer, 83(6), 1142-1152. 

Buzdar, A. U., Singletary, S. E., Valero, V., Booser, D. J., Ibrahim, N. K., Rahman, Z., . . . Hortobagyi, G. N. (2002). Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res, 8(5), 1073-1079. 

Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., . . . Hunt, K. K. (2013). Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol, 14(13), 1317-1325. doi:10.1016/s1470-2045(13)70502-3

Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., . . . Hunt, K. K. (2018). Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol. doi:10.1001/jamaoncol.2018.3691

Bychkovsky, B. L., Guo, H., Sutton, J., Spring, L., Faig, J., Dagogo-Jack, I., . . . Lin, N. U. (2016). Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist, 21(12), 1495-1501. doi:10.1634/theoncologist.2016-0157

Bygdeman, M., & Swahn, M. L. (1996). Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas, 23(3), 259-263. 

Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., . . . Narod, S. A. (2014). Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 147(2), 401-405. doi:10.1007/s10549-014-3100-x

Cai, B., Nickman, N. A., & Gaffney, D. K. (2013). The role of palliative external beam radiation therapy in boney metastases pain management. J Pain Palliat Care Pharmacother, 27(1), 28-34. doi:10.3109/15360288.2012.757267

Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., . . . Muto, M. G. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol, 25(25), 3985-3990. doi:10.1200/jco.2007.12.2622

Calsteren, K. V., Verbesselt, R., Devlieger, R., De Catte, L., Chai, D. C., Van Bree, R., . . . Amant, F. (2010). Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer, 20(9), 1456-1464. doi:10.1111/IGC.0b013e3181fb18c8

Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., . . . Geyer, C. E. (2008). A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112(3), 533-543. doi:10.1007/s10549-007-9885-0

Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., . . . Jackisch, C. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. doi:10.1016/s0140-6736(16)32616-2

Canavese, G., Catturich, A., Vecchio, C., Tomei, D., Gipponi, M., Villa, G., . . . Dozin, B. (2009). Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol, 20(6), 1001-1007. doi:10.1093/annonc/mdn746

Cancer i siffror 2018, Cancerfonden och Socialstyrelsen i samarbete. (2018). Retrieved from https://www.cancerfonden.se/cancer-i-siffror

Cancer risks in BRCA2 mutation carriers. (1999). J Natl Cancer Inst, 91(15), 1310-1316. 

Cancer under graviditet - Vägledning. (2019). Retrieved from https://kunskapsbanken.cancercentrum.se/diagnoser/cancer-under-graviditet/

Cano, A., Estevez, J., Usandizaga, R., Gallo, J. L., Guinot, M., Delgado, J. L., . . . Ferrer, J. (2012). The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause, 19(10), 1130-1139. doi:10.1097/gme.0b013e3182518e9a

Caparica, R., Bruzzone, M., Poggio, F., Ceppi, M., de Azambuja, E., & Lambertini, M. (2019). Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat, 174(1), 27-37. doi:10.1007/s10549-018-5055-9

Caragacianu, D. L., Mayer, E. L., Chun, Y. S., Caterson, S., Bellon, J. R., Wong, J. S., . . . Calvillo, K. Z. (2016). Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. J Surg Oncol, 114(2), 140-143. doi:10.1002/jso.24308

Cardonick, E., Dougherty, R., Grana, G., Gilmandyar, D., Ghaffar, S., & Usmani, A. (2010). Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J, 16(1), 76-82. doi:10.1097/PPO.0b013e3181ce46f9

Cardonick, E., Gilmandyar, D., & Somer, R. A. (2012). Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol, 120(6), 1267-1272. doi:http://10.1097/AOG.0b013e31826c32d9

Cardonick, E. H., Gringlas, M. B., Hunter, K., & Greenspan, J. (2015). Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol, 212(5), 658.e651-658. doi:10.1016/j.ajog.2014.11.032

Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-Konefka, E., Fallowfield, L. J., . . . Force, E.-M. T. (2009). International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst, 101(17), 1174-1181. doi:10.1093/jnci/djp235

Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C. H., . . . Winer, E. (2017). 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol, 28(1), 16-33. doi:10.1093/annonc/mdw544

Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., . . . Harbeck, N. (2012). The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer, 48(18), 3355-3377. doi:10.1016/j.ejca.2012.10.004

Cardoso, F., Senkus-Konefka, E., Fallowfield, L., Costa, A., Castiglione, M., & Group, E. G. W. (2010). Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v15-19. doi:10.1093/annonc/mdq160

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., . . . Winer, E. P. (2018). 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Annals of Oncology, 29(8), 1634-1657. doi:10.1093/annonc/mdy192 %J Annals of Oncology

Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., . . . Piccart, M. (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med, 375(8), 717-729. doi:10.1056/NEJMoa1602253

Caresia Aroztegui, A. P., Garcia Vicente, A. M., Alvarez Ruiz, S., Delgado Bolton, R. C., Orcajo Rincon, J., Garcia Garzon, J. R., . . . Garcia-Velloso, M. J. (2017). 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumour Biol, 39(10), 1010428317728285. doi:10.1177/1010428317728285

Carlson, G. W., Bostwick, J., 3rd, Styblo, T. M., Moore, B., Bried, J. T., Murray, D. R., & Wood, W. C. (1997). Skin-sparing mastectomy. Oncologic and reconstructive considerations. Ann Surg, 225(5), 570-575; discussion 575-578. 

Carpenter, J. S., Andrykowski, M. A., Cordova, M., Cunningham, L., Studts, J., McGrath, P., . . . Munn, R. (1998). Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer, 82(9), 1682-1691. 

Carpenter, J. S., Johnson, D., Wagner, L., & Andrykowski, M. (2002). Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum, 29(3), E16-25. doi:10.1188/02.onf.e16-e25

Casey, M. J., Synder, C., Bewtra, C., Narod, S. A., Watson, P., & Lynch, H. T. (2005). Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol, 97(2), 457-467. doi:10.1016/j.ygyno.2005.01.039

Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., . . . Eeles, R. (2013). Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol, 31(14), 1748-1757. doi:10.1200/jco.2012.43.1882

Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y., Petrakova, K., . . . de Oliveira, C. T. (2006). Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer, 106(10), 2095-2103. doi:10.1002/cncr.21872

Celebioglu, F., Sylvan, M., Perbeck, L., Bergkvist, L., & Frisell, J. (2006). Intraoperative sentinel lymph node examination by frozen section, immunohistochemistry and imprint cytology during breast surgery--a prospective study. Eur J Cancer, 42(5), 617-620. doi:10.1016/j.ejca.2005.12.003

Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., & Howell, A. (2006). Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat, 100(3), 273-284. doi:10.1007/s10549-006-9260-6

Chagpar, A. B., Horowitz, N., Sanft, T., Wilson, L. D., Silber, A., Killelea, B., . . . Lannin, D. R. (2017). Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? Am J Surg, 214(6), 1082-1088. doi:10.1016/j.amjsurg.2017.07.036

Chagpar, A. B., McMasters, K. M., & Edwards, M. J. (2009). Can sentinel node biopsy be avoided in some elderly breast cancer patients? Ann Surg, 249(3), 455-460. doi:10.1097/SLA.0b013e318194d16b

Chan, D. S., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., . . . Norat, T. (2014). Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol, 25(10), 1901-1914. doi:10.1093/annonc/mdu042

Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004). Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol, 15(10), 1527-1534. doi:10.1093/annonc/mdh393

Chan, S., Friedrichs, K., Noel, D., Pinter, T., Van Belle, S., Vorobiof, D., . . . Study, G. (1999). Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol, 17(8), 2341-2354. 

Chang, D. W., Youssef, A., Cha, S., & Reece, G. P. (2002). Autologous breast reconstruction with the extended latissimus dorsi flap. Plast Reconstr Surg, 110(3), 751-759; discussion 760-751. 

Chang, J., Yang, W. T., & Choo, H. F. (1999). Mammography in Asian patients with BRCA1 mutations. Lancet, 353(9169), 2070-2071. 

Chang, J. H., Vines, E., Bertsch, H., Fraker, D. L., Czerniecki, B. J., Rosato, E. F., . . . Solin, L. J. (2001). The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer, 91(7), 1231-1237. 

Chavez-MacGregor, M., Clarke, C. A., Lichtensztajn, D. Y., & Giordano, S. H. (2016). Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. JAMA Oncol, 2(3), 322-329. doi:10.1001/jamaoncol.2015.3856

Chavez-Macgregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., . . . Giordano, S. H. (2013). Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol, 31(33), 4222-4228. doi:10.1200/jco.2013.48.7884

Chen, Q., Lang, L., Wu, W., Xu, G., Zhang, X., Li, T., & Huang, H. (2013). A meta-analysis on the relationship between exposure to ELF-EMFs and the risk of female breast cancer. PLoS One, 8(7), e69272. doi:10.1371/journal.pone.0069272

Chen, S., & Parmigiani, G. (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol, 25(11), 1329-1333. doi:10.1200/jco.2006.09.1066

Cheung, W. Y., Lai, E. C., Ruan, J. Y., Chang, J. T., & Setoguchi, S. (2015). Comparative adherence to oral hormonal agents in older women with breast cancer. Breast Cancer Res Treat, 152(2), 419-427. doi:10.1007/s10549-015-3455-7

Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., . . . Prentice, R. L. (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. Jama, 304(15), 1684-1692. doi:10.1001/jama.2010.1500

Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., . . . McTiernan, A. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Jama, 289(24), 3243-3253. doi:10.1001/jama.289.24.3243

Choi, J., Laws, A., Hu, J., Barry, W., Golshan, M., & King, T. (2018). Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Ann Surg Oncol, 25(12), 3541-3547. doi:10.1245/s10434-018-6702-4

Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., & Lutz, S. (2012). Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol), 24(2), 112-124. doi:10.1016/j.clon.2011.11.004

Chua, T. C., Saxena, A., Liauw, W., Chu, F., & Morris, D. L. (2011). Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer, 47(15), 2282-2290. doi:10.1016/j.ejca.2011.06.024

Cibula, D., Gompel, A., Mueck, A. O., La Vecchia, C., Hannaford, P. C., Skouby, S. O., . . . Dusek, L. (2010). Hormonal contraception and risk of cancer. Hum Reprod Update, 16(6), 631-650. doi:10.1093/humupd/dmq022

Clarke, M., Coates, A. S., Darby, S. C., Davies, C., Gelber, R. D., Godwin, J., . . . Wood, W. C. (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet, 371(9606), 29-40. doi:10.1016/s0140-6736(08)60069-0

Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., . . . Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366(9503), 2087-2106. doi:10.1016/s0140-6736(05)67887-7

Classe, J. M., Bordes, V., Campion, L., Mignotte, H., Dravet, F., Leveque, J., . . . Giard, S. (2009). Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol, 27(5), 726-732. doi:10.1200/jco.2008.18.3228

Classe, J. M., Loaec, C., Gimbergues, P., Alran, S., de Lara, C. T., Dupre, P. F., . . . Campion, L. (2019). Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat, 173(2), 343-352. doi:10.1007/s10549-018-5004-7

Clemens, M. W., Medeiros, L. J., Butler, C. E., Hunt, K. K., Fanale, M. A., Horwitz, S., . . . Miranda, R. N. (2016). Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol, 34(2), 160-168. doi:10.1200/jco.2015.63.3412

Clemens, M. W., Nava, M. B., Rocco, N., & Miranda, R. N. (2017). Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. Gland Surg, 6(2), 169-184. doi:10.21037/gs.2016.11.03

Clough, K. B., Cuminet, J., Fitoussi, A., Nos, C., & Mosseri, V. (1998). Cosmetic sequelae after conservative treatment for breast cancer: classification and results of surgical correction. Ann Plast Surg, 41(5), 471-481. 

Clough, K. B., Kroll, S. S., & Audretsch, W. (1999). An approach to the repair of partial mastectomy defects. Plast Reconstr Surg, 104(2), 409-420. 

Clough, K. B., Nos, C., Salmon, R. J., Soussaline, M., & Durand, J. C. (1995). Conservative treatment of breast cancers by mammaplasty and irradiation: a new approach to lower quadrant tumors. Plast Reconstr Surg, 96(2), 363-370. 

Clough, K. B., O'Donoghue, J. M., Fitoussi, A. D., Nos, C., & Falcou, M. C. (2001). Prospective evaluation of late cosmetic results following breast reconstruction: I. Implant reconstruction. Plast Reconstr Surg, 107(7), 1702-1709. 

Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., . . . Slamon, D. J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17(9), 2639-2648. 

Cochrane, R. A., Valasiadou, P., Wilson, A. R., Al-Ghazal, S. K., & Macmillan, R. D. (2003). Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg, 90(12), 1505-1509. doi:10.1002/bjs.4344

Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., . . . Papadopoulos, N. (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 359(6378), 926-930. doi:10.1126/science.aar3247

Cold, S., Jensen, N. V., Brincker, H., & Rose, C. (1993). The influence of chemotherapy on survival after recurrence in breast cancer--a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer, 29A(8), 1146-1152. 

Coleman, R., de Boer, R., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., . . . Bundred, N. (2013). Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol, 24(2), 398-405. doi:10.1093/annonc/mds277

Coleman, R. E., Finkelstein, D., Barrios, C. H., Martin, M., Iwata, H., Glaspy, J. A., . . . Chan, A. (2018). Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. 36(15_suppl), 501-501. doi:10.1200/JCO.2018.36.15_suppl.501

Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., . . . Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 390(10099), 1048-1060. doi:10.1016/s0140-6736(17)31145-5

Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., . . . Goldhirsch, A. (2018). Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 19(1), 127-138. doi:10.1016/s1470-2045(17)30715-5

Colleoni, M., Sun, Z., Price, K. N., Karlsson, P., Forbes, J. F., Thurlimann, B., . . . Goldhirsch, A. (2016). Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol, 34(9), 927-935. doi:10.1200/jco.2015.62.3504

Colombo, A., Meroni, C. A., Cipolla, C. M., & Cardinale, D. (2013). Managing cardiotoxicity of chemotherapy. Curr Treat Options Cardiovasc Med, 15(4), 410-424. doi:10.1007/s11936-013-0248-3

Colzani, E., Johansson, A. L., Liljegren, A., Foukakis, T., Clements, M., Adolfsson, J., . . . Czene, K. (2014). Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer, 110(5), 1378-1384. doi:10.1038/bjc.2014.5

Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. (2017). Obstet Gynecol, 130(4), e210-e216. doi:10.1097/aog.0000000000002355

Comprehensive molecular portraits of human breast tumours. (2012). Nature, 490(7418), 61-70. doi:10.1038/nature11412

Compston, J. (2017). Safety of long-term denosumab therapy for osteoporosis. Lancet Diabetes Endocrinol, 5(7), 485-487. doi:10.1016/s2213-8587(17)30178-x

Conte, P., Bisagni, G., Frassoldati, A., Brandes, A., Anselmi, E., Giotta, F., . . . Guarneri, V. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian Short-HER Study. Paper presented at the ASCO Annual Meeting 2017, Chicago, USA. 

Continuous Update Project Report: Diet, Nutrition, Physical Activity and Breast Cancer. (2017). Retrieved from http://www.wcrf.org/int/research-we-fund/continuous-update-project-findings-reports/breast-cancer

Continuous Update Project Report: Diet, Nutrition, Physical Activity and Breast Cancer Surviviors. (2014). Retrieved from http://www.wcrf.org/sites/default/files/Breast-Cancer-Survivors-2014-Report.pdf

Cordeiro, P. G., Pusic, A. L., Disa, J. J., McCormick, B., & VanZee, K. (2004). Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg, 113(3), 877-881. 

Cornelissen, A. J. M., Kool, M., Lopez Penha, T. R., Keuter, X. H. A., Piatkowski, A. A., Heuts, E., . . . Qiu, S. S. (2017). Lymphatico-venous anastomosis as treatment for breast cancer-related lymphedema: a prospective study on quality of life. Breast Cancer Res Treat, 163(2), 281-286. doi:10.1007/s10549-017-4180-1

Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., . . . Darby, S. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr, 2010(41), 162-177. doi:10.1093/jncimonographs/lgq039

Cortadellas, T., Córdoba, O., Gascón, A., Haladjian, C., Bernabeu, A., Alcalde, A., . . . Gil-Moreno, A. (2015). Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution. European Journal of Surgical Oncology, 41(5), 635-640. doi:10.1016/j.ejso.2015.01.027

Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., . . . von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384(9938), 164-172. doi:10.1016/s0140-6736(13)62422-8

Cortes, J., Baselga, J., Im, Y. H., Im, S. A., Pivot, X., Ross, G., . . . Swain, S. M. (2013). Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol, 24(10), 2630-2635. doi:10.1093/annonc/mdt274

Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., . . . investigators, E. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 377(9769), 914-923. doi:10.1016/S0140-6736(11)60070-6

Couzi, R. J., Helzlsouer, K. J., & Fetting, J. H. (1995). Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol, 13(11), 2737-2744. 

Cramp, F., & Byron-Daniel, J. (2012). Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev, 11, Cd006145. doi:10.1002/14651858.CD006145.pub3

Cramp, F., James, A., & Lambert, J. (2010). The effects of resistance training on quality of life in cancer: a systematic literature review and meta-analysis. Support Care Cancer, 18(11), 1367-1376. doi:10.1007/s00520-010-0904-z

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., . . . Slamon, D. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 17(4), 425-439. doi:10.1016/s1470-2045(15)00613-0

Crivellari, D., Sun, Z., Coates, A. S., Price, K. N., Thurlimann, B., Mouridsen, H., . . . Goldhirsch, A. (2008). Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol, 26(12), 1972-1979. doi:10.1200/jco.2007.14.0459

Croshaw, R., Shapiro-Wright, H., Svensson, E., Erb, K., & Julian, T. (2011). Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol, 18(11), 3160-3163. doi:10.1245/s10434-011-1919-5

Crump, M., Gluck, S., Tu, D., Stewart, D., Levine, M., Kirkbride, P., . . . Pritchard, K. I. (2008). Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol, 26(1), 37-43. doi:10.1200/JCO.2007.11.8851

Cserni, G., Gregori, D., Merletti, F., Sapino, A., Mano, M. P., Ponti, A., . . . Bussolati, G. (2004). Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg, 91(10), 1245-1252. doi:10.1002/bjs.4725

Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., . . . Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 361(8), 756-765. doi:10.1056/NEJMoa0809493

Curigliano, G., Burstein, H. J., E, P. W., Gnant, M., Dubsky, P., Loibl, S., . . . Xu, B. (2017). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol, 28(8), 1700-1712. doi:10.1093/annonc/mdx308

Curigliano, G. e. a. (2017). De-escalating and escalating treatments for early-stage brest cancer. Paper presented at the The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. 

Cuzick, J., Ambroisine, L., Davidson, N., Jakesz, R., Kaufmann, M., Regan, M., & Sainsbury, R. (2007). Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet, 369(9574), 1711-1723. doi:10.1016/s0140-6736(07)60778-8

Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., . . . Wickerham, D. L. (2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, 381(9880), 1827-1834. doi:10.1016/s0140-6736(13)60140-3

Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., . . . Howell, A. (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383(9922), 1041-1048. doi:10.1016/s0140-6736(13)62292-8

Cuzick, J., Sestak, I., Pinder, S. E., Ellis, I. O., Forsyth, S., Bundred, N. J., . . . George, W. D. (2011). Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol, 12(1), 21-29. doi:10.1016/s1470-2045(10)70266-7

Cybulski, C., Kluzniak, W., Huzarski, T., Wokolorczyk, D., Kashyap, A., Jakubowska, A., . . . Lubinski, J. (2015). Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol, 16(6), 638-644. doi:10.1016/s1470-2045(15)70142-7

D'Souza, N., Darmanin, G., & Fedorowicz, Z. (2011). Immediate versus delayed reconstruction following surgery for breast cancer. Cochrane Database Syst Rev(7), Cd008674. doi:10.1002/14651858.CD008674.pub2

Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., & Murray, S. (2008). Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist, 13(6), 620-630. doi:10.1634/theoncologist.2008-0001

Daidone, M. G., Coradini, D., Martelli, G., & Veneroni, S. (2003). Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol, 45(3), 313-325. 

Dalberg, K., Eriksson, J., & Holmberg, L. (2006). Birth outcome in women with previously treated breast cancer--a population-based cohort study from Sweden. PLoS Med, 3(9), e336. doi:10.1371/journal.pmed.0030336

Dall, P., Lenzen, G., Gohler, T., Lerchenmuller, C., Feisel-Schwickardi, G., Koch, T., . . . Hinke, A. (2015). Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol, 6(6), 462-469. doi:10.1016/j.jgo.2015.06.003

Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Friedman, S., Garber, J. E., . . . Farmer, M. (2019, Januari 18, 2019). NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and ovarian. Version 3.  . Retrieved from https://www.nccn.org/professionals/physician_gls/default.aspx#detection 

Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., . . . Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378(9804), 1707-1716. doi:10.1016/s0140-6736(11)61629-2

Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., . . . Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med, 368(11), 987-998. doi:10.1056/NEJMoa1209825

Daugherty, E. C., Daugherty, M. R., Bogart, J. A., & Shapiro, A. (2016). Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. Clin Breast Cancer, 16(6), 500-506.e502. doi:10.1016/j.clbc.2016.06.017

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., . . . Peto, R. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805-816. doi:10.1016/s0140-6736(12)61963-1

Davis, A. L., Klitus, M., & Mintzer, D. M. (2005). Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer, 6(5), 421-424. doi:10.3816/CBC.2005.n.046

de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., . . . Baselga, J. (2014). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol, 15(10), 1137-1146. doi:10.1016/s1470-2045(14)70320-1

de Bock, G. H., van der Hage, J. A., Putter, H., Bonnema, J., Bartelink, H., & van de Velde, C. J. (2006). Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer, 42(3), 351-356. doi:10.1016/j.ejca.2005.10.006

de Boer, M., van Leeuwen, F. E., Hauptmann, M., Overbeek, L. I. H., de Boer, J. P., Hijmering, N. J., . . . de Jong, D. (2018). Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. JAMA Oncol, 4(3), 335-341. doi:10.1001/jamaoncol.2017.4510

de Glas, N. A., Jonker, J. M., Bastiaannet, E., de Craen, A. J., van de Velde, C. J., Siesling, S., . . . Hamaker, M. E. (2014). Impact of omission of surgery on survival of older patients with breast cancer. Br J Surg, 101(11), 1397-1404. doi:10.1002/bjs.9616

de Haes, J. C., Curran, D., Aaronson, N. K., & Fentiman, I. S. (2003). Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer, 39(7), 945-951. 

de Nonneville, A., Goncalves, A., Zemmour, C., Classe, J. M., Cohen, M., Lambaudie, E., . . . Houvenaeghel, G. (2017). Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Res Treat, 162(2), 307-316. doi:10.1007/s10549-017-4136-5

De Placido, S., Gallo, C., De Laurentiis, M., Bisagni, G., Arpino, G., Sarobba, M. G., . . . Perrone, F. (2018). Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol, 19(4), 474-485. doi:10.1016/s1470-2045(18)30116-5

De Santis, M., Straface, G., Cavaliere, A. F., Carducci, B., & Caruso, A. (2007). Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol Scand, 86(1), 99-101. doi:10.1080/00016340600804639

Del Bianco, P., Zavagno, G., Burelli, P., Scalco, G., Barutta, L., Carraro, P., . . . De Salvo, G. L. (2008). Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol, 34(5), 508-513. doi:10.1016/j.ejso.2007.05.017

Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., . . . Cognetti, F. (2015). Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet, 385(9980), 1863-1872. doi:10.1016/s0140-6736(14)62048-1

Delay, E., Gounot, N., Bouillot, A., Zlatoff, P., & Rivoire, M. (1998). Autologous latissimus breast reconstruction: a 3-year clinical experience with 100 patients. Plast Reconstr Surg, 102(5), 1461-1478. 

DeMichele, A., Putt, M., Zhang, Y., Glick, J. H., & Norman, S. (2003). Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer, 97(9), 2150-2159. doi:10.1002/cncr.11338

Denkert, C., Loibl, S., Noske, A., Roller, M., Muller, B. M., Komor, M., . . . von Minckwitz, G. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 28(1), 105-113. doi:10.1200/jco.2009.23.7370

DeSnyder, S. M., Mittendorf, E. A., Le-Petross, C., Krishnamurthy, S., Whitman, G. J., Ueno, N. T., . . . Lucci, A. (2018). Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clin Breast Cancer, 18(1), e73-e77. doi:10.1016/j.clbc.2017.06.014

Deutsch, M. (2002). Radiotherapy after lumpectomy for breast cancer in very old women. Am J Clin Oncol, 25(1), 48-49. 

Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., . . . Martin, M. (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol, 28(30), 4594-4600. doi:10.1200/JCO.2010.28.8415

Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lonning, P. E., Janni, W., . . . Bachelot, T. (2018). Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 19(1), 87-100. doi:10.1016/s1470-2045(17)30688-5

Diab, S. G., Elledge, R. M., & Clark, G. M. (2000). Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst, 92(7), 550-556. 

Diel, I. J., Solomayer, E. F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., . . . Bastert, G. (1998). Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med, 339(6), 357-363. doi:10.1056/NEJM199808063390601

Dietz, J., Lundgren, P., Veeramani, A., O'Rourke, C., Bernard, S., Djohan, R., . . . Yetman, R. (2012). Autologous inferior dermal sling (autoderm) with concomitant skin-envelope reduction mastectomy: an excellent surgical choice for women with macromastia and clinically significant ptosis. Ann Surg Oncol, 19(10), 3282-3288. doi:10.1245/s10434-012-2549-2

Dodwell, D., Taylor, C., McGale, P., Coles, C. E., Duane, F., Gray, R., . . . Whelan, T. Regional node irradiation: Meta-analysis of 13,500 women in 14 trials. . Paper presented at the San Antonio Breast Cancer Conference 2018, San Antonio. 

Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., . . . Trunet, P. F. (1998). Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol, 16(2), 453-461. 

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., . . . Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama, 304(9), 967-975. doi:10.1001/jama.2010.1237

Donker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J., Mansel, R. E., . . . Rutgers, E. J. (2014). Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol, 15(12), 1303-1310. doi:10.1016/s1470-2045(14)70460-7

Donnelly, E. H., Smith, J. M., Farfan, E. B., & Ozcan, I. (2011). Prenatal radiation exposure: background material for counseling pregnant patients following exposure to radiation. Disaster Med Public Health Prep, 5(1), 62-68. doi:10.1001/dmp.2011.2

Dooley, W. C., Bong, J., & Parker, J. (2011). Mechanisms of improved outcomes for breast cancer between surgical oncologists and general surgeons. Ann Surg Oncol, 18(12), 3248-3251. doi:10.1245/s10434-011-1771-7

dos Santos, L. V., Souza, F. H., Brunetto, A. T., Sasse, A. D., & da Silveira Nogueira Lima, J. P. (2012). Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst, 104(17), 1280-1292. doi:10.1093/jnci/djs335

Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., . . . Peto, R. (2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol, 28(3), 509-518. doi:10.1200/jco.2009.23.1274

Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara, T., Bliss, J., . . . Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 386(10001), 1341-1352. doi:10.1016/s0140-6736(15)61074-1

Dowsett, M., & Haynes, B. P. (2003). Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol, 86(3-5), 255-263. 

Duijts, S. F., van Beurden, M., Oldenburg, H. S., Hunter, M. S., Kieffer, J. M., Stuiver, M. M., . . . Aaronson, N. K. (2012). Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol, 30(33), 4124-4133. doi:10.1200/jco.2012.41.8525

Duijts, S. F., Zeegers, M. P., & Borne, B. V. (2003). The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer, 107(6), 1023-1029. doi:10.1002/ijc.11504

Duncan, P. G., Pope, W. D., Cohen, M. M., & Greer, N. (1986). Fetal risk of anesthesia and surgery during pregnancy. Anesthesiology, 64(6), 790-794. 

Durbecq, V., Ameye, L., Veys, I., Paesmans, M., Desmedt, C., Sirtaine, N., . . . Larsimont, D. (2008). A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol, 67(1), 80-92. doi:10.1016/j.critrevonc.2007.12.008

Dödsorsaksregistret. (2019, 2019-05-29). Retrieved from https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/dodsorsaksregistret/

Eaker, S., Dickman, P. W., Bergkvist, L., & Holmberg, L. (2006). Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med, 3(3), e25. doi:10.1371/journal.pmed.0030025

Easton, D. F., Ford, D., & Bishop, D. T. (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet, 56(1), 265-271. 

Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., . . . Foulkes, W. D. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med, 372(23), 2243-2257. doi:10.1056/NEJMsr1501341

Eaton, B. R., Jiang, R., Torres, M. A., Kahn, S. T., Godette, K., Lash, T. L., & Ward, K. C. (2016). Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. Cancer, 122(19), 3059-3068. doi:10.1002/cncr.30142

EBCTCG. (1988). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med, 319(26), 1681-1692. doi:10.1056/nejm198812293192601

EBCTCG. (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet, 339(8785), 71-85. 

EBCTCG. (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 351(9114), 1451-1467. 

EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 365(9472), 1687-1717. doi:10.1016/s0140-6736(05)66544-0

EBCTCG. (2015). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, 386(10001), 1353-1361. doi:10.1016/s0140-6736(15)60908-4

EBCTCG. (2017). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. doi:http://dx.doi.org/10.1016/S1470-2045(17)30777-5

EBCTCG, Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., . . . Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 366(9503), 2087-2106. doi:10.1016/s0140-6736(05)67887-7

EBCTCG, Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., . . . Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 378(9804), 1707-1716. doi:10.1016/s0140-6736(11)61629-2

EBCTCG, McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., . . . Darby, S. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 383(9935), 2127-2135. doi:10.1016/s0140-6736(14)60488-8

EBCTCG, Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., . . . Pritchard, K. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 379(9814), 432-444. doi:10.1016/s0140-6736(11)61625-5

Ehinger, A., Malmstrom, P., Bendahl, P. O., Elston, C. W., Falck, A. K., Forsare, C., . . . Ferno, M. (2017). Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol, 56(1), 68-74. doi:10.1080/0284186x.2016.1237778

Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., . . . Borgs, M. (2001). Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol, 12(11), 1527-1532. 

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228-247. doi:10.1016/j.ejca.2008.10.026

Ekin, M., Yasar, L., Savan, K., Temur, M., Uhri, M., Gencer, I., & Kivanc, E. (2011). The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet, 283(3), 539-543. doi:10.1007/s00404-010-1382-8

Elder, E. E., Brandberg, Y., Bjorklund, T., Rylander, R., Lagergren, J., Jurell, G., . . . Sandelin, K. (2005). Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast, 14(3), 201-208. doi:10.1016/j.breast.2004.10.008

Elkin, E. B., Hurria, A., Mitra, N., Schrag, D., & Panageas, K. S. (2006). Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol, 24(18), 2757-2764. doi:10.1200/jco.2005.03.6053

Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiowka, M., Hewson, N., . . . Robertson, J. F. (2015). Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J Clin Oncol, 33(32), 3781-3787. doi:10.1200/jco.2015.61.5831

Emaus, M. J., Bakker, M. F., Peeters, P. H., Loo, C. E., Mann, R. M., de Jong, M. D., . . . van Gils, C. H. (2015). MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50-75 Years with Extremely Dense Breasts: The DENSE Trial Study Design. Radiology, 277(2), 527-537. doi:10.1148/radiol.2015141827

Engholm, G., Ferlay, J., Christensen, N., Kejs, A. M. T., Hertzum-Larsen, R., Johannesen, T. B., . . . Storm, H. H. (2014, 25.04.2014). NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Association of the Nordic Cancer Registries. Danish Cancer Society. Version 6.1. Retrieved from www.ancr.nu

Engholm, G., Ferlay, J., Christensen, N., Kejs, A. M. T., Hertzum-Larsen, R., Johannesen, T. B., . . . Storm, H. H. (2016, 08.07.2016). NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Version 7.3. Retrieved from https://www.ancr.nu/cancer-data/nordcan-on-the-web/

Eriksen, C., Frisell, J., Wickman, M., Lidbrink, E., Krawiec, K., & Sandelin, K. (2011). Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study. Breast Cancer Res Treat, 127(2), 439-446. doi:10.1007/s10549-011-1437-y

Eriksson, M., Anveden, L., Celebioglu, F., Dahlberg, K., Meldahl, I., Lagergren, J., . . . de Boniface, J. (2013). Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort. Breast Cancer Res Treat, 142(3), 591-601. doi:10.1007/s10549-013-2770-0

Erven, K., Weltens, C., Nackaerts, K., Fieuws, S., Decramer, M., & Lievens, Y. (2012). Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Biol Phys, 82(2), 701-707. doi:10.1016/j.ijrobp.2010.12.058

Esposito, S., Tenconi, R., Preti, V., Groppali, E., & Principi, N. (2016). Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Medicine (Baltimore), 95(38), e4899. doi:10.1097/md.0000000000004899

Estourgie, S. H., Nieweg, O. E., Olmos, R. A., Rutgers, E. J., & Kroon, B. B. (2004). Lymphatic drainage patterns from the breast. Ann Surg, 239(2), 232-237. doi:10.1097/01.sla.0000109156.26378.90

European Medicines Agency. The role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165781.pdf

Evans, G. R., Schusterman, M. A., Kroll, S. S., Miller, M. J., Reece, G. P., Robb, G. L., & Ainslie, N. (1995). Reconstruction and the radiated breast: is there a role for implants? Plast Reconstr Surg, 96(5), 1111-1115; discussion, 1116-1118. 

Evans, T. R., Yellowlees, A., Foster, E., Earl, H., Cameron, D. A., Hutcheon, A. W., . . . Mansi, J. L. (2005). Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol, 23(13), 2988-2995. doi:10.1200/JCO.2005.06.156

Extermann, M. (2004). Management issues for elderly patients with breast cancer. Curr Treat Options Oncol, 5(2), 161-169. 

Extermann, M., Balducci, L., & Lyman, G. H. (2000). What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol, 18(8), 1709-1717. 

Fabre, A., Fournier, A., Mesrine, S., Desreux, J., Gompel, A., Boutron-Ruault, M. C., & Clavel-Chapelon, F. (2007). Oral progestagens before menopause and breast cancer risk. Br J Cancer, 96(5), 841-844. doi:10.1038/sj.bjc.6603618

Fahlen, M., Fornander, T., Johansson, H., Johansson, U., Rutqvist, L. E., Wilking, N., & von Schoultz, E. (2013). Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer, 49(1), 52-59. doi:10.1016/j.ejca.2012.07.003

Falato, C., Taylor, S. K., Szulkin, R., Nordblom, A., Eriksson, L., Sofiadis, A., . . . Foukakis, T. (2018). Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry. Breast Cancer Res Treat, 172(3), 703-712. doi:10.1007/s10549-018-4936-2

Falck, A. K., Bendahl, P. O., Chebil, G., Olsson, H., Ferno, M., & Ryden, L. (2013). Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res Treat, 140(1), 93-104. doi:10.1007/s10549-013-2617-8

Falk, R. S., Hofvind, S., Skaane, P., & Haldorsen, T. (2013). Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer, 133(3), 705-712. doi:10.1002/ijc.28052

Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004). Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol, 22(21), 4261-4271. 

Fallowfield, L. J., Bliss, J. M., Porter, L. S., Price, M. H., Snowdon, C. F., Jones, S. E., . . . Hall, E. (2006). Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol, 24(6), 910-917. doi:10.1200/jco.2005.03.3654

Fansa, H., Schirmer, S., Warnecke, I. C., Cervelli, A., & Frerichs, O. (2008). The transverse myocutaneous gracilis muscle flap: a fast and reliable method for breast reconstruction. Plast Reconstr Surg, 122(5), 1326-1333. doi:10.1097/PRS.0b013e318188205f

Faverly, D. R., Burgers, L., Bult, P., & Holland, R. (1994). Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol, 11(3), 193-198. 

Feher, O., Vodvarka, P., Jassem, J., Morack, G., Advani, S. H., Khoo, K. S., . . . von Minckwitz, G. (2005). First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol, 16(6), 899-908. doi:10.1093/annonc/mdi181

Fenig, E., Mishaeli, M., Kalish, Y., & Lishner, M. (2001). Pregnancy and radiation. Cancer Treat Rev, 27(1), 1-7. doi:10.1053/ctrv.2000.0193

Fennessy, M., Bates, T., MacRae, K., Riley, D., Houghton, J., & Baum, M. (2004). Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg, 91(6), 699-704. doi:10.1002/bjs.4603

Figueiredo, M. I., Cullen, J., Hwang, Y. T., Rowland, J. H., & Mandelblatt, J. S. (2004). Breast cancer treatment in older women: does getting what you want improve your long-term body image and mental health? J Clin Oncol, 22(19), 4002-4009. doi:10.1200/jco.2004.07.030

Filipits, M., Dubsky, P., Rudas, M., Greil, R., Balic, M., Bago-Horvath, Z., . . . Gnant, M. (2019). Prediction of Distant Recurrence Using EndoPredict Among Women with ER(+), HER2(-) Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res, 25(13), 3865-3872. doi:10.1158/1078-0432.Ccr-19-0376

Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., . . . Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol, 32(15), 1547-1553. doi:10.1200/jco.2013.53.2820

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., . . . Slamon, D. J. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol, 16(1), 25-35. doi:10.1016/s1470-2045(14)71159-3

Finn, R. S., et al. (2017). Overall Survival Results From the Randomized Phase 2 Study of Palbociclib in Combination With Letrozole vs Letrozole Alone for First-Line Treatment of ER+/HER2‒ Advanced Breast Cancer (PALOMA-1; TRIO-18) Paper presented at the ASCO Annual Meeting. http://www.am.asco.org./

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., . . . Slamon, D. J. (2016). Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 375(20), 1925-1936. doi:10.1056/NEJMoa1607303

Firlik, K. S., Kondziolka, D., Flickinger, J. C., & Lunsford, L. D. (2000). Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol, 7(5), 333-338. 

Fischer, J. P., Wes, A. M., Nelson, J. A., Basta, M., Rohrbach, J. I., Wu, L. C., . . . Kovach, S. J. (2014). Propensity-matched, longitudinal outcomes analysis of complications and cost: comparing abdominal free flaps and implant-based breast reconstruction. J Am Coll Surg, 219(2), 303-312. doi:10.1016/j.jamcollsurg.2014.02.028

Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., . . . Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 347(16), 1233-1241. doi:10.1056/NEJMoa022152

Fisher, B., Anderson, S., DeCillis, A., Dimitrov, N., Atkins, J. N., Fehrenbacher, L., . . . Wolmark, N. (1999). Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol, 17(11), 3374-3388. 

Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Dimitrov, N., Mamounas, E., . . . Deckers, P. (1997). Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol, 15(5), 1858-1869. 

Fisher, B., Jeong, J. H., Bryant, J., Anderson, S., Dignam, J., Fisher, E. R., & Wolmark, N. (2004). Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet, 364(9437), 858-868. doi:10.1016/s0140-6736(04)16981-x

Fitzal, F., Balic, M., Bjelic-Radisic, V., Hubalek, M., Singer, C. F., Steger, G. G., . . . Gnant, M. (2017). Primary operation in synchroneous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIVE trial. Journal of Clinical Oncology, 35(15_suppl), 557-557. doi:10.1200/JCO.2017.35.15_suppl.557

Fitzal, F., Helfgott, R., Moinfar, F., & Gnant, M. (2017). Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer. Ann Surg Oncol, 24(Suppl 3), 555-556. doi:10.1245/s10434-017-6156-0

Fitzal, F., Riedl, O., Wutzl, L., Draxler, W., Rudas, M., Pluschnig, U., . . . Gnant, M. (2007). Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Breast Cancer Res Treat, 103(1), 45-52. doi:10.1007/s10549-006-9325-6

Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., . . . Schnitt, S. J. (2000). Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124(7), 966-978. doi:10.1043/0003-9985(2000)124<0966:pfibc>2.0.co;2

Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., . . . Naghavi, M. (2016). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. doi:10.1001/jamaoncol.2016.5688

Fong, D. Y., Ho, J. W., Hui, B. P., Lee, A. M., Macfarlane, D. J., Leung, S. S., . . . Cheng, K. K. (2012). Physical activity for cancer survivors: meta-analysis of randomised controlled trials. Bmj, 344, e70. doi:10.1136/bmj.e70

Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., . . . Cuzick, J. (2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet, 387(10021), 866-873. doi:10.1016/s0140-6736(15)01129-0

Ford, D., Easton, D. F., & Peto, J. (1995). Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet, 57(6), 1457-1462. 

Forward, D. P., Cheung, K. L., Jackson, L., & Robertson, J. F. (2004). Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer, 90(3), 590-594. doi:10.1038/sj.bjc.6601557

Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., . . . Liberati, A. (1998). Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol, 16(10), 3439-3460. 

Foukakis, T., Astrom, G., Lindstrom, L., Hatschek, T., & Bergh, J. (2012). When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol, 23 Suppl 10, x349-353. doi:10.1093/annonc/mds297

Foukakis, T., Fornander, T., Lekberg, T., Hellborg, H., Adolfsson, J., & Bergh, J. (2011). Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat, 130(2), 553-560. doi:10.1007/s10549-011-1594-z

Foukakis, T., von Minckwitz, G., Bengtsson, N. O., Brandberg, Y., Wallberg, B., Fornander, T., . . . Bergh, J. (2016). Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. Jama, 316(18), 1888-1896. doi:10.1001/jama.2016.15865

Foulkes, W. D. (2008). Inherited susceptibility to common cancers. N Engl J Med, 359(20), 2143-2153. doi:10.1056/NEJMra0802968

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Lang, I., . . . Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med, 379(2), 122-137. doi:10.1056/NEJMoa1803164

Fredholm, H., Magnusson, K., Lindstrom, L. S., Garmo, H., Falt, S. E., Lindman, H., . . . Fredriksson, I. (2016). Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat, 160(1), 131-143. doi:10.1007/s10549-016-3983-9

Fredriksson, I., Liljegren, G., Arnesson, L. G., Emdin, S. O., Palm-Sjovall, M., Fornander, T., . . . Holmberg, L. (2001). Time trends in the results of breast conservation in 4694 women. Eur J Cancer, 37(12), 1537-1544. 

Fredriksson, I., Liljegren, G., Arnesson, L. G., Emdin, S. O., Palm-Sjovall, M., Fornander, T., . . . Frisell, J. (2002). Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. Eur J Cancer, 38(14), 1860-1870. 

Fredriksson, I., Liljegren, G., Palm-Sjovall, M., Arnesson, L. G., Emdin, S. O., Fornander, T., . . . Frisell, J. (2003). Risk factors for local recurrence after breast-conserving surgery. Br J Surg, 90(9), 1093-1102. doi:10.1002/bjs.4206

Freedman, R. A., Hughes, M. E., Ottesen, R. A., Weeks, J. C., He, Y., Wong, Y. N., . . . Keating, N. L. (2013). Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer, 119(4), 839-846. doi:10.1002/cncr.27831

Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., . . . Turner, N. C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol, 34(25), 2961-2968. doi:10.1200/jco.2016.67.3061

Friedel, G., Pastorino, U., Ginsberg, R. J., Goldstraw, P., Johnston, M., Pass, H., . . . Toomes, H. (2002). Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg, 22(3), 335-344. 

Fromm, S., Bartsch, R., Rudas, M., de Vries, A., Wenzel, C., Steger, G. G., . . . Dieckmann, K. (2008). Factors influencing the time to development of brain metastases in breast cancer. Breast, 17(5), 512-516. doi:10.1016/j.breast.2008.03.008

Fu, Y., & Zhuang, Z. (2014). Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol, 7(10), 6419-6429. 

Fujii, T., Le Du, F., Xiao, L., Kogawa, T., Barcenas, C. H., Alvarez, R. H., . . . Ueno, N. T. (2015). Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol, 1(9), 1311-1318. doi:10.1001/jamaoncol.2015.3062

Furlanetto, J., Jackisch, C., Untch, M., Schneeweiss, A., Schmatloch, S., Aktas, B., . . . von Minckwitz, G. (2017). Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat, 163(3), 495-506. doi:10.1007/s10549-017-4200-1

Fyles, A. W., McCready, D. R., Manchul, L. A., Trudeau, M. E., Merante, P., Pintilie, M., . . . Olivotto, I. A. (2004). Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med, 351(10), 963-970. doi:10.1056/NEJMoa040595

Gabel, M., Hilton, N. E., & Nathanson, S. D. (1997). Multidisciplinary breast cancer clinics. Do they work? Cancer, 79(12), 2380-2384. 

Gagliato Dde, M., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L., Giordano, S. H., Valero, V., . . . Chavez-Macgregor, M. (2014). Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol, 32(8), 735-744. doi:10.1200/jco.2013.49.7693

Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst, 81(24), 1879-1886. 

Gajdos, C., Tartter, P. I., Bleiweiss, I. J., Lopchinsky, R. A., & Bernstein, J. L. (2001). The consequence of undertreating breast cancer in the elderly. J Am Coll Surg, 192(6), 698-707. 

Galimberti, V., Cole, B. F., Viale, G., Veronesi, P., Vicini, E., Intra, M., . . . Goldhirsch, A. (2018). Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol, 19(10), 1385-1393. doi:10.1016/s1470-2045(18)30380-2

Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., . . . Veronesi, U. (2013). Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol, 14(4), 297-305. doi:10.1016/s1470-2045(13)70035-4

Galimberti, V., Ribeiro Fontana, S. K., Maisonneuve, P., Steccanella, F., Vento, A. R., Intra, M., . . . Luini, A. (2016). Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol, 42(3), 361-368. doi:10.1016/j.ejso.2015.11.019

Galimberti, V., Veronesi, P., Arnone, P., De Cicco, C., Renne, G., Intra, M., . . . Veronesi, U. (2002). Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol, 9(9), 924-928. 

Ganz, P. A., Schag, A. C., Lee, J. J., Polinsky, M. L., & Tan, S. J. (1992). Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer, 69(7), 1729-1738. 

Gao, D. L., Hu, Y. W., Wang, W. W., Chen, F. L., Pan, L. D., Yuan, Y., . . . Qian, F. (2006). [Evaluation on the effect of intervention regarding breast self-examination for decreasing breast cancer mortality]. Zhonghua Liu Xing Bing Xue Za Zhi, 27(11), 985-990. 

Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., . . . Bonanni, B. (2009). Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol, 16(12), 3380-3387. doi:10.1245/s10434-009-0638-7

Gartlehner, G., Thaler, K., Chapman, A., Kaminski-Hartenthaler, A., Berzaczy, D., Van Noord, M. G., & Helbich, T. H. (2013). Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev(4), Cd009632. doi:10.1002/14651858.CD009632.pub2

Gazet, J. C., Ford, H. T., Coombes, R. C., Bland, J. M., Sutcliffe, R., Quilliam, J., & Lowndes, S. (1994). Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol, 20(3), 207-214. 

Gazet, J. C., & Sutcliffe, R. (2011). A randomised trial comparing tamoxifen vs. surgery in patients over the age of 70 with operable breast cancer--final results after 28 years of follow-up. Eur J Surg Oncol, 37(9), 754-757. doi:10.1016/j.ejso.2011.06.011

Gelmon, K. A., Boyle, F. M., Kaufman, B., Huntsman, D. G., Manikhas, A., Di Leo, A., . . . Parulekar, W. R. (2015). Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol, 33(14), 1574-1583. doi:10.1200/jco.2014.56.9590

Geng, C., Chen, X., Pan, X., & Li, J. (2016). The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis. PLoS One, 11(9), e0162605. doi:10.1371/journal.pone.0162605

Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., . . . Bruzzi, P. (2011). Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol, 29(16), 2144-2149. doi:10.1200/JCO.2010.31.5374

Gennari, R., Curigliano, G., Rotmensz, N., Robertson, C., Colleoni, M., Zurrida, S., . . . Goldhirsch, A. (2004). Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer, 101(6), 1302-1310. doi:10.1002/cncr.20535

Gennari, R., Griguolo, G., Dieci, M. V., Guarneri, V., Tavaniello, B., Sibilio, A., & Conte, P. (2016). Fat grafting for breast cancer patients: From basic science to clinical studies. Eur J Surg Oncol, 42(8), 1088-1102. doi:10.1016/j.ejso.2016.04.062

Gentilini, O., Cremonesi, M., Toesca, A., Colombo, N., Peccatori, F., Sironi, R., . . . Paganelli, G. (2010). Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging, 37(1), 78-83. doi:10.1007/s00259-009-1217-7

Gentilini, O., Cremonesi, M., Trifiro, G., Ferrari, M., Baio, S. M., Caracciolo, M., . . . Paganelli, G. (2004). Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol, 15(9), 1348-1351. doi:10.1093/annonc/mdh355

Gervais, M. K., Maki, E., Schiller, D. E., Crystal, P., & McCready, D. R. (2017). Preoperative MRI of the breast and ipsilateral breast tumor recurrence: Long-term follow up. J Surg Oncol, 115(3), 231-237. doi:10.1002/jso.24520

Ghersi, D., Wilcken, N., Simes, J., & Donoghue, E. (2003). Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev(3), CD003366. doi:10.1002/14651858.CD003366

Ghersi, D., Willson, M. L., Chan, M. M., Simes, J., Donoghue, E., & Wilcken, N. (2015). Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev(6), Cd003366. doi:10.1002/14651858.CD003366.pub3

Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., . . . Baselga, J. (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375(9712), 377-384. doi:10.1016/S0140-6736(09)61964-4

Gianni, L., Pienkowski, T., Im, Y. H., Roman, L., Tseng, L. M., Liu, M. C., . . . Valagussa, P. (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 13(1), 25-32. doi:10.1016/S1470-2045(11)70336-9

Gill, P. S., Hunt, J. P., Guerra, A. B., Dellacroce, F. J., Sullivan, S. K., Boraski, J., . . . Allen, R. J. (2004). A 10-year retrospective review of 758 DIEP flaps for breast reconstruction. Plast Reconstr Surg, 113(4), 1153-1160. 

Gillis, C. R., & Hole, D. J. (1996). Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland. Bmj, 312(7024), 145-148. 

Giordano, S. H., Duan, Z., Kuo, Y. F., Hortobagyi, G. N., & Goodwin, J. S. (2006). Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol, 24(18), 2750-2756. doi:10.1200/jco.2005.02.3028

Giuliano, A. E., Ballman, K., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., . . . Hunt, K. K. (2016). Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg, 264(3), 413-420. doi:10.1097/sla.0000000000001863

Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., . . . Morrow, M. (2017). Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Jama, 318(10), 918-926. doi:10.1001/jama.2017.11470

Giuliano, A. E., Jones, R. C., Brennan, M., & Statman, R. (1997). Sentinel lymphadenectomy in breast cancer. J Clin Oncol, 15(6), 2345-2350. 

Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., . . . Generali, D. (2019). Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol, 20(10), 1360-1369. doi:10.1016/s1470-2045(19)30420-6

Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Kainberger, F., Kassmann, H., Piswanger-Solkner, J. C., . . . Jakesz, R. (2008). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol, 9(9), 840-849. doi:10.1016/s1470-2045(08)70204-3

Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., . . . Marth, C. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 360(7), 679-691. doi:10.1056/NEJMoa0806285

Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., . . . Greil, R. (2015). Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol, 26(2), 313-320. doi:10.1093/annonc/mdu544

Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., . . . Singer, C. F. (2015). Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, 386(9992), 433-443. doi:10.1016/s0140-6736(15)60995-3

Gnant, M., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., . . . Singer, C. F. (2019). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 20(3), 339-351. doi:10.1016/s1470-2045(18)30862-3

Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., . . . Cuzick, J. (2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol, 26(8), 1685-1691. doi:10.1093/annonc/mdv215

Gnant, M., Steger, G., Greil, R., Fitzal, F., Mlineritsch, B., Manfreda, D., . . . Jakesz, R. (2018). Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial (Vol. 78).

Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., . . . Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat, 101(1), 113-121. doi:10.1007/s10549-006-9428-0

Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., . . . Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), 1021-1028. doi:10.1016/s0140-6736(13)61094-6

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B., & Senn, H. J. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 24(9), 2206-2223. doi:10.1093/annonc/mdt303

Goldvaser, H., Barnes, T. A., Seruga, B., Cescon, D. W., Ocana, A., Ribnikar, D., & Amir, E. (2018). Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. J Natl Cancer Inst, 110(1). doi:10.1093/jnci/djx141

Gonzalez, V., Sandelin, K., Karlsson, A., Aberg, W., Lofgren, L., Iliescu, G., . . . Arver, B. (2014). Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World J Surg, 38(7), 1685-1693. doi:10.1007/s00268-014-2605-0

Gori, J., Castano, R., Engel, H., Toziano, M., Fischer, C., & Maletti, G. (2000). Conservative treatment vs. mastectomy without radiotherapy in aged women with breast cancer--a prospective and randomized trial. Zentralbl Gynakol, 122(6), 311-317. 

Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., . . . Pater, J. L. (2005). Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst, 97(17), 1262-1271. doi:10.1093/jnci/dji250

Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., . . . Parulekar, W. R. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med, 375(3), 209-219. doi:10.1056/NEJMoa1604700

Gosset, M., Hamy, A. S., Mallon, P., Delomenie, M., Mouttet, D., Pierga, J. Y., . . . Feron, J. G. (2016). Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. PLoS One, 11(8), e0159888. doi:10.1371/journal.pone.0159888

Gotzsche, P. C., & Jorgensen, K. J. (2013). Screening for breast cancer with mammography. Cochrane Database Syst Rev, 6, Cd001877. doi:10.1002/14651858.CD001877.pub5

Goulart, J., Truong, P., Woods, R., Speers, C. H., Kennecke, H., & Nichol, A. (2011). Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys, 80(3), 758-764. doi:10.1016/j.ijrobp.2010.02.014

Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., . . . Kumar, R. (2017). NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw, 15(4), 433-451. 

Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., . . . O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23(31), 7794-7803. doi:10.1200/jco.2005.04.937

Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., . . . Schmutzler, R. K. (2009). Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 27(35), 5887-5892. doi:10.1200/jco.2008.19.9430

Granader, E. J., Dwamena, B., & Carlos, R. C. (2008). MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol, 15(12), 1590-1595. doi:10.1016/j.acra.2008.06.006

Granados, R., Lumbreras, E. M., Delgado, M., Aramburu, J. A., & Tardio, J. C. (2016). Cytological Diagnosis of Bilateral Breast Implant-Associated Lymphoma of the ALK-Negative Anaplastic Large-Cell Type. Clinical Implications of Peri-Implant Breast Seroma Cytological Reporting. Diagn Cytopathol, 44(7), 623-627. doi:10.1002/dc.23485

Grantzau, T., Thomsen, M. S., Vaeth, M., & Overgaard, J. (2014). Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol, 111(3), 366-373. doi:10.1016/j.radonc.2014.05.004

Granzow, J. W., Soderberg, J. M., Kaji, A. H., & Dauphine, C. (2014). Review of current surgical treatments for lymphedema. Ann Surg Oncol, 21(4), 1195-1201. doi:10.1245/s10434-014-3518-8

Graversen, H. P., Blichert-Toft, M., Andersen, J. A., & Zedeler, K. (1988). Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol, 14(5), 407-412. 

Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., . . . Zambetti, M. (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet, 393(10179), 1440-1452. doi:https://doi.org/10.1016/S0140-6736(18)33137-4

Gray, R. R., Handley, K., & Bowden, S. J. (2013). aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. . Journal of Clinical Oncology, 31(15 May 20 Supplement):2013:5. 

Green, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., . . . Hortobagyi, G. N. (2005). Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol, 23(25), 5983-5992. doi:10.1200/jco.2005.06.232

Greskovich, J. F., Jr., & Macklis, R. M. (2000). Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol, 27(6), 633-645. 

Groen, J. W., Negenborn, V. L., Twisk, D. J., Rizopoulos, D., Ket, J. C., Smit, J. M., & Mullender, M. G. (2016). Autologous fat grafting in onco-plastic breast reconstruction: A systematic review on oncological and radiological safety, complications, volume retention and patient/surgeon satisfaction. J Plast Reconstr Aesthet Surg, 69(6), 742-764. doi:10.1016/j.bjps.2016.03.019

Gropper, A. B., Calvillo, K. Z., Dominici, L., Troyan, S., Rhei, E., Economy, K. E., . . . Mayer, E. L. (2014). Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol, 21(8), 2506-2511. doi:10.1245/s10434-014-3718-2

Grunfeld, E. (2009). Optimizing follow-up after breast cancer treatment. Curr Opin Obstet Gynecol, 21(1), 92-96. 

Grunfeld, E., Fitzpatrick, R., Mant, D., Yudkin, P., Adewuyi-Dalton, R., Stewart, J., . . . Vessey, M. (1999). Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract, 49(446), 705-710. 

Grunfeld, E., Levine, M. N., Julian, J. A., Coyle, D., Szechtman, B., Mirsky, D., . . . Whelan, T. (2006). Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol, 24(6), 848-855. doi:10.1200/jco.2005.03.2235

Grunfeld, E., Mant, D., Yudkin, P., Adewuyi-Dalton, R., Cole, D., Stewart, J., . . . Vessey, M. (1996). Routine follow up of breast cancer in primary care: randomised trial. Bmj, 313(7058), 665-669. 

Grunfeld, E., Noorani, H., McGahan, L., Paszat, L., Coyle, D., van Walraven, C., . . . Sawka, C. (2002). Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast, 11(3), 228-235. doi:10.1054/brst.2001.0404

Guidance for Industry. Pathological Complete Response in Neoadjuvant Treatment of Hogh-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Retrieved from http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

Gupta, S., King, W. D., Korzeniowski, M., Wallace, D. L., & Mackillop, W. J. (2016). The Effect of Waiting Times for Postoperative Radiotherapy on Outcomes for Women Receiving Partial Mastectomy for Breast Cancer: a Systematic Review and Meta-Analysis. Clin Oncol (R Coll Radiol), 28(12), 739-749. doi:10.1016/j.clon.2016.07.010

Guth, U., Huang, D. J., Bitzer, J., Tirri, B. F., & Moffat, R. (2016). Contraception counseling for young breast cancer patients: A practical needs assessment and a survey among medical oncologists. Breast, 30, 217-221. doi:10.1016/j.breast.2015.10.003

Güth, U., Myrick, M. E., Kandler, C., & Vetter, M. (2013). The use of adjuvant endocrine breast cancer therapy in the oldest old. The Breast, 22(5), 863-868. doi:https://doi.org/10.1016/j.breast.2013.03.001

Hadji, P. (2010). Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol, 73(2), 156-166. doi:10.1016/j.critrevonc.2009.02.001

Hadji, P., Aapro, M. S., Body, J. J., Gnant, M., Brandi, M. L., Reginster, J. Y., . . . Coleman, R. E. (2017). Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol, 7, 1-12. doi:10.1016/j.jbo.2017.03.001

Hadji, P., Kauka, A., Ziller, M., Birkholz, K., Baier, M., Muth, M., & Bauer, M. (2014). Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporos Int, 25(4), 1369-1378. doi:10.1007/s00198-013-2615-z

Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., . . . Alvarez-Franco, M. (2002). Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet, 359(9316), 1471-1477. doi:10.1016/s0140-6736(02)08434-9

Hallam, S., Govindarajulu, S., Huckett, B., & Bahl, A. (2015). BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review. Clin Oncol (R Coll Radiol), 27(9), 527-535. doi:10.1016/j.clon.2015.06.001

Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., & Fineberg, B. (1990). Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys, 19(4), 851-858. 

Han, S. N., Amant, F., Cardonick, E. H., Loibl, S., Peccatori, F. A., Gheysens, O., . . . Gentilini, O. (2018). Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Res Treat, 168(2), 551-557. doi:10.1007/s10549-017-4611-z

Hannoun-Levi, J. M., Houvenaeghel, G., Ellis, S., Teissier, E., Alzieu, C., Lallement, M., & Cowen, D. (2004). Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys, 60(5), 1385-1392. doi:10.1016/j.ijrobp.2004.05.035

Hannoun-Levi, J. M., Resch, A., Gal, J., Kauer-Dorner, D., Strnad, V., Niehoff, P., . . . Polgar, C. (2013). Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol, 108(2), 226-231. doi:10.1016/j.radonc.2013.03.026

Hanrahan, E. O., Broglio, K., Frye, D., Buzdar, A. U., Theriault, R. L., Valero, V., . . . Hortobagyi, G. N. (2006). Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer, 106(11), 2327-2336. doi:10.1002/cncr.21906

Hanrahan, E. O., Broglio, K. R., Buzdar, A. U., Theriault, R. L., Valero, V., Cristofanilli, M., . . . Rivera, E. (2005). Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer, 104(6), 1158-1171. doi:10.1002/cncr.21305

Hansson, E., Elander, A., Hallberg, H., & Sandman, L. (2019). Should immediate breast reconstruction be performed in the setting of radiotherapy? An ethical analysis. J Plast Surg Hand Surg, 1-6. doi:10.1080/2000656x.2019.1688165

Harbeck, N., Gluz, O., Christgen, M., Kates, R. E., Braun, M., Kuemmel, S., . . . Nitz, U. A. (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin Oncol, 35(26), 3046-3054. doi:10.1200/jco.2016.71.9815

Hardefeldt, P. J., Eslick, G. D., & Edirimanne, S. (2012). Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat, 133(3), 1169-1177. doi:10.1007/s10549-012-2019-3

Harris, L. N., Ismaila, N., McShane, L. M., & Hayes, D. F. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract, 12(4), 384-389. doi:10.1200/jop.2016.010868

Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., . . . Jenkins, R. B. (1999). Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med, 340(2), 77-84. doi:10.1056/nejm199901143400201

Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., . . . Jenkins, R. B. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 93(21), 1633-1637. 

Harvey, V., Mouridsen, H., Semiglazov, V., Jakobsen, E., Voznyi, E., Robinson, B. A., . . . Cold, S. (2006). Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol, 24(31), 4963-4970. doi:10.1200/JCO.2005.05.0294

Haspels, A. A., Luisi, M., & Kicovic, P. M. (1981). Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas, 3(3-4), 321-327. 

Haviland, J. S., Mannino, M., Griffin, C., Porta, N., Sydenham, M., Bliss, J. M., & Yarnold, J. R. (2018). Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol, 126(1), 155-162. doi:10.1016/j.radonc.2017.10.033

Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., . . . Yarnold, J. R. (2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol, 14(11), 1086-1094. doi:10.1016/s1470-2045(13)70386-3

Henderson, T. O., Amsterdam, A., Bhatia, S., Hudson, M. M., Meadows, A. T., Neglia, J. P., . . . Oeffinger, K. C. (2010). Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med, 152(7), 444-455; W144-454. doi:10.7326/0003-4819-152-7-201004060-00009

Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., . . . Romestaing, P. (2013). Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys, 86(5), 860-866. doi:10.1016/j.ijrobp.2013.03.021

Henriksson, L., Stjernquist, M., Boquist, L., Cedergren, I., & Selinus, I. (1996). A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol, 174(1 Pt 1), 85-92. 

Hereditary Diffuse Gastric Cancer  [updated July 31, 2014. (2014). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK1139/

Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., . . . Neugut, A. I. (2011). Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat, 126(2), 529-537. doi:10.1007/s10549-010-1132-4

Hickey, B. E., James, M. L., Lehman, M., Hider, P. N., Jeffery, M., Francis, D. P., & See, A. M. (2016). Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev, 7, Cd003860. doi:10.1002/14651858.CD003860.pub4

Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., . . . Shapiro, C. L. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. Jama, 317(1), 48-58. doi:10.1001/jama.2016.19425

Hind, D., Wyld, L., Beverley, C. B., & Reed, M. W. (2006). Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev(1), CD004272. doi:10.1002/14651858.CD004272.pub2

Hinkula, M., Pukkala, E., Kyyronen, P., & Kauppila, A. (2001). Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control, 12(6), 491-500. 

Hoffner, M., Ohlin, K., Svensson, B., Manjer, J., Hansson, E., Troeng, T., & Brorson, H. (2018). Liposuction Gives Complete Reduction of Arm Lymphedema following Breast Cancer Treatment-A 5-year Prospective Study in 105 Patients without Recurrence. Plast Reconstr Surg Glob Open, 6(8), e1912. doi:10.1097/gox.0000000000001912

Hogg, R., & Friedlander, M. (2004). Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol, 22(7), 1315-1327. doi:10.1200/jco.2004.07.179

Hojris, I., Overgaard, M., Christensen, J. J., & Overgaard, J. (1999). Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet, 354(9188), 1425-1430. 

Holland, R., Veling, S. H., Mravunac, M., & Hendriks, J. H. (1985). Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer, 56(5), 979-990. 

Holli, K., & Hakama, M. (1989). Effectiveness of routine and spontaneous follow-up visits for breast cancer. Eur J Cancer Clin Oncol, 25(2), 251-254. 

Holmberg, L., & Anderson, H. (2004). HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet, 363(9407), 453-455. doi:10.1016/s0140-6736(04)15493-7

Holmberg, L., Iversen, O. E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., . . . Maenpaa, J. (2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst, 100(7), 475-482. doi:10.1093/jnci/djn058

Horio, A., Fujita, T., Hayashi, H., Hattori, M., Kondou, N., Yamada, M., . . . Iwata, H. (2012). High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol, 17(2), 131-136. doi:10.1007/s10147-011-0269-4

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med, 375(18), 1738-1748. doi:10.1056/NEJMoa1609709

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . O'Shaughnessy, J. (2018). Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol, 29(7), 1541-1547. doi:10.1093/annonc/mdy155

Hortobagyi, G. N., Van Poznak, C., Harker, W. G., Gradishar, W. J., Chew, H., Dakhil, S. R., . . . Lipton, A. (2017). Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol, 3(7), 906-912. doi:10.1001/jamaoncol.2016.6316

Houssami, N., Macaskill, P., Marinovich, M. L., & Morrow, M. (2014). The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol, 21(3), 717-730. doi:10.1245/s10434-014-3480-5

Houssami, N., & Sainsbury, R. (2006). Breast cancer: multidisciplinary care and clinical outcomes. Eur J Cancer, 42(15), 2480-2491. doi:10.1016/j.ejca.2006.05.023

Houssami, N., Turner, R., Macaskill, P., Turnbull, L. W., McCready, D. R., Tuttle, T. M., . . . Solin, L. J. (2014). An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol, 32(5), 392-401. doi:10.1200/jco.2013.52.7515

Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J. F., . . . Tobias, J. S. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365(9453), 60-62. doi:10.1016/s0140-6736(04)17666-6

Howell, A., Robertson, J. F., Abram, P., Lichinitser, M. R., Elledge, R., Bajetta, E., . . . Osborne, C. K. (2004). Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol, 22(9), 1605-1613. doi:10.1200/JCO.2004.02.112

Howlader, M., Heaton, N., & Rela, M. (2011). Resection of liver metastases from breast cancer: towards a management guideline. Int J Surg, 9(4), 285-291. doi:10.1016/j.ijsu.2011.01.009

Hu, X. C., Zhang, J., Xu, B. H., Cai, L., Ragaz, J., Wang, Z. H., . . . Shao, Z. M. (2015). Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 16(4), 436-446. doi:10.1016/s1470-2045(15)70064-1

Huang, O., Wang, L., Shen, K., Lin, H., Hu, Z., Liu, G., . . . Shen, Z. (2008). Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat, 107(3), 379-387. doi:10.1007/s10549-007-9561-4

Hug, V., Hortobagyi, G. N., Drewinko, B., & Finders, M. (1985). Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol, 3(12), 1672-1677. doi:10.1200/jco.1985.3.12.1672

Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., . . . Wood, W. C. (2013). Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol, 31(19), 2382-2387. doi:10.1200/jco.2012.45.2615

Hughes, K. S., Schnaper, L. A., Berry, D., Cirrincione, C., McCormick, B., Shank, B., . . . Norton, L. (2004). Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med, 351(10), 971-977. doi:10.1056/NEJMoa040587

Hunt, K. K., Yi, M., Mittendorf, E. A., Guerrero, C., Babiera, G. V., Bedrosian, I., . . . Meric-Bernstam, F. (2009). Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg, 250(4), 558-566. doi:10.1097/SLA.0b013e3181b8fd5e

Huober, J., Fasching, P. A., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., . . . Harbeck, N. (2012). Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast, 21(1), 27-33. doi:10.1016/j.breast.2011.07.006

Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., . . . Tew, W. P. (2011). Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol, 29(25), 3457-3465. doi:10.1200/jco.2011.34.7625

Hurvitz, S., Chan, A., Iannotti, N., Ibrahim, E., Chien, J., Chan, N., . . . Rugo, H. S. (2018). Abstract P3-14-01: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial. Cancer Research, 78(4 Supplement), P3-14-01. doi:10.1158/1538-7445.SABCS17-P3-14-01

Hurvitz, S. A., Martin, M., Jung, K. H., Huang, C. S., Harbeck, N., Valero, V., . . . Slamon, D. (2019). Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol, 37(25), 2206-2216. doi:10.1200/jco.19.00882

Hwang, E. S., Lichtensztajn, D. Y., Gomez, S. L., Fowble, B., & Clarke, C. A. (2013). Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer, 119(7), 1402-1411. doi:10.1002/cncr.27795

IARC. (2009). A review of human carcinogens. Part E: Personal habits and indoor combustions. Retrieved from Lyon: 

Ibrahim, N. K., Buzdar, A. U., Asmar, L., Theriault, R. L., & Hortobagyi, G. N. (2000). Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol, 11(12), 1597-1601. 

Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., . . . Tripathy, D. (2019). Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. doi:10.1056/NEJMoa1903765

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. (1994). Jama, 271(20), 1587-1592. 

Inno, A., Barni, S., Ghidini, A., Zaniboni, A., & Petrelli, F. (2019). One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat, 173(2), 247-254. doi:10.1007/s10549-018-5001-x

Ioannidis, J. P., Hesketh, P. J., & Lau, J. (2000). Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol, 18(19), 3409-3422. 

Ishitobi, M., Fukui, R., Hashimoto, Y., Kittaka, N., Nakayama, T., & Tamaki, Y. (2017). Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence. Anticancer Res, 37(9), 5293-5299. doi:10.21873/anticanres.11955

Ishitobi, M., Okumura, Y., Nishimura, R., Nakatsukasa, K., Tanabe, M., Yoshida, A., . . . Inaji, H. (2014). Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR. Breast Cancer, 21(6), 754-760. doi:10.1007/s12282-013-0454-6

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., . . . Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307. 

Ivens, D., Hoe, A. L., Podd, T. J., Hamilton, C. R., Taylor, I., & Royle, G. T. (1992). Assessment of morbidity from complete axillary dissection. Br J Cancer, 66(1), 136-138. 

Ivshina, A. V., George, J., Senko, O., Mow, B., Putti, T. C., Smeds, J., . . . Miller, L. D. (2006). Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res, 66(21), 10292-10301. doi:10.1158/0008-5472.can-05-4414

Iwuchukwu, O. C., Harvey, J. R., Dordea, M., Critchley, A. C., & Drew, P. J. (2012). The role of oncoplastic therapeutic mammoplasty in breast cancer surgery--a review. Surg Oncol, 21(2), 133-141. doi:10.1016/j.suronc.2011.01.002

Jacobson, M. H., Mertens, A. C., Spencer, J. B., Manatunga, A. K., & Howards, P. P. (2016). Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. Fertil Steril, 105(3), 765-772.e764. doi:10.1016/j.fertnstert.2015.11.020

Jacquet, E., Lardy-Cleaud, A., Pistilli, B., Franck, S., Cottu, P., Delaloge, S., . . . Bachelot, T. (2018). Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer, 95, 93-101. doi:10.1016/j.ejca.2018.03.013

Jacquin, J. P., Jones, S., Magne, N., Chapelle, C., Ellis, P., Janni, W., . . . Laporte, S. (2012). Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Res Treat, 134(3), 903-913. doi:10.1007/s10549-011-1933-0

Jagsi, R., Chadha, M., Moni, J., Ballman, K., Laurie, F., Buchholz, T. A., . . . Haffty, B. G. (2014). Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol, 32(32), 3600-3606. doi:10.1200/jco.2014.56.5838

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. doi:10.1002/cncr.22452

Jakesz, R., Greil, R., Gnant, M., Schmid, M., Kwasny, W., Kubista, E., . . . Samonigg, H. (2007). Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst, 99(24), 1845-1853. doi:10.1093/jnci/djm246

Jakesz, R., Hausmaninger, H., Kubista, E., Gnant, M., Menzel, C., Bauernhofer, T., . . . Samonigg, H. (2002). Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol, 20(24), 4621-4627. 

Janni, W., Friedl, T. W. P., Fehm, T., Müller, V., Lichtenegger, W., Blohmer, J., . . . Rack, B. (2018). Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study. Cancer Research, 78(4 Supplement), GS1-06. doi:10.1158/1538-7445.SABCS17-GS1-06

Jansen, L., Doting, M. H., Rutgers, E. J., de Vries, J., Olmos, R. A., & Nieweg, O. E. (2000). Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg, 87(7), 920-925. doi:10.1046/j.1365-2168.2000.01437.x

Jansson, T., Westlin, J. E., Ahlstrom, H., Lilja, A., Langstrom, B., & Bergh, J. (1995). Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol, 13(6), 1470-1477. 

Jassem, J., Pienkowski, T., Pluzanska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., . . . Israel Pacitaxel Breast Cancer Study, G. (2001). Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol, 19(6), 1707-1715. 

Jatoi, I., Chen, B. E., Anderson, W. F., & Rosenberg, P. S. (2007). Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol, 25(13), 1683-1690. doi:10.1200/jco.2006.09.2106

Jenkins, E. O., Deal, A. M., Anders, C. K., Prat, A., Perou, C. M., Carey, L. A., & Muss, H. B. (2014). Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist, 19(10), 1076-1083. doi:10.1634/theoncologist.2014-0184

Jerusalem, G., de Boer, R. H., Hurvitz, S., Yardley, D. A., Kovalenko, E., Ejlertsen, B., . . . Burris, H. (2018). Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol, 4(10), 1367-1374. doi:10.1001/jamaoncol.2018.2262

Jin, H., Tu, D., Zhao, N., Shepherd, L. E., & Goss, P. E. (2012). Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol, 30(7), 718-721. doi:10.1200/jco.2010.34.4010

Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., . . . Kellokumpu-Lehtinen, P. L. (2009). Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol, 27(34), 5685-5692. doi:10.1200/jco.2008.21.4577

Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., . . . Lindman, H. (2017). A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer. Paper presented at the San Antonio Breast Cancer Symposium - December 5-9, 2017. 

Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., . . . Isola, J. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med, 354(8), 809-820. doi:10.1056/NEJMoa053028

Joensuu, H., Kellokumpu-Lehtinen, P. L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Asola, R., . . . Lindman, H. (2009). Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol, 10(12), 1145-1151. doi:10.1016/s1470-2045(09)70307-9

Johansson, A. L., Andersson, T. M., Hsieh, C. C., Jirstrom, K., Dickman, P., Cnattingius, S., & Lambe, M. (2013). Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat, 139(1), 183-192. doi:10.1007/s10549-013-2522-1

Johansson, A. L. V., Andersson, T. M., Hsieh, C. C., Jirstrom, K., Cnattingius, S., Fredriksson, I., . . . Lambe, M. (2018). Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer, 142(7), 1343-1354. doi:10.1002/ijc.31174

Johansson, L. A., Bjorkenstam, C., & Westerling, R. (2009). Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995. J Clin Epidemiol, 62(11), 1202-1209. doi:10.1016/j.jclinepi.2009.01.010

Johansson, S., Svensson, H., & Denekamp, J. (2002). Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys, 52(5), 1207-1219. 

Johnson, K. C., Miller, A. B., Collishaw, N. E., Palmer, J. R., Hammond, S. K., Salmon, A. G., . . . Turcotte, F. (2011). Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control, 20(1), e2. doi:10.1136/tc.2010.035931

Johnsson, A., Fornander, T., Rutqvist, L. E., & Olsson, M. (2010). Factors influencing return to work: a narrative study of women treated for breast cancer. Eur J Cancer Care (Engl), 19(3), 317-323. doi:10.1111/j.1365-2354.2008.01043.x

Johnston, S., Martin, M., Di Leo, A., Im, S. A., Awada, A., Forrester, T., . . . Goetz, M. P. (2019). MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer, 5, 5. doi:10.1038/s41523-018-0097-z

Johnston, S., Pippen, J., Jr., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., . . . Pegram, M. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 27(33), 5538-5546. doi:10.1200/JCO.2009.23.3734

Johnston, S. J., Kenny, F. S., Syed, B. M., Robertson, J. F., Pinder, S. E., Winterbottom, L., . . . Cheung, K. L. (2012). A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol, 23(9), 2296-2300. doi:10.1093/annonc/mdr630

Johnston, S. R. (2006). Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res, 12(3 Pt 2), 1061s-1068s. doi:10.1158/1078-0432.CCR-05-2125

Johnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., . . . Bliss, J. M. (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol, 14(10), 989-998. doi:10.1016/s1470-2045(13)70322-x

Johnston, S. R. D., Hegg, R., Im, S. A., Park, I. H., Burdaeva, O., Kurteva, G., . . . Gradishar, W. J. (2018). Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. J Clin Oncol, 36(8), 741-748. doi:10.1200/jco.2017.74.7824

Jones, S., Winer, E., Vogel, C., Laufman, L., Hutchins, L., O'Rourke, M., . . . Hohneker, J. (1995). Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol, 13(10), 2567-2574. 

Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., . . . Ravdin, P. M. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 23(24), 5542-5551. doi:10.1200/jco.2005.02.027

Josefsson, M. L., & Leinster, S. J. (2010). Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast, 19(2), 76-83. doi:10.1016/j.breast.2009.12.010

Jozan, S., Kreitmann, B., & Bayard, F. (1981). Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. Acta Endocrinol (Copenh), 98(1), 73-80. 

Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., . . . Baselga, J. (2018). Phosphatidylinositol 3-Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol, 36(13), 1291-1299. doi:10.1200/jco.2017.72.7107

Kaas, R., Verhoef, S., Wesseling, J., Rookus, M. A., Oldenburg, H. S., Peeters, M. J., & Rutgers, E. J. (2010). Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg, 251(3), 488-492. doi:10.1097/SLA.0b013e3181c3c36d

Kakoulidis, I., Skagias, L., & Politi, E. (2015). Pregnancy associated breast cancer (PABC): aspects in diagnosis. Breast Dis, 35(3), 157-166. doi:10.3233/bd-150408

Kal, H. B., & Struikmans, H. (2005). Radiotherapy during pregnancy: fact and fiction. Lancet Oncol, 6(5), 328-333. doi:10.1016/s1470-2045(05)70169-8

Kalager, M., Zelen, M., Langmark, F., & Adami, H. O. (2010). Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med, 363(13), 1203-1210. doi:10.1056/NEJMoa1000727

Kalam, K., & Marwick, T. H. (2013). Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer, 49(13), 2900-2909. doi:10.1016/j.ejca.2013.04.030

Kanal, E., Barkovich, A. J., Bell, C., Borgstede, J. P., Bradley, W. G., Jr., Froelich, J. W., . . . Hernandez, D. (2013). ACR guidance document on MR safe practices: 2013. J Magn Reson Imaging, 37(3), 501-530. doi:10.1002/jmri.24011

Kantor, O., Pesce, C., Liederbach, E., Wang, C. H., Winchester, D. J., & Yao, K. (2016). Surgery and hormone therapy trends in octogenarians with invasive breast cancer. Am J Surg, 211(3), 541-545. doi:10.1016/j.amjsurg.2015.11.005

Kaplan, S. S. (2001). Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology, 221(3), 641-649. 

Karavasilis, V., Papadimitriou, C., Gogas, H., Kouvatseas, G., Pentheroudakis, G., Koutras, A., . . . Fountzilas, G. (2016). Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clin Breast Cancer, 16(4), 291-298.e293. doi:10.1016/j.clbc.2015.12.001

Karlsson, E., Appelgren, J., Solterbeck, A., Bergenheim, M., Alvariza, V., & Bergh, J. (2014). Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. Eur J Cancer, 50(17), 2916-2924. doi:10.1016/j.ejca.2014.08.014

Kataoka, M., Yamaguchi, Y., Moriya, Y., Sawada, N., Yasuno, H., Kondoh, K., . . . Hayashi, S. (2012). Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. Oncol Rep, 27(2), 303-310. doi:10.3892/or.2011.1541

Kauff, N. D., & Barakat, R. R. (2007). Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol, 25(20), 2921-2927. doi:10.1200/jco.2007.11.3449

Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., . . . Jones, A. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol, 27(33), 5529-5537. doi:10.1200/JCO.2008.20.6847

Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., . . . Cortes, J. (2015). Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J Clin Oncol. doi:10.1200/jco.2013.52.4892

Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., . . . Massimini, G. (2000). Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol, 18(7), 1399-1411. 

Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J. M., Erazo, A., Lluch, A., . . . Tendler, C. (2004). Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol, 22(19), 3893-3901. doi:10.1200/JCO.2004.08.157

Kemeny, M. M. (2004). Surgery in older patients. Semin Oncol, 31(2), 175-184. 

Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol, 17(4), 584-587. 

Kenemans, P., Bundred, N. J., Foidart, J. M., Kubista, E., von Schoultz, B., Sismondi, P., . . . Beckmann, M. W. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol, 10(2), 135-146. doi:10.1016/s1470-2045(08)70341-3

Kenis, C., Bron, D., Libert, Y., Decoster, L., Van Puyvelde, K., Scalliet, P., . . . Wildiers, H. (2013). Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol, 24(5), 1306-1312. doi:10.1093/annonc/mds619

Kennedy, F., Haslam, C., Munir, F., & Pryce, J. (2007). Returning to work following cancer: a qualitative exploratory study into the experience of returning to work following cancer. Eur J Cancer Care (Engl), 16(1), 17-25. doi:10.1111/j.1365-2354.2007.00729.x

Kenny, F. S., Robertson, J. F. R., Ellis, I. O., Elston, C.W., Blamey, R. W. (1998). Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. The Breast, 7, 335-339. 

Keulers, B. J., Scheltinga, M. R., Houterman, S., Van Der Wilt, G. J., & Spauwen, P. H. (2008). Surgeons underestimate their patients' desire for preoperative information. World J Surg, 32(6), 964-970. doi:10.1007/s00268-008-9581-1

Key, T. J. (2011). Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids, 76(8), 812-815. doi:10.1016/j.steroids.2011.02.029

Khan, A. A., Hernan, I., Adamthwaite, J. A., & Ramsey, K. W. D. (2019). Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis surgery for breast cancer-related lymphoedema. Br J Surg, 106(1), 100-110. doi:10.1002/bjs.10983

Khatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., . . . Davidson, N. E. (2013). Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31(7), 961-965. doi:10.1200/jco.2012.45.9859

Khera, S. Y., Kiluk, J. V., Hasson, D. M., Meade, T. L., Meyers, M. P., Dupont, E. L., . . . Cox, C. E. (2008). Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J, 14(3), 250-254. doi:10.1111/j.1524-4741.2008.00570.x

Khouri, R. K., Rigotti, G., Khouri, R. K., Jr., Cardoso, E., Marchi, A., Rotemberg, S. C., . . . Biggs, T. M. (2015). Tissue-engineered breast reconstruction with Brava-assisted fat grafting: a 7-year, 488-patient, multicenter experience. Plast Reconstr Surg, 135(3), 643-658. doi:10.1097/prs.0000000000001039

Kiely, B. E., Soon, Y. Y., Tattersall, M. H., & Stockler, M. R. (2011). How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol, 29(4), 456-463. doi:10.1200/JCO.2010.30.2174

Killander, F., Karlsson, P., Anderson, H., Mattsson, J., Holmberg, E., Lundstedt, D., . . . Malmstrom, P. (2016). No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT. Eur J Cancer, 67, 57-65. doi:10.1016/j.ejca.2016.08.001

Kilpivaara, O., Vahteristo, P., Falck, J., Syrjakoski, K., Eerola, H., Easton, D., . . . Nevanlinna, H. (2004). CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer, 111(4), 543-547. doi:10.1002/ijc.20299

Kim, Y. J., Shin, K. H., & Kim, K. (2019). Omitting Adjuvant Radiotherapy for Hormone ReceptorPositive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis. Cancer Res Treat, 51(1), 326-336. doi:10.4143/crt.2018.163

Kimmick, G., Fleming, S. T., Sabatino, S. A., Wu, X. C., Hwang, W., Wilson, J. F., . . . Anderson, R. T. (2014). Comorbidity burden and guideline-concordant care for breast cancer. J Am Geriatr Soc, 62(3), 482-488. doi:10.1111/jgs.12687

Kindts, I., Laenen, A., Depuydt, T., & Weltens, C. (2017). Tumour bed boost radiotherapy for women after breast-conserving surgery. Cochrane Database Syst Rev, 11, Cd011987. doi:10.1002/14651858.CD011987.pub2

King, M. C., Marks, J. H., & Mandell, J. B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-646. doi:10.1126/science.1088759

Kiricuta, C. I., & Tausch, J. (1992). A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer, 69(10), 2496-2501. 

Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., . . . Fourquet, A. (2010). Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat, 120(1), 119-126. doi:10.1007/s10549-009-0685-6

Kissin, M. W., Querci della Rovere, G., Easton, D., & Westbury, G. (1986). Risk of lymphoedema following the treatment of breast cancer. Br J Surg, 73(7), 580-584. 

Klijn, J. G., Blamey, R. W., Boccardo, F., Tominaga, T., Duchateau, L., Sylvester, R., . . . Treatment of, C. (2001). Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol, 19(2), 343-353. 

Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., . . . Mueller, R. P. (2011). Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol, 29(2), 134-141. doi:10.1200/jco.2010.30.1655

Koinberg, I., Langius-Eklof, A., Holmberg, L., & Fridlund, B. (2006). The usefulness of a multidisciplinary educational programme after breast cancer surgery: a prospective and comparative study. Eur J Oncol Nurs, 10(4), 273-282. doi:10.1016/j.ejon.2005.11.005

Koinberg, I. L., Fridlund, B., Engholm, G. B., & Holmberg, L. (2004). Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs, 8(2), 109-117; discussion 118-120. doi:10.1016/j.ejon.2003.12.005

Kolb, T. M., Lichy, J., & Newhouse, J. H. (2002). Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology, 225(1), 165-175. 

Kolben, T., Schwarz, T. M., Goess, C., Blume, C., Degenhardt, T., Engel, J., . . . Kahlert, S. (2015). Surgical management of ipsilateral breast tumor recurrence. Int J Surg, 23(Pt A), 141-146. doi:10.1016/j.ijsu.2015.08.084

Kondziolka, D., Kano, H., Harrison, G. L., Yang, H. C., Liew, D. N., Niranjan, A., . . . Lunsford, L. D. (2011). Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg, 114(3), 792-800. doi:10.3171/2010.8.jns10461

Kooistra, B., Wauters, C., Strobbe, L., & Wobbes, T. (2010). Preoperative cytological and histological diagnosis of breast lesions: A critical review. Eur J Surg Oncol, 36(10), 934-940. doi:10.1016/j.ejso.2010.06.014

Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., . . . Sparano, J. A. (2018). Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol, 36(16), 1556-1563. doi:10.1200/jco.2017.76.9331

Kotsopoulos, J., Huzarski, T., Gronwald, J., Singer, C. F., Moller, P., Lynch, H. T., . . . Narod, S. A. (2017). Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst, 109(1). doi:10.1093/jnci/djw177

Kourie, H. R., Chaix, M., Gombos, A., Aftimos, P., & Awada, A. (2016). Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol, 12(8), 947-957. doi:10.1080/17425255.2016.1198317

Kozak, M. M., Xiang, M., Pollom, E. L., & Horst, K. C. (2019). Adjuvant treatment and survival in older women with triple negative breast cancer: A Surveillance, Epidemiology, and End Results analysis. Breast J, 25(3), 469-473. doi:10.1111/tbj.13251

Krag, D., Weaver, D., Ashikaga, T., Moffat, F., Klimberg, V. S., Shriver, C., . . . Beitsch, P. (1998). The sentinel node in breast cancer--a multicenter validation study. N Engl J Med, 339(14), 941-946. doi:10.1056/nejm199810013391401

Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Ashikaga, T., . . . Wolmark, N. (2007). Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol, 8(10), 881-888. doi:10.1016/s1470-2045(07)70278-4

Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., . . . Wolmark, N. (2010). Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 11(10), 927-933. doi:10.1016/s1470-2045(10)70207-2

Kreike, B., Hart, A. A., van de Velde, T., Borger, J., Peterse, H., Rutgers, E., . . . van de Vijver, M. J. (2008). Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys, 71(4), 1014-1021. doi:10.1016/j.ijrobp.2007.11.029

Kristensen, B., Ejlertsen, B., Mouridsen, H. T., Jensen, M. B., Andersen, J., Bjerregaard, B., . . . Bergh, J. (2008). Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol, 47(4), 740-746. doi:10.1080/02841860801964988

Kronowitz, S. J., Feledy, J. A., Hunt, K. K., Kuerer, H. M., Youssef, A., Koutz, C. A., & Robb, G. L. (2006). Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg, 117(1), 1-11; discussion 12-14. 

Kronowitz, S. J., Mandujano, C. C., Liu, J., Kuerer, H. M., Smith, B., Garvey, P., . . . Valero, V. (2016). Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg, 137(2), 385-393. doi:10.1097/01.prs.0000475741.32563.50

Kronowitz, S. J., & Robb, G. L. (2004). Breast reconstruction with postmastectomy radiation therapy: current issues. Plast Reconstr Surg, 114(4), 950-960. 

Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., . . . Stearns, V. (2017). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol, 35(24), 2838-2847. doi:10.1200/jco.2017.74.0472

Krop, I. E., Kim, S. B., Martin, A. G., LoRusso, P. M., Ferrero, J. M., Badovinac-Crnjevic, T., . . . Wildiers, H. (2017). Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol, 18(6), 743-754. doi:10.1016/s1470-2045(17)30313-3

Krueger, E. A., Wilkins, E. G., Strawderman, M., Cederna, P., Goldfarb, S., Vicini, F. A., & Pierce, L. J. (2001). Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J Radiat Oncol Biol Phys, 49(3), 713-721. 

Krumboeck, A., Giovanoli, P., & Plock, J. A. (2013). Fat grafting and stem cell enhanced fat grafting to the breast under oncological aspects--recommendations for patient selection. Breast, 22(5), 579-584. doi:10.1016/j.breast.2013.05.006

Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., . . . Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama, 317(23), 2402-2416. doi:10.1001/jama.2017.7112

Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., . . . Untch, M. (2013). Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol, 14(7), 609-618. doi:10.1016/s1470-2045(13)70166-9

Kuehn, T., Vogl, F. D., Helms, G., Pueckler, S. V., Schirrmeister, H., Strueber, R., . . . Kreienberg, R. (2004). Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol, 30(3), 252-259. doi:10.1016/j.ejso.2003.11.016

Kummel, S., Holtschmidt, J., & Loibl, S. (2014). Surgical treatment of primary breast cancer in the neoadjuvant setting. Br J Surg, 101(8), 912-924. doi:10.1002/bjs.9545

Kunkler, I. H., Williams, L. J., Jack, W. J., Cameron, D. A., & Dixon, J. M. (2015). Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol, 16(3), 266-273. doi:10.1016/s1470-2045(14)71221-5

Kuo, S. H., Huang, C. S., Kuo, W. H., Cheng, A. L., Chang, K. J., & Chia-Hsien Cheng, J. (2008). Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. Int J Radiat Oncol Biol Phys, 72(5), 1456-1464. doi:10.1016/j.ijrobp.2008.03.042

Kusano, A. S., Trichopoulos, D., Terry, K. L., Chen, W. Y., Willett, W. C., & Michels, K. B. (2006). A prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer, 118(8), 2031-2034. doi:10.1002/ijc.21588

Kwa, M. J., & Adams, S. (2018). Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer, 124(10), 2086-2103. doi:10.1002/cncr.31272

L'Esperance, S., Frenette, S., Dionne, A., & Dionne, J. Y. (2013). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer, 21(5), 1461-1474. doi:10.1007/s00520-013-1732-8

Laenkholm, A. V., Jensen, M. B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., . . . Ejlertsen, B. (2018). PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. J Clin Oncol, 36(8), 735-740. doi:10.1200/jco.2017.74.6586

Lagendijk, M., van Maaren, M. C., Saadatmand, S., Strobbe, L. J. A., Poortmans, P. M. P., Koppert, L. B., . . . Siesling, S. (2018). Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. Int J Cancer, 142(1), 165-175. doi:10.1002/ijc.31034

Lakhani, S. R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J. (2012). WHO Classification of Tumours (Vol. 4). Lyon: International Agency for Research on Cancer (IARC).

Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., . . . Del Mastro, L. (2015). Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. Jama, 314(24), 2632-2640. doi:10.1001/jama.2015.17291

Lambertini, M., Ferreira, A. R., Di Meglio, A., Poggio, F., Puglisi, F., Sottotetti, F., . . . Del Mastro, L. (2017). Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients&#xa0;With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. Clin Breast Cancer, 17(8), 601-610.e602. doi:10.1016/j.clbc.2017.04.002

Lambertini, M., Kamal, N. S., Peccatori, F. A., Del Mastro, L., & Azim, H. A., Jr. (2015). Exploring the safety of chemotherapy for treating breast cancer during pregnancy. Expert Opin Drug Saf, 14(9), 1395-1408. doi:10.1517/14740338.2015.1061500

Lambertini, M., Kroman, N., Ameye, L., Cordoba, O., Pinto, A., Benedetti, G., . . . Azim, H. A., Jr. (2018). Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. J Natl Cancer Inst, 110(4), 426-429. doi:10.1093/jnci/djx206

Lambertini, M., Moore, H. C. F., Leonard, R. C. F., Loibl, S., Munster, P., Bruzzone, M., . . . Del Mastro, L. (2018). Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol, 36(19), 1981-1990. doi:10.1200/jco.2018.78.0858

Langagergaard, V., Gislum, M., Skriver, M. V., Norgard, B., Lash, T. L., Rothman, K. J., & Sorensen, H. T. (2006). Birth outcome in women with breast cancer. Br J Cancer, 94(1), 142-146. doi:10.1038/sj.bjc.6602878

Langley, R. E., Carmichael, J., Jones, A. L., Cameron, D. A., Qian, W., Uscinska, B., . . . Parmar, M. (2005). Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol, 23(33), 8322-8330. doi:10.1200/JCO.2005.01.1817

Lanitis, S., Tekkis, P. P., Sgourakis, G., Dimopoulos, N., Al Mufti, R., & Hadjiminas, D. J. (2010). Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg, 251(4), 632-639. doi:10.1097/SLA.0b013e3181d35bf8

Lanning, R. M., Morrow, M., Riaz, N., McArthur, H. L., Dang, C., Moo, T. A., . . . Ho, A. (2015). The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. Ann Surg Oncol, 22(8), 2517-2525. doi:10.1245/s10434-014-4321-2

Larsson, S. C., Mantzoros, C. S., & Wolk, A. (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer, 121(4), 856-862. doi:10.1002/ijc.22717

Lavelle, K., Todd, C., Moran, A., Howell, A., Bundred, N., & Campbell, M. (2007). Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer, 96(8), 1197-1203. doi:10.1038/sj.bjc.6603709

Leach, M. O., Boggis, C. R., Dixon, A. K., Easton, D. F., Eeles, R. A., Evans, D. G., . . . Warren, R. M. (2005). Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet, 365(9473), 1769-1778. doi:10.1016/s0140-6736(05)66481-1

Leach, M. O., Eeles, R. A., Turnbull, L. W., Dixon, A. K., Brown, J., Hoff, R. J., . . . Rubin, C. (2002). The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res, 21(3 Suppl), 107-114. 

Lehman, C. D., Isaacs, C., Schnall, M. D., Pisano, E. D., Ascher, S. M., Weatherall, P. T., . . . Gatsonis, C. (2007). Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology, 244(2), 381-388. doi:10.1148/radiol.2442060461

Leidenius, M. H., Vironen, J. H., Riihela, M. S., Krogerus, L. A., Toivonen, T. S., von Smitten, K. A., & Heikkila, P. S. (2005). The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Eur J Surg Oncol, 31(1), 13-18. doi:10.1016/j.ejso.2004.09.012

LeMasters, T., Madhavan, S. S., Sambamoorthi, U., Hazard-Jenkins, H. W., Kelly, K. M., & Long, D. (2018). Receipt of Guideline-Concordant Care Among Older Women With Stage I-III Breast Cancer: A Population-Based Study. J Natl Compr Canc Netw, 16(6), 703-710. doi:10.6004/jnccn.2018.7004

Lemos Duarte, I., da Silveira Nogueira Lima, J. P., Passos Lima, C. S., & Deeke Sasse, A. (2012). Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast, 21(3), 343-349. doi:10.1016/j.breast.2012.02.011

Leonard, R. C., Lind, M., Twelves, C., Coleman, R., van Belle, S., Wilson, C., . . . Crown, J. (2004). Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst, 96(14), 1076-1083. doi:10.1093/jnci/djh188

Leonard, R. C. F., Adamson, D. J. A., Bertelli, G., Mansi, J., Yellowlees, A., Dunlop, J., . . . Anderson, R. A. (2017). GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol, 28(8), 1811-1816. doi:10.1093/annonc/mdx184

Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., . . . Kote-Jarai, Z. (2012). Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer, 106(10), 1697-1701. doi:10.1038/bjc.2012.146

Li-Fraumeni Syndrome 2013 (2013). In.

Li, T., Marinovich, M. L., & Houssami, N. (2018). Digital breast tomosynthesis (3D mammography) for breast cancer screening and for assessment of screen-recalled findings: review of the evidence. Expert Rev Anticancer Ther, 18(8), 785-791. doi:10.1080/14737140.2018.1483243

Liberman, L., Giess, C. S., Dershaw, D. D., Deutch, B. M., & Petrek, J. A. (1994). Imaging of pregnancy-associated breast cancer. Radiology, 191(1), 245-248. 

Liedtke, C., Jackisch, C., Thill, M., Thomssen, C., Muller, V., & Janni, W. (2018). AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018. Breast Care (Basel), 13(3), 196-208. doi:10.1159/000489329

Liljegren, A., Gunnarsson, P., Landgren, B. M., Robeus, N., Johansson, H., & Rotstein, S. (2012). Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Res Treat, 135(3), 791-798. doi:10.1007/s10549-010-1283-3

Liljegren, G., & Holmberg, L. (1997). Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer, 33(2), 193-199. 

Lin, N. U., Dieras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H. J., . . . Winer, E. P. (2009). Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res, 15(4), 1452-1459. doi:10.1158/1078-0432.CCR-08-1080

Lin, N. U., Thomssen, C., Cardoso, F., Cameron, D., Cufer, T., Fallowfield, L., . . . Force, E.-M. T. (2013). International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast, 22(3), 203-210. doi:10.1016/j.breast.2013.03.006

Lin, P. P., Allison, D. C., Wainstock, J., Miller, K. D., Dooley, W. C., Friedman, N., & Baker, R. R. (1993). Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol, 11(8), 1536-1544. 

Lin, Y., Wang, C., Zhong, Y., Huang, X., Peng, L., Shan, G., . . . Sun, Q. (2013). Striking life events associated with primary breast cancer susceptibility in women: a meta-analysis study. J Exp Clin Cancer Res, 32(1), 53. doi:10.1186/1756-9966-32-53

Lind, P. A., Wennberg, B., Gagliardi, G., & Fornander, T. (2001). Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast Cancer Res Treat, 68(3), 199-210. 

Lindegren, A., Schultz, I., Sinha, I., Cheung, L., Khan, A. A., Tekle, M., . . . Halle, M. (2019). Autologous fat transplantation alters gene expression patterns related to inflammation and hypoxia in the irradiated human breast. Br J Surg, 106(5), 563-573. doi:10.1002/bjs.11072

Lindstrom, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., . . . Bergh, J. (2012). Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol, 30(21), 2601-2608. doi:10.1200/jco.2011.37.2482

Lindström, L., Howell, Sacha., Åström, G., Wilking, U., Lidbrin, E., Armstrong, A., Karlsson, E., Hatschek,Thomas., Bergh, J. (2010). Controversies in the Management of Metastatic Breast Cancer: Biologic Evaluation of Breast Cancer - should metastases be biopsied? : American Society of Clinical Oncology.

Linsell, L., Burgess, C. C., & Ramirez, A. J. (2008). Breast cancer awareness among older women. Br J Cancer, 99(8), 1221-1225. doi:10.1038/sj.bjc.6604668

Lippitz, B., Lindquist, C., Paddick, I., Peterson, D., O'Neill, K., & Beaney, R. (2014). Stereotactic radiosurgery in the treatment of brain metastases: The current evidence. Cancer Treat Rev, 40(1), 48-59. doi:10.1016/j.ctrv.2013.05.002

Lithner, M. Z., T. (1998). Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). Vård i Norden (Vol. 18).

Litiere, S., Werutsky, G., Fentiman, I. S., Rutgers, E., Christiaens, M. R., Van Limbergen, E., . . . Bartelink, H. (2012). Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol, 13(4), 412-419. doi:10.1016/s1470-2045(12)70042-6

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Goncalves, A., Lee, K. H., . . . Blum, J. L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med, 379(8), 753-763. doi:10.1056/NEJMoa1802905

Litton, J. K., Warneke, C. L., Hahn, K. M., Palla, S. L., Kuerer, H. M., Perkins, G. H., . . . Theriault, R. L. (2013). Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist, 18(4), 369-376. doi:10.1634/theoncologist.2012-0340

Liu, F. F., Shi, W., Done, S. J., Miller, N., Pintilie, M., Voduc, D., . . . Fyles, A. W. (2015). Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. J Clin Oncol, 33(18), 2035-2040. doi:10.1200/jco.2014.57.7999

Liu, T., Freijs, C., Klein, H. J., Feinbaum, A., Svee, A., Lorenzo, A. R., . . . Mani, M. (2018). Patients with abdominal-based free flap breast reconstruction a decade after surgery: A comprehensive long-term follow-up study. J Plast Reconstr Aesthet Surg, 71(9), 1301-1309. doi:10.1016/j.bjps.2018.06.009

Liu, Y., Ye, G., Yan, D.,  Zhang, L., Fan, F., Feng, J. (2017). Role of nab-paclitaxel in metastatic breast cancer: a metaanalysis of randomized clinical trials. Retrieved from www.impactjournals.com/oncotarget/

Ljungman, P., Bjorkstrand, B., Fornander, T., Hoglund, M., Juliusson, G., Lindman, H., . . . Bergh, J. (1998). High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. Bone Marrow Transplant, 22(5), 445-448. doi:10.1038/sj.bmt.1701367

Lobbezoo, D. J., van Kampen, R. J., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F., Smilde, T. J., . . . Tjan-Heijnen, V. C. (2016). In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol, 27(2), 256-262. doi:10.1093/annonc/mdv544

Loblaw, D. A., Mitera, G., Ford, M., & Laperriere, N. J. (2012). A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys, 84(2), 312-317. doi:10.1016/j.ijrobp.2012.01.014

Loch-Wilkinson, A., Beath, K. J., Knight, R. J. W., Wessels, W. L. F., Magnusson, M., Papadopoulos, T., . . . Deva, A. K. (2017). Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. Plast Reconstr Surg, 140(4), 645-654. doi:10.1097/prs.0000000000003654

Lohmander, F., Lagergren, J., Roy, P. G., Johansson, H., Brandberg, Y., Eriksen, C., & Frisell, J. (2019). Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment. Ann Surg, 269(5), 836-841. doi:10.1097/sla.0000000000003054

Lohsiriwat, V., Peccatori, F. A., Martella, S., Azim, H. A., Jr., Sarno, M. A., Galimberti, V., . . . Gentilini, O. (2013). Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast, 22(5), 657-660. doi:10.1016/j.breast.2013.06.005

Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., . . . Amant, F. (2012). Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol, 13(9), 887-896. doi:10.1016/s1470-2045(12)70261-9

Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., . . . Geyer, C. E., Jr. (2018). Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol, 19(4), 497-509. doi:10.1016/s1470-2045(18)30111-6

Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., . . . Amant, F. (2015). Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol, 1(8), 1145-1153. doi:10.1001/jamaoncol.2015.2413

Loibl, S., von Minckwitz, G., Gwyn, K., Ellis, P., Blohmer, J. U., Schlegelberger, B., . . . Kaufmann, M. (2006). Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer, 106(2), 237-246. doi:10.1002/cncr.21610

Long, H. D., Lin, Y. E., Zhang, J. J., Zhong, W. Z., & Zheng, R. N. (2016). Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis. Oncologist, 21(5), 547-554. doi:10.1634/theoncologist.2015-0424

Lonning, P. E., & Geisler, J. (2008). Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opin Drug Metab Toxicol, 4(7), 987-997. doi:10.1517/17425255.4.7.987

Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., . . . Christensen, B. J. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet, 356(9247), 2059-2063. doi:10.1016/s0140-6736(00)03403-6

Lotz, J. P., Cure, H., Janvier, M., Asselain, B., Morvan, F., Legros, M., . . . Gisselbrecht, C. (2005). High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer, 41(1), 71-80. doi:10.1016/j.ejca.2004.09.006

Louwman, W. J., Vulto, J. C., Verhoeven, R. H., Nieuwenhuijzen, G. A., Coebergh, J. W., & Voogd, A. C. (2007). Clinical epidemiology of breast cancer in the elderly. Eur J Cancer, 43(15), 2242-2252. doi:10.1016/j.ejca.2007.08.005

Lowery, A. J., Kell, M. R., Glynn, R. W., Kerin, M. J., & Sweeney, K. J. (2012). Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat, 133(3), 831-841. doi:10.1007/s10549-011-1891-6

Lu, K. H., Garber, J. E., Cramer, D. W., Welch, W. R., Niloff, J., Schrag, D., . . . Muto, M. G. (2000). Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol, 18(14), 2728-2732. 

Luck, H., Thomssen, C., Untch, M. et al. (2000). Multicentric phase III study in first line treatment of advanced breast cancer (ABC): Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC) Paper presented at the ASCO Annual meeting, New Orleans. 

Ludwig, K. K., Neuner, J., Butler, A., Geurts, J. L., & Kong, A. L. (2016). Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg, 212(4), 660-669. doi:10.1016/j.amjsurg.2016.06.010

Lundstedt, D., Gustafsson, M., Steineck, G., Sundberg, A., Wilderang, U., Holmberg, E., . . . Karlsson, P. (2015). Radiation Therapy to the Plexus Brachialis in Breast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume. Int J Radiat Oncol Biol Phys, 92(2), 277-283. doi:10.1016/j.ijrobp.2015.01.016

Luo, M., Zeng, J., Li, F., He, L., & Li, T. (2014). Safety of pregnancy after surgical treatment for breast cancer: a meta-analysis. Int J Gynecol Cancer, 24(8), 1366-1372. doi:10.1097/igc.0000000000000242

Lynch, S. P., Lei, X., Hsu, L., Meric-Bernstam, F., Buchholz, T. A., Zhang, H., . . . Valero, V. (2013). Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist, 18(11), 1167-1173. doi:10.1634/theoncologist.2013-0167

Lyytinen, H. K., Dyba, T., Ylikorkala, O., & Pukkala, E. I. (2010). A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer, 126(2), 483-489. doi:10.1002/ijc.24738

Maaskant-Braat, A. J., Roumen, R. M., Voogd, A. C., Pijpers, R., Luiten, E. J., Rutgers, E. J., & Nieuwenhuijzen, G. A. (2013). Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol, 20(2), 620-626. doi:10.1245/s10434-012-2625-7

Maaskant-Braat, A. J., Voogd, A. C., Roumen, R. M., & Nieuwenhuijzen, G. A. (2013). Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat, 138(1), 13-20. doi:10.1007/s10549-013-2409-1

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

Maclennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev(4), Cd002978. doi:10.1002/14651858.CD002978.pub2

Magnusson, C. R., G. (2005). Hormonbehandling i klimakteriet ökar risken för bröstcancer Läkartidningen, 102.

Maguire, G. P., Lee, E. G., Bevington, D. J., Kuchemann, C. S., Crabtree, R. J., & Cornell, C. E. (1978). Psychiatric problems in the first year after mastectomy. Br Med J, 1(6118), 963-965. 

Mahajan, A., Ahmed, S., McAleer, M. F., Weinberg, J. S., Li, J., Brown, P., . . . Rao, G. (2017). Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol, 18(8), 1040-1048. doi:10.1016/s1470-2045(17)30414-x

Maisonneuve, P., Disalvatore, D., Rotmensz, N., Curigliano, G., Colleoni, M., Dellapasqua, S., . . . Goldhirsch, A. (2014). Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res, 16(3), R65. doi:10.1186/bcr3679

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter. , 102.

Malmstrom, P., Holmberg, L., Anderson, H., Mattsson, J., Jonsson, P. E., Tennvall-Nittby, L., . . . Wallgren, A. (2003). Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer, 39(12), 1690-1697. 

Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L., . . . Bernstein, J. L. (2010). Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol, 28(14), 2404-2410. doi:10.1200/jco.2009.24.2495

Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Jr., Rastogi, P., . . . Wolmark, N. (2019). Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 20(1), 88-99. doi:10.1016/s1470-2045(18)30621-1

Mamounas, E. P., Jeong, J. H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., . . . Wolmark, N. (2008). Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol, 26(12), 1965-1971. doi:10.1200/jco.2007.14.0228

Manabe, J., Kawaguchi, N., Matsumoto, S., & Tanizawa, T. (2005). Surgical treatment of bone metastasis: indications and outcomes. Int J Clin Oncol, 10(2), 103-111. doi:10.1007/s10147-005-0478-9

Mani, M., Wang, T., Harris, P., & James, S. (2016). Breast reconstruction with the deep inferior epigastric perforator flap is a reliable alternative in slim patients. Microsurgery, 36(7), 552-558. doi:10.1002/micr.22524

Mann, R. M., Hoogeveen, Y. L., Blickman, J. G., & Boetes, C. (2008). MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat, 107(1), 1-14. doi:10.1007/s10549-007-9528-5

Mannino, M., & Yarnold, J. R. (2009). Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol, 90(1), 14-22. doi:10.1016/j.radonc.2008.05.002

Mansel, R. E., Fallowfield, L., Kissin, M., Goyal, A., Newcombe, R. G., Dixon, J. M., . . . Ell, P. J. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst, 98(9), 599-609. doi:10.1093/jnci/djj158

Margolese, R. G., Cecchini, R. S., Julian, T. B., Ganz, P. A., Costantino, J. P., Vallow, L. A., . . . Wolmark, N. (2016). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, 387(10021), 849-856. doi:10.1016/s0140-6736(15)01168-x

Marino, J. L., Saunders, C. M., Emery, L. I., Green, H., Doherty, D. A., & Hickey, M. (2014). Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause, 21(3), 267-274. doi:10.1097/GME.0b013e3182976f46

Marinovich, M. L., Azizi, L., Macaskill, P., Irwig, L., Morrow, M., Solin, L. J., & Houssami, N. (2016). The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol, 23(12), 3811-3821. doi:10.1245/s10434-016-5446-2

Marinovich, M. L., Hunter, K. E., Macaskill, P., & Houssami, N. (2018). Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall. J Natl Cancer Inst, 110(9), 942-949. doi:10.1093/jnci/djy121

Marmot, M. G., Altman, D. G., Cameron, D. A., Dewar, J. A., Thompson, S. G., & Wilcox, M. (2013). The benefits and harms of breast cancer screening: an independent review. Br J Cancer, 108(11), 2205-2240. doi:10.1038/bjc.2013.177

Martelli, G., Miceli, R., Costa, A., Coradini, D., Zurrida, S., Piromalli, D., . . . Greco, M. (2008). Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study. Cancer, 112(3), 481-488. doi:10.1002/cncr.23213

Martin, M., Bell, R., Bourgeois, H., Brufsky, A., Diel, I., Eniu, A., . . . Braun, A. (2012). Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res, 18(17), 4841-4849. doi:10.1158/1078-0432.CCR-11-3310

Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., . . . Chan, A. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 18(12), 1688-1700. doi:10.1016/s1470-2045(17)30717-9

Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., . . . Vogel, C. (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352(22), 2302-2313. 

Martín, M., Zielinski, C., Ruiz Borrego, M., & et al. (2019, December 10-14, 2019). Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at the 2019 San Antonio Breast Cancer Symposium, San Antonio, TX.

Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., . . . Extra, J. M. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23(19), 4265-4274. doi:10.1200/JCO.2005.04.173

Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., . . . Toi, M. (2017). Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med, 376(22), 2147-2159. doi:10.1056/NEJMoa1612645

Matuschek, C., Bolke, E., Haussmann, J., Mohrmann, S., Nestle-Kramling, C., Gerber, P. A., . . . Budach, W. (2017). The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol, 12(1), 60. doi:10.1186/s13014-017-0796-x

Mauri, D., Kamposioras, K., Tsali, L., Bristianou, M., Valachis, A., Karathanasi, I., . . . Polyzos, N. P. (2010). Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev, 36(1), 69-74. doi:10.1016/j.ctrv.2009.10.006

Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. (2006). Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst, 98(18), 1285-1291. doi:10.1093/jnci/djj357

Mazonakis, M., Tzedakis, A., & Damilakis, J. (2016). Monte Carlo Simulation of Radiotherapy for Breast Cancer in Pregnant Patients: How to Reduce the Radiation Dose and Risks to Fetus? Radiat Prot Dosimetry. doi:10.1093/rpd/ncw260

McArthur, H. L., Mahoney, K. M., Morris, P. G., Patil, S., Jacks, L. M., Howard, J., . . . Hudis, C. A. (2011). Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer, 117(24), 5461-5468. doi:10.1002/cncr.26171

McCarthy, C. M., Pusic, A. L., Disa, J. J., McCormick, B. L., Montgomery, L. L., & Cordeiro, P. G. (2005). Unilateral postoperative chest wall radiotherapy in bilateral tissue expander/implant reconstruction patients: a prospective outcomes analysis. Plast Reconstr Surg, 116(6), 1642-1647. 

McCarthy, C. M., Pusic, A. L., Sclafani, L., Buchanan, C., Fey, J. V., Disa, J. J., . . . Cordeiro, P. G. (2008). Breast cancer recurrence following prosthetic, postmastectomy reconstruction: incidence, detection, and treatment. Plast Reconstr Surg, 121(2), 381-388. doi:10.1097/01.prs.0000298316.74743.dd

McCollough, C. H., Schueler, B. A., Atwell, T. D., Braun, N. N., Regner, D. M., Brown, D. L., & LeRoy, A. J. (2007). Radiation exposure and pregnancy: when should we be concerned? Radiographics, 27(4), 909-917; discussion 917-908. doi:10.1148/rg.274065149

McCormack, V. A., & dos Santos Silva, I. (2006). Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15(6), 1159-1169. doi:10.1158/1055-9965.epi-06-0034

McCulley, S. J., & Macmillan, R. D. (2005). Planning and use of therapeutic mammoplasty--Nottingham approach. Br J Plast Surg, 58(7), 889-901. doi:10.1016/j.bjps.2005.03.008

McNaught, J., Reid, R. L., Provencher, D. M., Lea, R. H., Jeffrey, J. F., Oza, A., & Swenerton, K. D. (2006). Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Can, 28(7), 616-639. 

McPherson, K., Steel, C. M., & Dixon, J. M. (2000). ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. Bmj, 321(7261), 624-628. 

McTiernan, A., Irwin, M., & Vongruenigen, V. (2010). Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol, 28(26), 4074-4080. doi:10.1200/jco.2010.27.9752

Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., . . . Hortobagyi, G. N. (2012). Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med, 367(5), 435-444. doi:10.1056/NEJMoa1201622

Meijers-Heijboer, H., van Geel, B., van Putten, W. L., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B., . . . Klijn, J. G. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 345(3), 159-164. doi:10.1056/nejm200107193450301

Melamed, M., Castano, E., Notides, A. C., & Sasson, S. (1997). Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol, 11(12), 1868-1878. 

Melnikow, J., Fenton, J. J., Whitlock, E. P., Miglioretti, D. L., Weyrich, M. S., Thompson, J. H., & Shah, K. (2016). Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med, 164(4), 268-278. doi:10.7326/m15-1789

Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., . . . Turner, N. C. (2018). Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med, 142(10), 1242-1253. doi:10.5858/arpa.2018-0901-SA

Mestak, O., Hromadkova, V., Fajfrova, M., Molitor, M., & Mestak, J. (2016). Evaluation of Oncological Safety of Fat Grafting After Breast-Conserving Therapy: A Prospective Study. Ann Surg Oncol, 23(3), 776-781. doi:10.1245/s10434-015-4908-2

Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., . . . Narod, S. A. (2011). Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat, 127(1), 287-296. doi:10.1007/s10549-010-1336-7

Mettler, L., & Olsen, P. G. (1991). Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas, 14(1), 23-31. doi:0378-5122(91)90144-F [pii]

Meyer, L., & Aspegren, K. (1989). Long-term psychological sequelae of mastectomy and breast conserving treatment for breast cancer. Acta Oncol, 28(1), 13-18. 

Michels, K. B., Xue, F., Colditz, G. A., & Willett, W. C. (2007). Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med, 167(8), 814-820. doi:10.1001/archinte.167.8.814

Mieog, J. S., van der Hage, J. A., & van de Velde, C. J. (2007). Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev(2), CD005002. doi:10.1002/14651858.CD005002.pub2

Milano, M. T., Zhang, H., Metcalfe, S. K., Muhs, A. G., & Okunieff, P. (2009). Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat, 115(3), 601-608. doi:10.1007/s10549-008-0157-4

Miles, D., André, F., Gligorov, J., Verma, S., Xu, B., Cameron, D., . . . Shaughnessy, J. (2018). Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC). Cancer Research, 78(4 Supplement), OT1-01-01. doi:10.1158/1538-7445.SABCS17-OT1-01-01

Mirzabeigi, M. N., Lanni, M., Chang, C. S., Stark, R. Y., Kovach, S. J., Wu, L. C., . . . Bucky, L. P. (2017). Treating Breast Conservation Therapy Defects with Brava and Fat Grafting: Technique, Outcomes, and Safety Profile. Plast Reconstr Surg, 140(3), 372e-381e. doi:10.1097/prs.0000000000003626

Mishra, S. I., Scherer, R. W., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Gotay, C. C., & Snyder, C. (2012). Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev(8), Cd007566. doi:10.1002/14651858.CD007566.pub2

Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. M., Berlanstein, D. R., & Topaloglu, O. (2012). Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev(8), Cd008465. doi:10.1002/14651858.CD008465.pub2

Mitchell, G., Antoniou, A. C., Warren, R., Peock, S., Brown, J., Davies, R., . . . Easton, D. F. (2006). Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res, 66(3), 1866-1872. doi:10.1158/0008-5472.can-05-3368

Mitra, S., & Dey, P. (2016). Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature. Cytojournal, 13, 18. doi:10.4103/1742-6413.189637

Mjelstad, A., Zakariasson, G., & Valachis, A. (2019). Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration. Support Care Cancer. doi:10.1007/s00520-019-04676-6

Mocellin, S., Pilati, P., Briarava, M., & Nitti, D. (2016). Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. J Natl Cancer Inst, 108(2). doi:10.1093/jnci/djv318

Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D'Amico, R. (2012). Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev, 4, Cd006243. doi:10.1002/14651858.CD006243.pub2

Molckovsky, A., & Madarnas, Y. (2008). Breast cancer in pregnancy: a literature review. Breast Cancer Res Treat, 108(3), 333-338. doi:10.1007/s10549-007-9616-6

Moody, L. C., Wen, X., McKnight, T., & Chao, C. (2012). Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer. Surgery, 152(3), 389-396. doi:10.1016/j.surg.2012.06.017

Moore, H. C., Green, S. J., Gralow, J. R., Bearman, S. I., Lew, D., Barlow, W. E., . . . Martino, S. (2007). Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol, 25(13), 1677-1682. doi:10.1200/jco.2006.08.9383

Moore, H. C. F., Unger, J. M., Phillips, K. A., Boyle, F., Hitre, E., Moseley, A., . . . Albain, K. S. (2019). Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst, 111(2), 210-213. doi:10.1093/jnci/djy185

Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., . . . Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol, 31(33), 4188-4198. doi:10.1200/jco.2013.48.9021

Moran, A., O'Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., . . . Evans, D. G. (2012). Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer, 11(2), 235-242. doi:10.1007/s10689-011-9506-2

Moran, M. S., Colasanto, J. M., Haffty, B. G., Wilson, L. D., Lund, M. W., & Higgins, S. A. (2005). Effects of breast-conserving therapy on lactation after pregnancy. Cancer J, 11(5), 399-403. 

Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., . . . Morrow, M. (2014). Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol, 32(14), 1507-1515. doi:10.1200/jco.2013.53.3935

Morris, T., Greer, H. S., & White, P. (1977). Psychological and social adjustment to mastectomy: a two-year follow-up study. Cancer, 40(5), 2381-2387. 

Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., . . . Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol, 34(33), 4040-4046. doi:10.1200/jco.2016.68.3573

Mortenson, M. M., Schneider, P. D., Khatri, V. P., Stevenson, T. R., Whetzel, T. P., Sommerhaug, E. J., . . . Bold, R. J. (2004). Immediate breast reconstruction after mastectomy increases wound complications: however, initiation of adjuvant chemotherapy is not delayed. Arch Surg, 139(9), 988-991. doi:10.1001/archsurg.139.9.988

Moschetti, I., Cinquini, M., Lambertini, M., Levaggi, A., & Liberati, A. (2016). Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev(5), Cd001768. doi:10.1002/14651858.CD001768.pub3

Moser, K., Patnick, J., & Beral, V. (2007). Do women know that the risk of breast cancer increases with age? Br J Gen Pract, 57(538), 404-406. 

Moss, S. M., Nystrom, L., Jonsson, H., Paci, E., Lynge, E., Njor, S., & Broeders, M. (2012). The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. J Med Screen, 19 Suppl 1, 26-32. doi:10.1258/jms.2012.012079

Mougalian, S. S., Hernandez, M., Lei, X., Lynch, S., Kuerer, H. M., Symmans, W. F., . . . Valero, V. (2016). Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol, 2(4), 508-516. doi:10.1001/jamaoncol.2015.4935

Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., . . . Dugan, M. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 19(10), 2596-2606. 

Mourits, M. J., Bockermann, I., de Vries, E. G., van der Zee, A. G., ten Hoor, K. A., van der Graaf, W. T., . . . Willemse, P. H. (2002). Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer, 86(10), 1546-1550. doi:10.1038/sj.bjc.6600294

Muacevic, A., Kreth, F. W., Tonn, J. C., & Wowra, B. (2004). Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer, 100(8), 1705-1711. doi:10.1002/cncr.20167

Munhoz, A. M., Montag, E., Arruda, E. G., Aldrighi, C., Gemperli, R., Aldrighi, J. M., & Ferreira, M. C. (2006). Critical analysis of reduction mammaplasty techniques in combination with conservative breast surgery for early breast cancer treatment. Plast Reconstr Surg, 117(4), 1091-1103; discussion 1104-1097. doi:10.1097/01.prs.0000202121.84583.0d

Murthy, R. K., Theriault, R. L., Barnett, C. M., Hodge, S., Ramirez, M. M., Milbourne, A., . . . Litton, J. K. (2014). Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res, 16(6), 500. doi:10.1186/s13058-014-0500-0

Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004). Participation in cancer clinical trials: race-, sex-, and age-based disparities. Jama, 291(22), 2720-2726. doi:10.1001/jama.291.22.2720

Muss, H. B. (2007). Adjuvant treatment of elderly breast cancer patients. Breast, 16 Suppl 2, S159-165. doi:10.1016/j.breast.2007.07.026

Muss, H. B., Berry, D. A., Cirrincione, C., Budman, D. R., Henderson, I. C., Citron, M. L., . . . Hudis, C. A. (2007). Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol, 25(24), 3699-3704. doi:10.1200/jco.2007.10.9710

Mustacchi, G., Ceccherini, R., Milani, S., Pluchinotta, A., De Matteis, A., Maiorino, L., . . . Sasso, F. (2003). Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol, 14(3), 414-420. 

Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., . . . von Euler, M. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 18(22), 3758-3767. 

Nabholtz, J. M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., . . . Group, T. A. X. S. (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol, 21(6), 968-975. 

Nabholtz, J. M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschenes, L., Douma, J., . . . et al. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol, 17(5), 1413-1424. 

Nagar, H., Mittendorf, E. A., Strom, E. A., Perkins, G. H., Oh, J. L., Tereffe, W., . . . Yu, T. K. (2011). Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys, 81(3), 782-787. doi:10.1016/j.ijrobp.2010.06.027

Nahabedian, M. Y., Tsangaris, T., Momen, B., & Manson, P. N. (2003). Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg, 112(2), 467-476. doi:10.1097/01.prs.0000070727.02992.54

Nanda, R. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer: Results for high-risk breast cancer: Results fron the I-SPY 2 Trial. Paper presented at the ASCO Annual Meeting. http://meetinglibrary.asco.org/record/153653/abstract

Narod, S. A. (2011). Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol, 8(11), 669-676. doi:10.1038/nrclinonc.2011.110

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Nationellt kvalitetsregister för Bröstcancer (NKBC). Retrieved from https://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/

Nationellt vårdprogram bukspottkörtelcancer Retrieved from https://kunskapsbanken.cancercentrum.se/diagnoser/bukspottkortelcancer/

Natori, A., Ethier, J. L., Amir, E., & Cescon, D. W. (2017). Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer, 77, 40-47. doi:10.1016/j.ejca.2017.02.024

Navarrete, M. A., Maier, C. M., Falzoni, R., Quadros, L. G., Lima, G. R., Baracat, E. C., & Nazario, A. C. (2005). Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res, 7(3), R306-313. doi:10.1186/bcr994

Needleman, S., & Powell, M. (2016). Radiation hazards in pregnancy and methods of prevention. Best Pract Res Clin Obstet Gynaecol, 33, 108-116. doi:10.1016/j.bpobgyn.2015.10.003

Negenborn, V. L., Smit, J. M., Dikmans, R. E. G., Winters, H. A. H., Twisk, J. W. R., Ruhe, P. Q., . . . Mullender, M. G. (2019). Short-term cost-effectiveness of one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage expander-implant reconstruction from a multicentre randomized clinical trial. Br J Surg, 106(5), 586-595. doi:10.1002/bjs.11102

Negenborn, V. L., Young-Afat, D. A., Dikmans, R. E. G., Smit, J. M., Winters, H. A. H., Don Griot, J. P. W., . . . Mullender, M. G. (2018). Quality of life and patient satisfaction after one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast reconstruction (BRIOS): primary outcome of a randomised, controlled trial. Lancet Oncol, 19(9), 1205-1214. doi:10.1016/s1470-2045(18)30378-4

Nelson, H. D., Tyne, K., Naik, A., Bougatsos, C., Chan, B. K., & Humphrey, L. (2009). Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med, 151(10), 727-737, w237-742. doi:10.7326/0003-4819-151-10-200911170-00009

Neuman, H. B., Schumacher, J. R., Francescatti, A. B., Adesoye, T., Edge, S. B., Vanness, D. J., . . . Greenberg, C. C. (2018). Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01). J Clin Oncol, 36(10), 975-980. doi:10.1200/jco.2017.75.5389

Neurofibromatosis 1  [updated September 4, 2014. (2014). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK1109/

Newcomb, P. A., & Carbone, P. P. (1993). Cancer treatment and age: patient perspectives. J Natl Cancer Inst, 85(19), 1580-1584. 

Newman, L. A., Sahin, A. A., Cunningham, J. E., Bondy, M. L., Mirza, N. Q., Vlastos, G. S., . . . Singletary, S. E. (2001). A case-control study of unilateral and bilateral breast carcinoma patients. Cancer, 91(10), 1845-1853. 

Newman, M. I., Swartz, K. A., Samson, M. C., Mahoney, C. B., & Diab, K. (2011). The true incidence of near-term postoperative complications in prosthetic breast reconstruction utilizing human acellular dermal matrices: a meta-analysis. Aesthetic Plast Surg, 35(1), 100-106. doi:10.1007/s00266-010-9631-6

Ngu, S. F., & Ngan, H. Y. (2016). Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol, 33, 86-101. doi:10.1016/j.bpobgyn.2015.10.007

Nijenhuis, M. V., & Rutgers, E. J. T. (2015). Conservative surgery for multifocal/multicentric breast cancer. The Breast, 24, S96-S99. doi:https://doi.org/10.1016/j.breast.2015.07.023

Nilsson, C., & Valachis, A. (2015). The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol, 114(1), 50-55. doi:10.1016/j.radonc.2015.01.001

Nilsson, G., Holmberg, L., Garmo, H., Duvernoy, O., Sjogren, I., Lagerqvist, B., & Blomqvist, C. (2012). Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol, 30(4), 380-386. doi:10.1200/jco.2011.34.5900

Nilsson, I. L., Zedenius, J., Yin, L., & Ekbom, A. (2007). The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer, 14(1), 135-140. doi:10.1677/erc.1.01261

Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, A., Henriksson, K., . . . Loman, N. (2014). High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat, 147(3), 571-578. doi:10.1007/s10549-014-3115-3

Nitz, U., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., . . . Harbeck, N. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol, 37(10), 799-808. doi:10.1200/jco.18.00028

Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. M., Augustin, D., Kuemmel, S., . . . Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann Oncol, 28(11), 2768-2772. doi:10.1093/annonc/mdx494

Njor, S., Nystrom, L., Moss, S., Paci, E., Broeders, M., Segnan, N., & Lynge, E. (2012). Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen, 19 Suppl 1, 33-41. doi:10.1258/jms.2012.012080

Nogi, H., Uchida, K., Mimoto, R., Kamio, M., Shioya, H., Toriumi, Y., . . . Takeyama, H. (2017). Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy. Clin Breast Cancer, 17(8), 644-649. doi:10.1016/j.clbc.2017.05.002

Noone, R. B., Frazier, T. G., Noone, G. C., Blanchet, N. P., Murphy, J. B., & Rose, D. (1994). Recurrence of breast carcinoma following immediate reconstruction: a 13-year review. Plast Reconstr Surg, 93(1), 96-106; discussion 107-108. 

Nordenskjold, A. E., Fohlin, H., Arnesson, L. G., Einbeigi, Z., Holmberg, E., Albertsson, P., & Karlsson, P. (2019). Breast cancer survival trends in different stages and age groups - a population-based study 1989-2013. Acta Oncol, 58(1), 45-51. doi:10.1080/0284186x.2018.1532601

Notelovitz, M., Funk, S., Nanavati, N., & Mazzeo, M. (2002). Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol, 99(4), 556-562. 

Novotny, D. B., Maygarden, S. J., Shermer, R. W., & Frable, W. J. (1991). Fine needle aspiration of benign and malignant breast masses associated with pregnancy. Acta Cytol, 35(6), 676-686. 

NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy. (2013). NTP Monogr(2), i-214. 

Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B., & Rutqvist, L. E. (2002). Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 359(9310), 909-919. doi:10.1016/s0140-6736(02)08020-0

O'Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., . . . Group, C. B. C. S. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol, 15(3), 440-449. 

O'Hea, B. J., Hill, A. D., El-Shirbiny, A. M., Yeh, S. D., Rosen, P. P., Coit, D. G., . . . Cody, H. S., 3rd. (1998). Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg, 186(4), 423-427. 

O'Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J. P., Cervantes, G., . . . Leonard, R. (2002). Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol, 20(12), 2812-2823. 

Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., . . . Heys, S. D. (2003). A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. The Breast, 12(5), 320-327. doi:https://doi.org/10.1016/S0960-9776(03)00106-1

Ogura, M., Mitsumori, M., Okumura, S., Yamauchi, C., Kawamura, S., Oya, N., . . . Hiraoka, M. (2003). Radiation therapy for brain metastases from breast cancer. Breast Cancer, 10(4), 349-355. 

Oh, M., Alkhushaym, N., Fallatah, S., Althagafi, A., Aljadeed, R., Alsowaida, Y., . . . Abraham, I. (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. doi:10.1002/pros.23795

Ohuchi, N., Suzuki, A., Sobue, T., Kawai, M., Yamamoto, S., Zheng, Y. F., . . . Ishida, T. (2016). Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet, 387(10016), 341-348. doi:10.1016/s0140-6736(15)00774-6

Olivari, N. (1976). The latissimus flap. Br J Plast Surg, 29(2), 126-128. 

Osei, E. K., & Faulkner, K. (1999). Fetal doses from radiological examinations. Br J Radiol, 72(860), 773-780. 

Owen, J. R., Ashton, A., Bliss, J. M., Homewood, J., Harper, C., Hanson, J., . . . Yarnold, J. R. (2006). Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol, 7(6), 467-471. doi:10.1016/s1470-2045(06)70699-4

Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., . . . Zedeler, K. (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med, 337(14), 949-955. doi:10.1056/nejm199710023371401

Overgaard, M., Jensen, M. B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., . . . Mouridsen, H. T. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet, 353(9165), 1641-1648. doi:10.1016/s0140-6736(98)09201-0

Owusu, C., Buist, D. S., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., . . . Silliman, R. A. (2008). Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol, 26(4), 549-555. doi:10.1200/jco.2006.10.1022

Paci, E. (2012). Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen, 19 Suppl 1, 5-13. doi:10.1258/jms.2012.012077

Pagani, O., Partridge, A., Korde, L., Badve, S., Bartlett, J., Albain, K., . . . Goldhirsch, A. (2011). Pregnancy after breast cancer: if you wish, ma'am. Breast Cancer Res Treat, 129(2), 309-317. doi:10.1007/s10549-011-1643-7

Pagani, O., Ruggeri, M., Manunta, S., Saunders, C., Peccatori, F., Cardoso, F., . . . Partridge, A. H. (2015). Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? Breast, 24(3), 201-207. doi:10.1016/j.breast.2015.01.005

Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., . . . Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 351(27), 2817-2826. doi:10.1056/NEJMoa041588

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., . . . Hayes, D. F. (2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med, 377(19), 1836-1846. doi:10.1056/NEJMoa1701830

Pandit-Taskar, N., Dauer, L. T., Montgomery, L., St Germain, J., Zanzonico, P. B., & Divgi, C. R. (2006). Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med, 47(7), 1202-1208. 

Papakonstantinou, A., Foukakis, T., Rodriguez-Wallberg, K. A., & Bergh, J. (2016). Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer? J Clin Oncol, 34(14), 1573-1579. doi:10.1200/jco.2015.65.3493

Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G., Gamucci, T., Houston, S., . . . Piccart, M. (2000). Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol, 18(4), 724-733. 

Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., . . . Therasse, P. (2008). Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol, 26(30), 4883-4890. doi:10.1200/JCO.2007.14.4659

Park, I. H., Lee, K. S., & Ro, J. (2015). Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer, 15(1), e55-62. doi:10.1016/j.clbc.2014.09.001

Park, Y. H., Kim, T. Y., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., . . . Im, S. A. (2019). Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol, 20(12), 1750-1759. doi:10.1016/s1470-2045(19)30565-0

Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., . . . Bernard, P. S. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27(8), 1160-1167. doi:10.1200/jco.2008.18.1370

Patani, N., & Mokbel, K. (2008). Oncological and aesthetic considerations of skin-sparing mastectomy. Breast Cancer Res Treat, 111(3), 391-403. doi:10.1007/s10549-007-9801-7

Patel, A., & Schwarz, E. B. (2012). Cancer and contraception. Release date May 2012. SFP Guideline #20121. Contraception, 86(3), 191-198. doi:10.1016/j.contraception.2012.05.008

Patel, K. M., Lin, C. Y., & Cheng, M. H. (2015). A Prospective Evaluation of Lymphedema-Specific Quality-of-Life Outcomes Following Vascularized Lymph Node Transfer. Ann Surg Oncol, 22(7), 2424-2430. doi:10.1245/s10434-014-4276-3

Patel, R. T., Webster, D. J., Mansel, R. E., & Hughes, L. E. (1993). Is immediate postmastectomy reconstruction safe in the long-term? Eur J Surg Oncol, 19(4), 372-375. 

Patenaude, Y., Pugash, D., Lim, K., Morin, L., Lim, K., Bly, S., . . . Salem, S. (2014). The use of magnetic resonance imaging in the obstetric patient. J Obstet Gynaecol Can, 36(4), 349-363. 

Patientlag 2014:821.  Retrieved from http://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/patientlag-2014821_sfs-2014-821

Patkar, V., Acosta, D., Davidson, T., Jones, A., Fox, J., & Keshtgar, M. (2011). Cancer multidisciplinary team meetings: evidence, challenges, and the role of clinical decision support technology. Int J Breast Cancer, 2011, 831605. doi:10.4061/2011/831605

Patnaik, J. L., Byers, T., Diguiseppi, C., Denberg, T. D., & Dabelea, D. (2011). The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst, 103(14), 1101-1111. doi:10.1093/jnci/djr188

Patterson, R. E., Cadmus, L. A., Emond, J. A., & Pierce, J. P. (2010). Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas, 66(1), 5-15. doi:10.1016/j.maturitas.2010.01.004

Peccatori, F. A., Azim, H. A., Jr., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24 Suppl 6, vi160-170. doi:10.1093/annonc/mdt199

Perez, E. A. (2004). Carboplatin in combination therapy for metastatic breast cancer. Oncologist, 9(5), 518-527. doi:10.1634/theoncologist.9-5-518

Perez, E. A., Barrios, C., Eiermann, W., Toi, M., Im, Y. H., Conte, P., . . . Ellis, P. (2017). Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol, 35(2), 141-148. doi:10.1200/jco.2016.67.4887

Perez, E. A., Holmes, E., de Azambuja, E., Dueck, A., Baselga, J., Viale, G., . . . Piccart-Gebhart, M. (2014). Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Paper presented at the ESMO, Madrid. 

Perez, E. A., Jenkins, R. B., Dueck, A. C., Wiktor, A. E., Bedroske, P. P., Anderson, S. K., . . . Reinholz, M. M. (2011). C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol, 29(6), 651-659. doi:10.1200/jco.2010.30.2125

Perez, E. A., Lopez-Vega, J. M., Petit, T., Zamagni, C., Easton, V., Kamber, J., . . . Andersson, M. (2016). Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res, 18(1), 126. doi:10.1186/s13058-016-0773-6

Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Sledge, G., Geyer, C. E., Jr., . . . Wolmark, N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 32(33), 3744-3752. doi:10.1200/jco.2014.55.5730

Perrone, F., De Laurentiis, M., De Placido, S., Orditura, M., Cinieri, S., Riccardi, F., . . . Gallo, C. (2019). Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. Eur J Cancer, 118, 178-186. doi:10.1016/j.ejca.2019.05.004

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer - Recommendations. (20 March 2019). Retrieved from https://www.nice.org.uk/guidance/ta569/chapter/1-Recommendations

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 102.

Petit, J. Y., Gentilini, O., Rotmensz, N., Rey, P., Rietjens, M., Garusi, C., . . . Luini, A. (2008). Oncological results of immediate breast reconstruction: long term follow-up of a large series at a single institution. Breast Cancer Res Treat, 112(3), 545-549. doi:10.1007/s10549-008-9891-x

Petit, J. Y., Maisonneuve, P., Rotmensz, N., Bertolini, F., & Rietjens, M. (2017). Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plast Reconstr Surg, 139(6), 1292-1296. doi:10.1097/prs.0000000000003339

Petit, J. Y., Rietjens, M., Botteri, E., Rotmensz, N., Bertolini, F., Curigliano, G., . . . Lohsiriwat, V. (2013). Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. Ann Oncol, 24(6), 1479-1484. doi:10.1093/annonc/mds660

Petrelli, F., & Barni, S. (2012). Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol, 29(5), 3282-3290. doi:10.1007/s12032-012-0310-0

Petrelli, F., & Barni, S. (2013). A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer. Clin Breast Cancer, 13(2), 81-87. doi:https://doi.org/10.1016/j.clbc.2012.11.008

Pettersson, A., Graff, R. E., Ursin, G., Santos Silva, I. D., McCormack, V., Baglietto, L., . . . Tamimi, R. M. (2014). Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst, 106(5). doi:10.1093/jnci/dju078

Peutz-Jeghers Syndrome  [updated July 14, 2016. (2016). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK1266

Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A. C., Viale, G., . . . Perez, E. A. (2016). Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol, 34(10), 1034-1042. doi:10.1200/jco.2015.62.1797

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., . . . Gelber, R. D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353(16), 1659-1672. doi:10.1056/NEJMoa052306

Piccart, M., Procter, M., Fumagalli, D., & al., e. (2019, December 10-14, 2019). Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.

Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., . . . Weber, B. L. (2006). Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol, 24(16), 2437-2443. doi:10.1200/jco.2005.02.7888

Pilewskie, M., & Morrow, M. (2018). Margins in breast cancer: How much is enough? Cancer, 124(7), 1335-1341. doi:10.1002/cncr.31221

Pivot, X., Manikhas, A., Zurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., . . . Semiglazov, V. (2015). CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol, 33(14), 1564-1573. doi:10.1200/jco.2014.57.1794

Pivot, X., Romieu, G., Debled, M., Pierga, J. Y., Kerbrat, P., Bachelot, T., . . . Kramar, A. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol, 14(8), 741-748. doi:10.1016/s1470-2045(13)70225-0

Plon, S. E., Eccles, D. M., Easton, D., Foulkes, W. D., Genuardi, M., Greenblatt, M. S., . . . Tavtigian, S. V. (2008). Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat, 29(11), 1282-1291. doi:10.1002/humu.20880

Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., . . . Lambertini, M. (2018). Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol, 29(7), 1497-1508. doi:10.1093/annonc/mdy127

Polgar, C., Van Limbergen, E., Potter, R., Kovacs, G., Polo, A., Lyczek, J., . . . group, G.-E. b. c. w. (2010). Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol, 94(3), 264-273. doi:10.1016/j.radonc.2010.01.014

Poodt, I. G. M., Vugts, G., Schipper, R. J., Roumen, R. M. H., Rutten, H. J. T., Maaskant-Braat, A. J. G., . . . Nieuwenhuijzen, G. A. P. (2019). Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. Br J Surg, 106(5), 574-585. doi:10.1002/bjs.11097

Poortmans, P. M., Collette, S., Kirkove, C., Van Limbergen, E., Budach, V., Struikmans, H., . . . Van den Bogaert, W. (2015). Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med, 373(4), 317-327. doi:10.1056/NEJMoa1415369

Potter, R., Gnant, M., Kwasny, W., Tausch, C., Handl-Zeller, L., Pakisch, B., . . . Jakesz, R. (2007). Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys, 68(2), 334-340. doi:10.1016/j.ijrobp.2006.12.045

Potter, S., Browning, D., Savovic, J., Holcombe, C., & Blazeby, J. M. (2015). Systematic review and critical appraisal of the impact of acellular dermal matrix use on the outcomes of implant-based breast reconstruction. Br J Surg, 102(9), 1010-1025. doi:10.1002/bjs.9804

Powles, T., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., . . . Pylkkanen, L. (2002). Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol, 20(15), 3219-3224. 

Praga, C., Bergh, J., Bliss, J., Bonneterre, J., Cesana, B., Coombes, R. C., . . . Rogers, D. (2005). Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol, 23(18), 4179-4191. doi:10.1200/jco.2005.05.029

Prat, A., Ellis, M. J., & Perou, C. M. (2012). Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol, 9(1), 48-57. doi:10.1038/nrclinonc.2011.178

Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. (2000). Br J Cancer, 83(10), 1301-1308. doi:10.1054/bjoc.2000.1407

Pritchard, K. I., Paterson, A. H., Paul, N. A., Zee, B., Fine, S., & Pater, J. (1996). Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol, 14(10), 2731-2737. doi:10.1200/jco.1996.14.10.2731

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525. 

A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. (1991). J Clin Oncol, 9(2), 305-312. 

Protani, M., Coory, M., & Martin, J. H. (2010). Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat, 123(3), 627-635. doi:10.1007/s10549-010-0990-0

Pruthi, S., Haakenson, C., Brost, B. C., Bryant, K., Reid, J. M., Singh, R., . . . Degnim, A. C. (2011). Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg, 201(1), 70-75. doi:10.1016/j.amjsurg.2009.03.013

PTEN Hamartoma Tumor Syndrome  [updated June 2, 2016. (2016). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK1488/

Puglisi, F., Follador, A., Minisini, A. M., Cardellino, G. G., Russo, S., Andreetta, C., . . . Piga, A. (2005). Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol, 16(2), 263-266. doi:10.1093/annonc/mdi063

Purushotham, A. D., Upponi, S., Klevesath, M. B., Bobrow, L., Millar, K., Myles, J. P., & Duffy, S. W. (2005). Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol, 23(19), 4312-4321. doi:10.1200/jco.2005.03.228

Pusic, A. L., Matros, E., Fine, N., Buchel, E., Gordillo, G. M., Hamill, J. B., . . . Wilkins, E. G. (2017). Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. J Clin Oncol, Jco2016699561. doi:10.1200/jco.2016.69.9561

Quaglia, A., Tavilla, A., Shack, L., Brenner, H., Janssen-Heijnen, M., Allemani, C., . . . Vercelli, M. (2009). The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer, 45(6), 1006-1016. doi:10.1016/j.ejca.2008.11.028

Rada, G., Capurro, D., Pantoja, T., Corbalan, J., Moreno, G., Letelier, L. M., & Vera, C. (2010). Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev(9), Cd004923. doi:10.1002/14651858.CD004923.pub2

Radosa, J. C., Eaton, A., Stempel, M., Khander, A., Liedtke, C., Solomayer, E. F., . . . King, T. A. (2017). Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. Ann Surg Oncol, 24(3), 698-704. doi:10.1245/s10434-016-5631-3

Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., . . . Olivotto, I. A. (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med, 337(14), 956-962. doi:10.1056/NEJM199710023371402

Rahman, Z. U., Frye, D. K., Buzdar, A. U., Smith, T. L., Asmar, L., Champlin, R. E., & Hortobagyi, G. N. (1997). Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol, 15(10), 3171-3177. 

Raphael, M. J., Biagi, J. J., Kong, W., Mates, M., Booth, C. M., & Mackillop, W. J. (2016). The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat, 160(1), 17-28. doi:10.1007/s10549-016-3960-3

Ravdin, P. M., De Laurentiis, M., Vendely, T., & Clark, G. M. (1994). Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst, 86(23), 1771-1775. 

Rebbeck, T. R. (2000). Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 18(21 Suppl), 100s-103s. 

Referens för graviditet och bisfosfonater 

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., . . . Gelber, R. D. (2016). Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol, 34(19), 2221-2231. doi:10.1200/jco.2015.64.3171

Reitman, E., & Flood, P. (2011). Anaesthetic considerations for non-obstetric surgery during pregnancy. Br J Anaesth, 107 Suppl 1, i72-78. doi:10.1093/bja/aer343

Renner, P., Milazzo, S., Liu, J. P., Zwahlen, M., Birkmann, J., & Horneber, M. (2012). Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev, 10, Cd007913. doi:10.1002/14651858.CD007913.pub2

Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Ciruelos, E., . . . Fleming, G. F. (2016). Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol, 34(14), 1601-1610. doi:10.1200/jco.2015.64.8675

Ribuffo, D., Atzeni, M., Guerra, M., Bucher, S., Politi, C., Deidda, M., . . . Lay, G. (2013). Treatment of irradiated expanders: protective lipofilling allows immediate prosthetic breast reconstruction in the setting of postoperative radiotherapy. Aesthetic Plast Surg, 37(6), 1146-1152. doi:10.1007/s00266-013-0221-2

Rimawi, B. H., Green, V., & Lindsay, M. (2016). Fetal Implications of Diagnostic Radiation Exposure During Pregnancy: Evidence-based Recommendations. Clin Obstet Gynecol, 59(2), 412-418. doi:10.1097/grf.0000000000000187

Rimawi, M., Ferrero, J. M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., . . . Arpino, G. (2018). First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol, 36(28), 2826-2835. doi:10.1200/jco.2017.76.7863

Ring, A., Sestak, I., Baum, M., Howell, A., Buzdar, A., Dowsett, M., . . . Cuzick, J. (2011). Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol, 29(32), 4266-4272. doi:10.1200/jco.2011.35.5545

Ringberg, A., Tengrup, I., Aspegren, K., & Palmer, B. (1999). Immediate breast reconstruction after mastectomy for cancer. Eur J Surg Oncol, 25(5), 470-476. doi:10.1053/ejso.1999.0681

Robertson, J. F., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., . . . Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. doi:10.1016/s0140-6736(16)32389-3

Robertson, J. F., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., . . . Ellis, M. J. (2009). Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol, 27(27), 4530-4535. doi:10.1200/JCO.2008.21.1136

Robertson, S., Azizpour, H., Smith, K., & Hartman, J. (2018). Digital image analysis in breast pathology-from image processing techniques to artificial intelligence. Transl Res, 194, 19-35. doi:10.1016/j.trsl.2017.10.010

Robinson, D. R., Wu, Y. M., Vats, P., Su, F., Lonigro, R. J., Cao, X., . . . Chinnaiyan, A. M. (2013). Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet, 45(12), 1446-1451. doi:10.1038/ng.2823

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., . . . Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 377(6), 523-533. doi:10.1056/NEJMoa1706450

Robson, M. E., Tung, N., Conte, P., Im, S. A., Senkus, E., Xu, B., . . . Domchek, S. M. (2019). OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. doi:10.1093/annonc/mdz012

Rodrigues, M. J., Peron, J., Frenel, J. S., Vano, Y. A., Wassermann, J., Debled, M., . . . Cottu, P. H. (2013). Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol, 24(4), 916-924. doi:10.1093/annonc/mds536

Rodriguez-Wallberg, K. A., Tanbo, T., Tinkanen, H., Thurin-Kjellberg, A., Nedstrand, E., Kitlinski, M. L., . . . Andersen, C. Y. (2016). Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand, 95(9), 1015-1026. doi:10.1111/aogs.12934

Rogers, N. E., & Allen, R. J. (2002). Radiation effects on breast reconstruction with the deep inferior epigastric perforator flap. Plast Reconstr Surg, 109(6), 1919-1924; discussion 1925-1916. 

Rojas, M. P., Telaro, E., Russo, A., Fossati, R., Confalonieri, C., & Liberati, A. (2000). Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev(4), Cd001768. doi:10.1002/14651858.cd001768

Romestaing, P., Lehingue, Y., Carrie, C., Coquard, R., Montbarbon, X., Ardiet, J. M., . . . Gerard, J. P. (1997). Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol, 15(3), 963-968. 

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., . . . Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353(16), 1673-1684. doi:10.1056/NEJMoa052122

Rosendahl, M., Ahlgren, J., Andersen, J., Bergh, J., Blomquist, C., Lidbrink, E., . . . Andersson, M. (2009). The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. Eur J Cancer, 45(18), 3198-3204. doi:10.1016/j.ejca.2009.09.019

Rossari, J. R., Metzger-Filho, O., Paesmans, M., Saini, K. S., Gennari, A., de Azambuja, E., & Piccart-Gebhart, M. (2012). Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol, 2012, 417673. doi:10.1155/2012/417673

Rosselli Del Turco, M., Palli, D., Cariddi, A., Ciatto, S., Pacini, P., & Distante, V. (1994). Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. Jama, 271(20), 1593-1597. 

Rossi, V., Berchialla, P., Giannarelli, D., Nistico, C., Ferretti, G., Gasparro, S., . . . Fabi, A. (2019). Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers (Basel), 11(11). doi:10.3390/cancers11111661

Rowell, N. P. (2010). Are mastectomy resection margins of clinical relevance? A systematic review. Breast, 19(1), 14-22. doi:10.1016/j.breast.2009.10.007

Ruddy, K. J., Guo, H., Barry, W., Dang, C. T., Yardley, D. A., Moy, B., . . . Tolaney, S. M. (2015). Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat, 151(3), 589-596. doi:10.1007/s10549-015-3426-z

Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., Rey, P., . . . Coates, A. S. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol, 24(3), 337-344. doi:10.1200/jco.2005.01.5784

Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M. B., Ejlertsen, B., de Azambuja, E., . . . Regan, M. M. (2019). Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol, 37(2), 105-114. doi:10.1200/jco.18.00440

Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., . . . Ganz, P. A. (2016). American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol, 34(6), 611-635. doi:10.1200/jco.2015.64.3809

Rutgers, E. J. (2001). Quality control in the locoregional treatment of breast cancer. Eur J Cancer, 37(4), 447-453. 

Ryden, L., Heibert Arnlind, M., Vitols, S., Hoistad, M., & Ahlgren, J. (2016). Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast, 26, 106-114. doi:10.1016/j.breast.2016.01.006

Rygiel, K. (2017). Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: An overview. J Cancer Res Ther, 13(2), 186-192. doi:10.4103/0973-1482.187303

Saad, F., Adachi, J. D., Brown, J. P., Canning, L. A., Gelmon, K. A., Josse, R. G., & Pritchard, K. I. (2008). Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol, 26(33), 5465-5476. doi:10.1200/jco.2008.18.4184

Saadatmand, S., Bretveld, R., Siesling, S., & Tilanus-Linthorst, M. M. (2015). Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. Bmj, 351, h4901. doi:10.1136/bmj.h4901

Saal, L. H., Vallon-Christersson, J., Hakkinen, J., Hegardt, C., Grabau, D., Winter, C., . . . Borg, A. (2015). The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med, 7(1), 20. doi:10.1186/s13073-015-0131-9

Saarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001). Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol, 19(1), 10-17. 

Sacre, R. A. (1986). Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol, 12(2), 169-173. 

Saha, P., Regan, M. M., Pagani, O., Francis, P. A., Walley, B. A., Ribi, K., . . . Fleming, G. F. (2017). Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol, 35(27), 3113-3122. doi:10.1200/jco.2016.72.0946

Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., . . . Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol, 26(2), 259-271. doi:10.1093/annonc/mdu450

Samain, E., Schauvliege, F., Deval, B., & Marty, J. (2003). Anesthesia for breast cancer surgery in the elderly. Crit Rev Oncol Hematol, 46(2), 115-120. 

Sánchez-Rovira P, H. A., Gil-Gil M, Antolín-Novoa S, García-Estévez L, Bermejo de las Heras B, Presa-Lorite J, Sánchez-Vigil de la Villa I, Suárez-Almarza J, Nieto-Magro C. (2017, 2017 Dec 5-9). 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, TX. Philadelphia (PA):.

Sandison, A. J., Gold, D. M., Wright, P., & Jones, P. A. (1996). Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg, 83(7), 994-996. 

Santos, M. C., Horta, B. L., Amaral, J. J., Fernandes, P. F., Galvao, C. M., & Fernandes, A. F. (2009). Association between stress and breast cancer in women: a meta-analysis. Cad Saude Publica, 25 Suppl 3, S453-463. 

Sardanelli, F., Podo, F., D'Agnolo, G., Verdecchia, A., Santaquilani, M., Musumeci, R., . . . Del Maschio, A. (2007). Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology, 242(3), 698-715. doi:10.1148/radiol.2423051965

Sawaki, M., Tokudome, N., Mizuno, T., Nakayama, T., Taira, N., Bando, H., . . . Ohashi, Y. (2011). Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol, 41(5), 709-712. doi:10.1093/jjco/hyr011

Savolt, A., Peley, G., Polgar, C., Udvarhelyi, N., Rubovszky, G., Kovacs, E., . . . Matrai, Z. (2017). Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol, 43(4), 672-679. doi:10.1016/j.ejso.2016.12.011

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., . . . Emens, L. A. (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med, 379(22), 2108-2121. doi:10.1056/NEJMoa1809615

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., . . . Emens, L. A. (2019). IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). 37(15_suppl), 1003-1003. doi:10.1200/JCO.2019.37.15_suppl.1003

Schmid, P., Cortés, J., Dent, R., Pusztai, L., McArthur, H. L., Kuemmel, S., . . . O’Shaughnessy, J. (2019). LBA8_PR - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Annals of Oncology, 30, v853-v854. doi:https://doi.org/10.1093/annonc/mdz394.003

Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., . . . Easton, D. F. (2016). Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol, 34(23), 2750-2760. doi:10.1200/jco.2016.66.5844

Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., . . . Cortes, J. (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 24(9), 2278-2284. doi:10.1093/annonc/mdt182

Schneider-Kolsky, M. E., Hart, S., Fox, J., Midolo, P., Stuckey, J., Hofman, M., & Ganju, V. (2010). The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res, 12(3), R37. doi:10.1186/bcr2591

Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., . . . Ecog. (2008). Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol, 26(28), 4672-4678. doi:10.1200/JCO.2008.16.1612

Schoemaker, M. J., Jones, M. E., Wright, L. B., Griffin, J., McFadden, E., Ashworth, A., & Swerdlow, A. J. (2016). Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom. Breast Cancer Res, 18(1), 72. doi:10.1186/s13058-016-0733-1

Schonberg, M. A., Davis, R. B., McCarthy, E. P., & Marcantonio, E. R. (2011). External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc, 59(8), 1444-1451. doi:10.1111/j.1532-5415.2011.03523.x

Schonberg, M. A., Marcantonio, E. R., Li, D., Silliman, R. A., Ngo, L., & McCarthy, E. P. (2010). Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol, 28(12), 2038-2045. doi:10.1200/jco.2009.25.9796

Schonberg, M. A., Marcantonio, E. R., Ngo, L., Li, D., Silliman, R. A., & McCarthy, E. P. (2011). Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol, 29(12), 1570-1577. doi:10.1200/jco.2010.33.0472

Schrijver, W., Suijkerbuijk, K. P. M., van Gils, C. H., van der Wall, E., Moelans, C. B., & van Diest, P. J. (2018). Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst, 110(6), 568-580. doi:10.1093/jnci/djx273

Screening, I. U. P. o. B. C. (2012). The benefits and harms of breast cancer screening: an independent review. Lancet, 380(9855), 1778-1786. doi:10.1016/s0140-6736(12)61611-0

Sechopoulos, I., Suryanarayanan, S., Vedantham, S., D'Orsi, C. J., & Karellas, A. (2008). Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology, 246(2), 434-443. doi:10.1148/radiol.2462070256

Sedlmayer, F., Zehentmayr, F., & Fastner, G. (2013). Partial breast re-irradiation for local recurrence of breast carcinoma: Benefit and long term side effects. Breast, 22 Suppl 2, S141-146. doi:10.1016/j.breast.2013.07.026

Seidman, A. D., & Aapro, M. (2002). Incorporating oral capecitabine into the treatment of breast cancer. Introduction. Oncologist, 7 Suppl 6, 1-3. 

Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., . . . Hudis, C. (2008). Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol, 26(10), 1642-1649. doi:10.1200/JCO.2007.11.6699

Semiglazov, V. F., Manikhas, A. G., Moiseenko, V. M., Protsenko, S. A., Kharikova, R. S., Seleznev, I. K., . . . Ivanov, V. G. (2003). [Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer]. Vopr Onkol, 49(4), 434-441. 

Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., . . . Cardoso, F. (2015). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 26 Suppl 5, v8-30. doi:10.1093/annonc/mdv298

Sestak, I., Buus, R., Cuzick, J., Dubsky, P., Kronenwett, R., Denkert, C., . . . Dowsett, M. (2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol, 4(4), 545-553. doi:10.1001/jamaoncol.2017.5524

Sestak, I., Martin, M., Dubsky, P., Kronenwett, R., Rojo, F., Cuzick, J., . . . Gnant, M. (2019). Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat, 176(2), 377-386. doi:10.1007/s10549-019-05226-8

Sestak, I., Singh, S., Cuzick, J., Blake, G. M., Patel, R., Gossiel, F., . . . Eastell, R. (2014). Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol, 15(13), 1460-1468. doi:10.1016/s1470-2045(14)71035-6

Shahedi, K., Emanuelsson, M., Wiklund, F., & Gronberg, H. (2006). High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer, 106(6), 1237-1242. doi:10.1002/cncr.21753

Shames, D. S., & Wistuba, II. (2014). The evolving genomic classification of lung cancer. J Pathol, 232(2), 121-133. doi:10.1002/path.4275

Shams, T., Firwana, B., Habib, F., Alshahrani, A., Alnouh, B., Murad, M. H., & Ferwana, M. (2014). SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med, 29(1), 204-213. doi:10.1007/s11606-013-2535-9

Sharp, L., Finnila, K., Johansson, H., Abrahamsson, M., Hatschek, T., & Bergenmar, M. (2013). No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions--results from a randomised blinded trial. Eur J Oncol Nurs, 17(4), 429-435. doi:10.1016/j.ejon.2012.11.003

Sheppard, C., Higgins, B., Wise, M., Yiangou, C., Dubois, D., & Kilburn, S. (2009). Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6-monthly clinical review. Eur J Oncol Nurs, 13(1), 2-8. doi:10.1016/j.ejon.2008.11.005

Siahpush, M., & Singh, G. K. (2002). Sociodemographic variations in breast cancer screening behavior among Australian women: results from the 1995 National Health Survey. Prev Med, 35(2), 174-180. 

Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., . . . Winer, E. P. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol, 33(1), 13-21. doi:10.1200/jco.2014.57.0572

Silva-Vergara, C., Fontdevila, J., Descarrega, J., Burdio, F., Yoon, T. S., & Grande, L. (2016). Oncological outcomes of lipofilling breast reconstruction: 195 consecutive cases and literature review. J Plast Reconstr Aesthet Surg, 69(4), 475-481. doi:10.1016/j.bjps.2015.12.029

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., . . . Garber, J. E. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28(7), 1145-1153. doi:10.1200/jco.2009.22.4725

Simmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., & Clemons, M. J. (2009). Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol, 20(9), 1499-1504. doi:10.1093/annonc/mdp028

Simonacci, F., Bertozzi, N., Grieco, M. P., Grignaffini, E., & Raposio, E. (2016). Autologous fat transplantation for breast reconstruction: A literature review. Ann Med Surg (Lond), 12, 94-100. doi:10.1016/j.amsu.2016.11.012

Sineshaw, H. M., Freedman, R. A., DeSantis, C. E., & Jemal, A. (2018). Treatment Patterns Among Women Diagnosed With Stage I-III Triple-negative Breast Cancer. Am J Clin Oncol, 41(10), 997-1007. doi:10.1097/coc.0000000000000418

Singh, R., Hellman, S., & Heimann, R. (2004). The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer, 100(9), 1807-1813. doi:10.1002/cncr.20206

Singletary, S. E. (2003). Rating the risk factors for breast cancer. Ann Surg, 237(4), 474-482. doi:10.1097/01.sla.0000059969.64262.87

Siva, S., MacManus, M., & Ball, D. (2010). Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol, 5(7), 1091-1099. doi:10.1097/JTO.0b013e3181de7143

Sjostrom, J., Blomqvist, C., Mouridsen, H., Pluzanska, A., Ottosson-Lonn, S., Bengtsson, N. O., . . . Bergh, J. (1999). Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer, 35(8), 1194-1201. 

Slamon, D., & al., e. (2019). Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Annals of Oncology, 30 (suppl_5), v851-v934. doi:10.1093/annonc/mdz394

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., . . . Crown, J. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 365(14), 1273-1283. doi:10.1056/NEJMoa0910383

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785), 177-182. 

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., . . . Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344(11), 783-792. doi:10.1056/nejm200103153441101

Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., . . . Llombart-Cussac, A. (2019). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. doi:10.1001/jamaoncol.2019.4782

Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., . . . Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol, Jco2017737585. doi:10.1200/jco.2017.73.7585

Smith, B. D., Haffty, B. G., Hurria, A., Galusha, D. H., & Gross, C. P. (2006). Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol, 24(30), 4901-4907. doi:10.1200/jco.2006.06.5938

Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., . . . Piccart-Gebhart, M. J. (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369(9555), 29-36. doi:10.1016/s0140-6736(07)60028-2

Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J. U., . . . Walsh, G. (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol, 23(22), 5108-5116. doi:10.1200/jco.2005.04.005

Smith, I. E., & Talbot, D. C. (1992). Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer, 65(6), 787-793. 

Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., . . . Wolff, A. C. (2006). 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 24(19), 3187-3205. doi:10.1200/jco.2006.06.4451

Smyth, L. M., Knight, K. A., Aarons, Y. K., & Wasiak, J. (2015). The cardiac dose-sparing benefits of deep inspiration breath-hold in left breast irradiation: a systematic review. J Med Radiat Sci, 62(1), 66-73. doi:10.1002/jmrs.89

Sobhani, N., Roviello, G., Corona, S. P., Scaltriti, M., Ianza, A., Bortul, M., . . . Generali, D. (2018). The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem, 119(6), 4287-4292. doi:10.1002/jcb.26687

Socialdepartementet. Hälso- och sjukvårdslag (2017:30), kap 5, § 7. Retrieved from https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/halso--och-sjukvardslag_sfs-2017-30

Socialdepartementet. Hälso- och sjukvårdslagen (1982:763). Retrieved from http://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/halso--och-sjukvardslag-1982763_sfs-1982-763

Socialdepartementet. (2009). En nationell cancerstrategi för framtiden, SOU 2009:11. Stockholm: Fritzes offentliga publikationer

Socialstyrelsen. Pregnancies, deliveries and newborn infants. The Swedish Medical Birth Register 1973-2014. Assisted reproduction, treatment 1991-2013 Retrieved from 

Socialstyrelsen. (2012). Cancer Incidence in Sweden 2011 - Cancerförekomst i Sverige 2011. Stockholm: Socialstyrelsen.

Socialstyrelsen. (2013a). Cancerincidens i Sverige 2012 - Nya diagnosticerade cancerfall år 2012. Stockholm: Socialstyrelsen.

Socialstyrelsen. (2013b). Nationell utvärdering 2013. Bröst-, prostata-, tjocktarms- och ändtarmscancervård. Retrieved from Stockholm: 

Socialstyrelsen. (2017). Statistik om nyupptäckta cancerfall 2017 Retrieved from https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/cancer/

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., . . . Reck, M. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 378(24), 2288-2301. doi:10.1056/NEJMoa1716948

Soini, T., Hurskainen, R., Grenman, S., Maenpaa, J., Paavonen, J., & Pukkala, E. (2014). Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol, 124(2 Pt 1), 292-299. doi:10.1097/aog.0000000000000356

Sola, M., Alberro, J. A., Fraile, M., Santesteban, P., Ramos, M., Fabregas, R., . . . Vidal, S. (2013). Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol, 20(1), 120-127. doi:10.1245/s10434-012-2569-y

Song, C. V., Teo, S. H., Taib, N. A., & Yip, C. H. (2018). Surgery for BRCA, TP53 and PALB2: a literature review. Ecancermedicalscience, 12, 863. doi:10.3332/ecancer.2018.863

Song, G., Gao, H., & Yuan, Z. (2013). Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol, 30(3), 667. doi:10.1007/s12032-013-0667-8

Sonmezer, M., Turkcuoglu, I., Coskun, U., & Oktay, K. (2011). Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril, 95(6), 2125.e2129-2111. doi:10.1016/j.fertnstert.2011.01.030

Soran, A., Ozmen, V., Ozbas, S., Karanlik, H., Muslumanoglu, M., Igci, A., . . . Lembersky, B. C. (2016). A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). 34(15_suppl), 1005-1005. doi:10.1200/JCO.2016.34.15_suppl.1005

Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., . . . Borresen-Dale, A. L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98(19), 10869-10874. doi:10.1073/pnas.191367098

Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., . . . Delorenzi, M. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst, 98(4), 262-272. doi:10.1093/jnci/djj052

Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkas, K., Couch, F., Tischkowitz, M., . . . Milne, R. L. (2016). PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet, 53(12), 800-811. doi:10.1136/jmedgenet-2016-103839

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 379(2), 111-121. doi:10.1056/NEJMoa1804710

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., . . . Sledge, G. W., Jr. (2019). Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med, 380(25), 2395-2405. doi:10.1056/NEJMoa1904819

Sparano, J. A., Makhson, A. N., Semiglazov, V. F., Tjulandin, S. A., Balashova, O. I., Bondarenko, I. N., . . . Rackoff, W. R. (2009). Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol, 27(27), 4522-4529. doi:10.1200/JCO.2008.20.5013

Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., . . . Davidson, N. E. (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358(16), 1663-1671. doi:10.1056/NEJMoa0707056

Spear, S. L., Coles, C. N., Leung, B. K., Gitlin, M., Parekh, M., & Macarios, D. (2016). The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast Surgery. Plast Reconstr Surg Glob Open, 4(8), e827. doi:10.1097/gox.0000000000000842

Spear, S. L., Willey, S. C., Feldman, E. D., Cocilovo, C., Sidawy, M., Al-Attar, A., . . . Nahabedian, M. Y. (2011). Nipple-sparing mastectomy for prophylactic and therapeutic indications. Plast Reconstr Surg, 128(5), 1005-1014. doi:10.1097/PRS.0b013e31822b6456

Sperduto, P. W., Kased, N., Roberge, D., Chao, S. T., Shanley, R., Luo, X., . . . Mehta, M. (2013). The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol, 112(3), 467-472. doi:10.1007/s11060-013-1083-9

Spielmann, M., Roche, H., Delozier, T., Canon, J. L., Romieu, G., Bourgeois, H., . . . Penault-Llorca, F. (2009). Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol, 27(36), 6129-6134. doi:10.1200/jco.2009.23.0946

Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., . . . Bardia, A. (2016). Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol, 2(11), 1477-1486. doi:10.1001/jamaoncol.2016.1897

Stadtmauer, E. A., O'Neill, A., Goldstein, L. J., Crilley, P. A., Mangan, K. F., Ingle, J. N., . . . Glick, J. H. (2000). Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med, 342(15), 1069-1076. doi:10.1056/NEJM200004133421501

Staley, H., McCallum, I., & Bruce, J. (2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev, 10, Cd007847. doi:10.1002/14651858.CD007847.pub2

Stalhammar, G., Fuentes Martinez, N., Lippert, M., Tobin, N. P., Molholm, I., Kis, L., . . . Hartman, J. (2016). Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol, 29(4), 318-329. doi:10.1038/modpathol.2016.34

Statistics on Cancer Incidence 2017 (2018). Retrieved from https://www.socialstyrelsen.se/publikationer2018/2018-12-51

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W. L., Davies, M., . . . Hennessy, B. T. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res, 68(15), 6084-6091. doi:10.1158/0008-5472.Can-07-6854

Storm, H. H., & Jensen, O. M. (1986). Risk of contralateral breast cancer in Denmark 1943-80. Br J Cancer, 54(3), 483-492. 

Strasser, B., Steindorf, K., Wiskemann, J., & Ulrich, C. M. (2013). Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc, 45(11), 2080-2090. doi:10.1249/MSS.0b013e31829a3b63

Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., . . . Tucker, M. A. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med, 336(20), 1401-1408. doi:10.1056/nejm199705153362001

Suckling, J., Lethaby, A., & Kennedy, R. (2003). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev(4), CD001500. 

Sung, J. S., Stamler, S., Brooks, J., Kaplan, J., Huang, T., Dershaw, D. D., . . . Comstock, C. E. (2016). Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results. Radiology, 280(3), 716-722. doi:10.1148/radiol.2016151419

Sutherland, S., Ashley, S., Miles, D., Chan, S., Wardley, A., Davidson, N., . . . Johnston, S. R. (2010). Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer, 102(6), 995-1002. doi:10.1038/sj.bjc.6605586

Sutherland, S., Miles, D., & Makris, A. (2016). Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer. Eur J Cancer, 69, 216-222. doi:10.1016/j.ejca.2016.09.019

Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., . . . Cortes, J. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med, 372(8), 724-734. doi:10.1056/NEJMoa1413513

Swain, S. M., Kim, S. B., Cortes, J., Ro, J., Semiglazov, V., Campone, M., . . . Baselga, J. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 14(6), 461-471. doi:10.1016/S1470-2045(13)70130-X

Swanson, R. S., Sawicka, J., & Wood, W. C. (1991). Treatment of carcinoma of the breast in the older geriatric patient. Surg Gynecol Obstet, 173(6), 465-469. 

Swedborg, I., & Wallgren, A. (1981). The effect of pre- and postmastectomy radiotherapy on the degree of edema, shoulder-joint mobility, and gripping force. Cancer, 47(5), 877-881. 

Svee, A., Mani, M., Sandquist, K., Audolfsson, T., Folkvaljon, Y., Isern, A. E., . . . Warnberg, F. (2018). Survival and risk of breast cancer recurrence after breast reconstruction with deep inferior epigastric perforator flap. Br J Surg, 105(11), 1446-1453. doi:10.1002/bjs.10888

Svensk Förening för Patologi. KVAST-dokument. Retrieved from http://www.svfp.se/brostpatologi

Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., . . . Pusztai, L. (2007). Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol, 25(28), 4414-4422. doi:10.1200/jco.2007.10.6823

Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., . . . Hortobagyi, G. N. (2017). Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol, 35(10), 1049-1060. doi:10.1200/jco.2015.63.1010

Szelei-Stevens, K. A., Kuske, R. R., Yantsos, V. A., Cederbom, G. J., Bolton, J. S., & Fineberg, B. B. (2000). The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. Int J Radiat Oncol Biol Phys, 48(4), 943-949. 

Tabar, L., Vitak, B., Chen, T. H., Yen, A. M., Cohen, A., Tot, T., . . . Duffy, S. W. (2011). Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology, 260(3), 658-663. doi:10.1148/radiol.11110469

Taghizadeh, R., Moustaki, M., Harris, S., Roblin, P., & Farhadi, J. (2015). Does post-mastectomy radiotherapy affect the outcome and prevalence of complications in immediate DIEP breast reconstruction? A prospective cohort study. J Plast Reconstr Aesthet Surg, 68(10), 1379-1385. doi:10.1016/j.bjps.2015.06.003

Talarico, L., Chen, G., & Pazdur, R. (2004). Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol, 22(22), 4626-4631. doi:10.1200/jco.2004.02.175

Tamirisa, N., Thomas, S. M., Fayanju, O. M., Greenup, R. A., Rosenberger, L. H., Hyslop, T., . . . Plichta, J. K. (2018). Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Ann Surg Oncol, 25(10), 2890-2898. doi:10.1245/s10434-018-6595-2

Tampellini, M., Berruti, A., Gerbino, A., Buniva, T., Torta, M., Gorzegno, G., . . . Dogliotti, L. (1997). Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75(5), 698-702. 

Tan, M. P., & Silva, E. (2018). Addressing the paradox of increasing mastectomy rates in an era of de-escalation of therapy: Communication strategies. Breast, 38, 136-143. doi:10.1016/j.breast.2017.12.010

Tan, V. K., Goh, B. K., Fook-Chong, S., Khin, L. W., Wong, W. K., & Yong, W. S. (2011). The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis. J Surg Oncol, 104(1), 97-103. doi:10.1002/jso.21911

Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., . . . McGale, P. (2017). Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol, Jco2016720722. doi:10.1200/jco.2016.72.0722

Taylor, C. W., & Kumar, S. (2005). The effect of immediate breast reconstruction on adjuvant chemotherapy. Breast, 14(1), 18-21. doi:10.1016/j.breast.2004.07.004

Taylor, C. W., Wang, Z., Macaulay, E., Jagsi, R., Duane, F., & Darby, S. C. (2015). Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013. Int J Radiat Oncol Biol Phys, 93(4), 845-853. doi:10.1016/j.ijrobp.2015.07.2292

Teissier, E. (1998). Boost in conservation treatment : 6 years results of randomized trial [abstract 345]. Breast Cancer Res Treat, 50, 287. 

Teshome, M., & Kuerer, H. M. (2017). Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. Eur J Surg Oncol, 43(5), 865-874. doi:10.1016/j.ejso.2017.02.002

Tham, Y. L., Sexton, K., Weiss, H., Elledge, R., Friedman, L. C., & Kramer, R. (2007). The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol, 30(2), 126-132. doi:10.1097/01.coc.0000251398.57630.4f

Thomas, D. B., Gao, D. L., Ray, R. M., Wang, W. W., Allison, C. J., Chen, F. L., . . . Self, S. G. (2002). Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst, 94(19), 1445-1457. 

Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., & Purdie, C. A. (2010). Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res, 12(6), R92. doi:10.1186/bcr2771

Thompson, D., & Easton, D. (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet, 68(2), 410-419. doi:10.1086/318181

Thorarinsson, A., Frojd, V., Kolby, L., Ljungdal, J., Taft, C., & Mark, H. (2017). Long-Term Health-Related Quality of Life after Breast Reconstruction: Comparing 4 Different Methods of Reconstruction. Plast Reconstr Surg Glob Open, 5(6), e1316. doi:10.1097/gox.0000000000001316

Thorlacius, S., Sigurdsson, S., Bjarnadottir, H., Olafsdottir, G., Jonasson, J. G., Tryggvadottir, L., . . . Eyfjord, J. E. (1997). Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet, 60(5), 1079-1084. 

Thorsen, L. B., Offersen, B. V., Dano, H., Berg, M., Jensen, I., Pedersen, A. N., . . . Overgaard, J. (2016). DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol, 34(4), 314-320. doi:10.1200/jco.2015.63.6456

Thorsen, L. B., Thomsen, M. S., Berg, M., Jensen, I., Josipovic, M., Overgaard, M., . . . Offersen, B. V. (2014). CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects. Acta Oncol, 53(8), 1027-1034. doi:10.3109/0284186x.2014.925579

Thurlimann, B., Keshaviah, A., Coates, A. S., Mouridsen, H., Mauriac, L., Forbes, J. F., . . . Goldhirsch, A. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med, 353(26), 2747-2757. doi:10.1056/NEJMoa052258

Tiboni, G. M. (2004). Aromatase inhibitors and teratogenesis. Fertil Steril, 81(4), 1158-1159; author reply 1159. doi:10.1016/j.fertnstert.2004.01.006

S0015028204000184 [pii]

Tilanus-Linthorst, M., Verhoog, L., Obdeijn, I. M., Bartels, K., Menke-Pluymers, M., Eggermont, A., . . . Brekelmans, C. (2002). A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer, 102(1), 91-95. doi:10.1002/ijc.10666

Tilanus-Linthorst, M. M., Obdeijn, I. M., Bartels, K. C., de Koning, H. J., & Oudkerk, M. (2000). First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat, 63(1), 53-60. 

Tinterri, C., Gatzemeier, W., Costa, A., Gentilini, M. A., Zanini, V., Regolo, L., . . . Andreoli, C. (2014). Breast-conservative surgery with and without radiotherapy in patients aged 55-75 years with early-stage breast cancer: a prospective, randomized, multicenter trial analysis after 108 months of median follow-up. Ann Surg Oncol, 21(2), 408-415. doi:10.1245/s10434-013-3233-x

Tinterri, C., Gatzemeier, W., Zanini, V., Regolo, L., Pedrazzoli, C., Rondini, E., . . . Andreoli, C. (2009). Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. Breast, 18(6), 373-377. doi:10.1016/j.breast.2009.09.013

Tirada, N., Dreizin, D., Khati, N. J., Akin, E. A., & Zeman, R. K. (2015). Imaging Pregnant and Lactating Patients. Radiographics, 35(6), 1751-1765. doi:10.1148/rg.2015150031

Tjan-Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., . . . Seynaeve, C. M. (2017). Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol, 18(11), 1502-1511. doi:10.1016/s1470-2045(17)30600-9

Todd, M., Shoag, M., & Cadman, E. (1983). Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol, 1(6), 406-408. 

Toesca, A., Gentilini, O., Peccatori, F., Azim, H. A., Jr., & Amant, F. (2014). Locoregional treatment of breast cancer during pregnancy. Gynecol Surg, 11(4), 279-284. doi:10.1007/s10397-014-0860-6

Toi M, e. a. (2015). Symposium S1-07. Paper presented at the Programs and Abstracts of the San Antonio Breast Cancer. 

Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., . . . Winer, E. P. (2015). Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med, 372(2), 134-141. doi:10.1056/NEJMoa1406281

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Torino, F., Barnabei, A., De Vecchis, L., Sini, V., Schittulli, F., Marchetti, P., & Corsello, S. M. (2014). Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol, 89(1), 27-42. doi:10.1016/j.critrevonc.2013.07.007

Tran, N. V., Chang, D. W., Gupta, A., Kroll, S. S., & Robb, G. L. (2001). Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg, 108(1), 78-82. 

Tran, N. V., Evans, G. R., Kroll, S. S., Baldwin, B. J., Miller, M. J., Reece, G. P., & Robb, G. L. (2000). Postoperative adjuvant irradiation: effects on tranverse rectus abdominis muscle flap breast reconstruction. Plast Reconstr Surg, 106(2), 313-317; discussion 318-320. 

Tripathy, D., Im, S. A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., . . . Lu, Y. S. (2018). Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol, 19(7), 904-915. doi:10.1016/s1470-2045(18)30292-4

Trombetta, M., Hall, M., & Julian, T. B. (2014). Long-term followup of breast preservation by re-excision and balloon brachytherapy after ipsilateral breast tumor recurrence. Brachytherapy, 13(5), 488-492. doi:10.1016/j.brachy.2014.05.017

Tsai, H. T., Isaacs, C., Fu, A. Z., Warren, J. L., Freedman, A. N., Barac, A., . . . Potosky, A. L. (2014). Risk of cardiovascular adverse events from trastuzumab (Herceptin((R))) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat, 144(1), 163-170. doi:10.1007/s10549-014-2836-7

Tsourdi, E., Langdahl, B., Cohen-Solal, M., Aubry-Rozier, B., Eriksen, E. F., Guanabens, N., . . . Zillikens, M. C. (2017). Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 105, 11-17. doi:10.1016/j.bone.2017.08.003

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Diagnostics guidance [DG34]  Published date: December 2018. (2018). Retrieved from https://www.nice.org.uk/guidance/dg34

Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., . . . Robson, M. E. (2016). Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol, 13(9), 581-588. doi:10.1038/nrclinonc.2016.90

Turnbull, L., Brown, S., Harvey, I., Olivier, C., Drew, P., Napp, V., . . . Brown, J. (2010). Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet, 375(9714), 563-571. doi:10.1016/s0140-6736(09)62070-5

Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., . . . Cristofanilli, M. (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373(3), 209-219. doi:10.1056/NEJMoa1505270

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., . . . Cristofanilli, M. (2018). Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med, 379(20), 1926-1936. doi:10.1056/NEJMoa1810527

Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., . . . Bliss, J. M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med, 24(5), 628-637. doi:10.1038/s41591-018-0009-7

Twelves, C., Awada, A., Cortes, J., Yelle, L., Velikova, G., Olivo, M. S., . . . Kaufman, P. A. (2016). Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer (Auckl), 10, 77-84. doi:10.4137/bcbcr.S39615

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. (2019). Lancet. doi:10.1016/s0140-6736(19)31709-x

Tyrer, J., Duffy, S. W., & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Stat Med, 23(7), 1111-1130. doi:10.1002/sim.1668

Ullah, I., Karthik, G. M., Alkodsi, A., Kjallquist, U., Stalhammar, G., Lovrot, J., . . . Bergh, J. (2018). Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J Clin Invest, 128(4), 1355-1370. doi:10.1172/jci96149

Underhill, C., Toulmonde, M., & Bonnefoi, H. (2011). A review of PARP inhibitors: from bench to bedside. Ann Oncol, 22(2), 268-279. doi:10.1093/annonc/mdq322

Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., . . . von Minckwitz, G. (2016). Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol, 17(3), 345-356. doi:10.1016/s1470-2045(15)00542-2

Untch, M., Muscholl, M., Tjulandin, S., Jonat, W., Meerpohl, H. G., Lichinitser, M., . . . Luck, H. J. (2010). First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol, 28(9), 1473-1480. doi:10.1200/JCO.2009.21.9709

Urruticoechea, A., Rizwanullah, M., Im, S. A., Ruiz, A. C. S., Lang, I., Tomasello, G., . . . Munoz, M. (2017). Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. J Clin Oncol, 35(26), 3030-3038. doi:10.1200/jco.2016.70.6267

Wadsten, C., Garmo, H., Fredriksson, I., Sund, M., & Warnberg, F. (2017). Risk of death from breast cancer after treatment for ductal carcinoma in situ. Br J Surg, 104(11), 1506-1513. doi:10.1002/bjs.10589

Wadsten, C., Wennstig, A. K., Garmo, H., Nilsson, G., Blomqvist, C., Holmberg, L., . . . Sund, M. (2018). Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. Breast Cancer Res Treat, 171(1), 95-101. doi:10.1007/s10549-018-4803-1

Waeber, M., Castiglione-Gertsch, M., Dietrich, D., Thurlimann, B., Goldhirsch, A., Brunner, K. W., & Borner, M. M. (2003). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol, 14(8), 1215-1221. 

Wahl, R. L., Siegel, B. A., Coleman, R. E., & Gatsonis, C. G. (2004). Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol, 22(2), 277-285. doi:10.1200/jco.2004.04.148

Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., . . . Baum, M. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet, 376(9735), 91-102. doi:10.1016/S0140-6736(10)60837-9

Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., . . . on behalf of the, T. t. g. (2013). Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. doi:10.1016/S0140-6736(13)61950-9

Vaidya, J. S., Vyas, J. J., Chinoy, R. F., Merchant, N., Sharma, O. P., & Mittra, I. (1996). Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer, 74(5), 820-824. 

Waked, K., Colle, J., Doornaert, M., Cocquyt, V., & Blondeel, P. (2017). Systematic review: The oncological safety of adipose fat transfer after breast cancer surgery. Breast, 31, 128-136. doi:10.1016/j.breast.2016.11.001

Waks, A. G., & Partridge, A. H. (2016). Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety. J Natl Compr Canc Netw, 14(3), 355-363. 

Valachis, A., Mauri, D., Polyzos, N. P., Chlouverakis, G., Mavroudis, D., & Georgoulias, V. (2011). Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast, 20(6), 485-490. doi:10.1016/j.breast.2011.06.009

Valachis, A., Nearchou, A., Lind, P., & Mauri, D. (2012). Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res Treat, 135(3), 655-662. doi:10.1007/s10549-012-2189-z

Valachis, A., Polyzos, N. P., Coleman, R. E., Gnant, M., Eidtmann, H., Brufsky, A. M., . . . Mauri, D. (2013). Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist, 18(4), 353-361. doi:10.1634/theoncologist.2012-0261

Valachis, A., Tsali, L., Pesce, L. L., Polyzos, N. P., Dimitriadis, C., Tsalis, K., & Mauri, D. (2010). Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv, 65(12), 786-793. doi:10.1097/OGX.0b013e31821285bf

Valentini, A., Lubinski, J., Byrski, T., Ghadirian, P., Moller, P., Lynch, H. T., . . . Narod, S. A. (2013). The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat, 142(1), 177-185. doi:10.1007/s10549-013-2729-1

Walstra, C., Schipper, R. J., Poodt, I. G. M., van Riet, Y. E., Voogd, A. C., van der Sangen, M. J. C., & Nieuwenhuijzen, G. A. P. (2019). Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review. Eur J Surg Oncol. doi:10.1016/j.ejso.2019.02.008

Van Calsteren, K., Verbesselt, R., Beijnen, J., Devlieger, R., De Catte, L., Chai, D. C., . . . Amant, F. (2010). Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol, 119(3), 594-600. doi:10.1016/j.ygyno.2010.08.019

Van Calsteren, K., Verbesselt, R., Ottevanger, N., Halaska, M., Heyns, L., Van Bree, R., . . . Amant, F. (2010). Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand, 89(10), 1338-1345. doi:10.3109/00016349.2010.512070

Van Calsteren, K., Verbesselt, R., Van Bree, R., Heyns, L., de Bruijn, E., de Hoon, J., & Amant, F. (2011). Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci, 18(1), 57-63. doi:10.1177/1933719110379650

van de Water, W., Bastiaannet, E., Hille, E. T., Meershoek-Klein Kranenbarg, E. M., Putter, H., Seynaeve, C. M., . . . van de Velde, C. J. (2012). Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist, 17(1), 55-63. doi:10.1634/theoncologist.2011-0037

van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P., Krol, A. D., Hauptmann, M., . . . van Leeuwen, F. E. (2016). Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol, 34(3), 235-243. doi:10.1200/jco.2015.63.4444

van Os, N. J., Roeleveld, N., Weemaes, C. M., Jongmans, M. C., Janssens, G. O., Taylor, A. M., . . . Willemsen, M. A. (2016). Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet, 90(2), 105-117. doi:10.1111/cge.12710

van Ramshorst, M. S., van der Voort, A., van Werkhoven, E. D., Mandjes, I. A., Kemper, I., Dezentje, V. O., . . . Sonke, G. S. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 19(12), 1630-1640. doi:10.1016/s1470-2045(18)30570-9

van Schoor, G., Moss, S. M., Otten, J. D., Donders, R., Paap, E., den Heeten, G. J., . . . Verbeek, A. L. (2011). Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer, 104(6), 910-914. doi:10.1038/bjc.2011.44

van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R., van Asperen, C. J., Rutgers, E. J., . . . Tollenaar, R. A. (2005). Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer, 93(3), 287-292. doi:10.1038/sj.bjc.6602703

van Walsum, G. A., de Ridder, J. A., Verhoef, C., Bosscha, K., van Gulik, T. M., Hesselink, E. J., . . . de Wilt, J. H. (2012). Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol, 38(10), 910-917. doi:10.1016/j.ejso.2012.04.015

van Wely, B. J., de Wilt, J. H., Francissen, C., Teerenstra, S., & Strobbe, L. J. (2015). Meta-analysis of ultrasound-guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumour burden in breast cancer. Br J Surg, 102(3), 159-168. doi:10.1002/bjs.9663

Wanders, J. O., Holland, K., Veldhuis, W. B., Mann, R. M., Pijnappel, R. M., Peeters, P. H., . . . Karssemeijer, N. (2017). Volumetric breast density affects performance of digital screening mammography. Breast Cancer Res Treat, 162(1), 95-103. doi:10.1007/s10549-016-4090-7

Vandeweyer, E., & Deraemaecker, R. (2000). Radiation therapy after immediate breast reconstruction with implants. Plast Reconstr Surg, 106(1), 56-58; discussion 59-60. 

Vandeweyer, E., Hertens, D., Nogaret, J. M., & Deraemaecker, R. (2001). Immediate breast reconstruction with saline-filled implants: no interference with the oncologic outcome? Plast Reconstr Surg, 107(6), 1409-1412. 

Wang, F., Yeung, K. L., Chan, W. C., Kwok, C. C., Leung, S. L., Wu, C., . . . Tse, L. A. (2013). A meta-analysis on dose-response relationship between night shift work and the risk of breast cancer. Ann Oncol, 24(11), 2724-2732. doi:10.1093/annonc/mdt283

Wang, Z., Wu, L. C., & Chen, J. Q. (2011). Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat, 129(3), 675-689. doi:10.1007/s10549-011-1665-1

Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., . . . Wolmark, N. (2011). Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst, 103(6), 478-488. doi:10.1093/jnci/djr027

Wapnir, I. L., Gelber, S., Anderson, S. J., Mamounas, E. P., Robidoux, A., Martin, M., . . . Aebi, S. (2017). Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. Ann Surg Oncol, 24(2), 398-406. doi:10.1245/s10434-016-5571-y

Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., . . . Holmberg, L. (2014). Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol, 32(32), 3613-3618. doi:10.1200/jco.2014.56.2595

Warner, E. (2018). Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer. Cancers (Basel), 10(12). doi:10.3390/cancers10120477

Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., . . . Narod, S. A. (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol, 29(13), 1664-1669. doi:10.1200/jco.2009.27.0835

Warner, E., Messersmith, H., Causer, P., Eisen, A., Shumak, R., & Plewes, D. (2008). Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med, 148(9), 671-679. 

Warner, E., Plewes, D. B., Hill, K. A., Causer, P. A., Zubovits, J. T., Jong, R. A., . . . Narod, S. A. (2004). Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. Jama, 292(11), 1317-1325. doi:10.1001/jama.292.11.1317

Vasen, H., Ibrahim, I., Ponce, C. G., Slater, E. P., Matthai, E., Carrato, A., . . . Bartsch, D. K. (2016). Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. J Clin Oncol, 34(17), 2010-2019. doi:10.1200/jco.2015.64.0730

Vashi, R., Hooley, R., Butler, R., Geisel, J., & Philpotts, L. (2013). Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy-associated breast cancer. AJR Am J Roentgenol, 200(2), 321-328. doi:10.2214/ajr.12.9814

10.2214/ajr.12.9853

Wei, E. K., Wolin, K. Y., & Colditz, G. A. (2010). Time course of risk factors in cancer etiology and progression. J Clin Oncol, 28(26), 4052-4057. doi:10.1200/jco.2009.26.9324

Weir, L., Speers, C., D'Yachkova, Y., & Olivotto, I. A. (2002). Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol, 20(7), 1793-1799. 

Weischer, M., Bojesen, S. E., Ellervik, C., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2008). CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol, 26(4), 542-548. doi:10.1200/jco.2007.12.5922

Weischer, M., Nordestgaard, B. G., Pharoah, P., Bolla, M. K., Nevanlinna, H., Van't Veer, L. J., . . . Bojesen, S. E. (2012). CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol, 30(35), 4308-4316. doi:10.1200/jco.2012.42.7336

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., . . . Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Welsh, J. L., Hoskin, T. L., Day, C. N., Habermann, E. B., Goetz, M. P., & Boughey, J. C. (2017). Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. Ann Surg Oncol, 24(10), 2881-2888. doi:10.1245/s10434-017-5932-1

Wennstig, A. K., Garmo, H., Isacsson, U., Gagliardi, G., Rintela, N., Lagerqvist, B., . . . Nilsson, G. (2019). The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. Radiat Oncol, 14(1), 40. doi:10.1186/s13014-019-1242-z

Verkooijen, H. M., Lim, G. H., Czene, K., Bhalla, V., Chow, K. Y., Yap, K. P., . . . Hartman, M. (2010). Effect of childbirth after treatment on long-term survival from breast cancer. Br J Surg, 97(8), 1253-1259. doi:10.1002/bjs.7131

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., . . . Group, E. S. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 367(19), 1783-1791. doi:10.1056/NEJMoa1209124

Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., . . . Marubini, E. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med, 347(16), 1227-1232. doi:10.1056/NEJMoa020989

Veronesi, U., Marubini, E., Mariani, L., Valagussa, P., & Zucali, R. (1999). The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer, 35(9), 1320-1325. 

Veronesi, U., Orecchia, R., Maisonneuve, P., Viale, G., Rotmensz, N., Sangalli, C., . . . Ballardini, B. (2013). Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol, 14(13), 1269-1277. doi:10.1016/S1470-2045(13)70497-2

Veronesi, U., Paganelli, G., Viale, G., Galimberti, V., Luini, A., Zurrida, S., . . . Scarpa, D. (1999). Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst, 91(4), 368-373. 

Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., . . . Gennari, R. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med, 349(6), 546-553. doi:10.1056/NEJMoa012782

Veronesi, U., Viale, G., Paganelli, G., Zurrida, S., Luini, A., Galimberti, V., . . . Vezzoli, D. (2010). Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg, 251(4), 595-600. doi:10.1097/SLA.0b013e3181c0e92a

Whelan, T., MacKenzie, R., Julian, J., Levine, M., Shelley, W., Grimard, L., . . . Szechtman, B. (2002). Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst, 94(15), 1143-1150. 

Whelan, T. J., Goss, P. E., Ingle, J. N., Pater, J. L., Tu, D., Pritchard, K., . . . Muss, H. B. (2005). Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol, 23(28), 6931-6940. doi:10.1200/jco.2005.11.181

Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., . . . Levine, M. N. (2015). Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med, 373(4), 307-316. doi:10.1056/NEJMoa1415340

Whelan, T. J., Pignol, J. P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., . . . Freeman, C. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med, 362(6), 513-520. doi:10.1056/NEJMoa0906260

Wickberg, A., Liljegren, G., Killander, F., Lindman, H., Bjohle, J., Carlberg, M., . . . Villman, K. (2018). Omitting radiotherapy in women >/= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe. Eur J Surg Oncol, 44(7), 951-956. doi:10.1016/j.ejso.2018.04.002

Wigertz, A., Ahlgren, J., Holmqvist, M., Fornander, T., Adolfsson, J., Lindman, H., . . . Lambe, M. (2012). Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat, 133(1), 367-373. doi:10.1007/s10549-012-1961-4

Wilcken, N., Hornbuckle, J., & Ghersi, D. (2003). Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev(2), Cd002747. doi:10.1002/14651858.Cd002747

Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., . . . Hurria, A. (2014). International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol, 32(24), 2595-2603. doi:10.1200/jco.2013.54.8347

Wilking, N., Lidbrink, E., Wiklund, T., Erikstein, B., Lindman, H., Malmstrom, P., . . . Bergh, J. (2007). Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol, 18(4), 694-700. doi:10.1093/annonc/mdl488

Wilking, U., Karlsson, E., Skoog, L., Hatschek, T., Lidbrink, E., Elmberger, G., . . . Bergh, J. (2011). HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat, 125(2), 553-561. doi:10.1007/s10549-010-1029-2

Wilson, A. R., Marotti, L., Bianchi, S., Biganzoli, L., Claassen, S., Decker, T., . . . Cataliotti, L. (2013). The requirements of a specialist Breast Centre. Eur J Cancer, 49(17), 3579-3587. doi:10.1016/j.ejca.2013.07.017

Wilson, C. R., Brown, I. M., Weiller-Mithoff, E., George, W. D., & Doughty, J. C. (2004). Immediate breast reconstruction does not lead to a delay in the delivery of adjuvant chemotherapy. Eur J Surg Oncol, 30(6), 624-627. doi:10.1016/j.ejso.2004.04.006

Winther, J. F., Olsen, J. H., Wu, H., Shyr, Y., Mulvihill, J. J., Stovall, M., . . . Boice, J. D., Jr. (2012). Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol, 30(1), 27-33. doi:10.1200/jco.2011.35.0504

Wiseman, M. (2008). The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc, 67(3), 253-256. doi:10.1017/s002966510800712x

Voduc, K. D., Cheang, M. C., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28(10), 1684-1691. doi:10.1200/jco.2009.24.9284

Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., . . . Schwartzberg, L. S. (2005). First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol, 23(6), 1178-1184. doi:10.1200/jco.2005.09.102

Vogl, T. J., Farshid, P., Naguib, N. N., & Zangos, S. (2013). Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur Radiol, 23(3), 797-804. doi:10.1007/s00330-012-2662-4

Woitek, R., Prayer, D., Hojreh, A., & Helbich, T. (2016). Radiological staging in pregnant patients with cancer. ESMO Open, 1(1), e000017. doi:10.1136/esmoopen-2015-000017

Volders, J. H., Haloua, M. H., Krekel, N. M., Negenborn, V. L., Barbe, E., Sietses, C., . . . van den Tol, M. P. (2016). Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol, 42(7), 986-993. doi:10.1016/j.ejso.2016.02.252

von Minckwitz, G., Blohmer, J. U., Costa, S. D., Denkert, C., Eidtmann, H., Eiermann, W., . . . Loibl, S. (2013). Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol, 31(29), 3623-3630. doi:10.1200/JCO.2012.45.0940

von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., . . . Loibl, S. (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol, 27(12), 1999-2006. doi:10.1200/JCO.2008.19.6618

von Minckwitz, G., Huang, C. S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., . . . Geyer, C. E., Jr. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med, 380(7), 617-628. doi:10.1056/NEJMoa1814017

von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., . . . Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med, 377(2), 122-131. doi:10.1056/NEJMoa1703643

von Minckwitz, G., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., . . . Untch, M. (2010). Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol, 28(12), 2015-2023. doi:10.1200/JCO.2009.23.8303

von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., . . . Untch, M. (2014). Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol, 15(7), 747-756. doi:10.1016/s1470-2045(14)70160-3

von Minckwitz, G., Untch, M., Nuesch, E., Loibl, S., Kaufmann, M., Kummel, S., . . . Juni, P. (2011). Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat, 125(1), 145-156. doi:10.1007/s10549-010-1228-x

von Schoultz, E., & Rutqvist, L. E. (2005). Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst, 97(7), 533-535. doi:10.1093/jnci/dji071

Wong, M. H., Stockler, M. R., & Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev, 2, CD003474. doi:10.1002/14651858.CD003474.pub3

Wong, S. M., & Golshan, M. (2018). Management of In-Breast Tumor Recurrence. Ann Surg Oncol, 25(10), 2846-2851. doi:10.1245/s10434-018-6605-4

World Health Organization (WHO), mortality database. (2014). Retrieved from http://www.who.int/healthinfo/statistics/mortality_rawdata/en/index.html

Vreemann, S., Gubern-Merida, A., Schlooz-Vries, M. S., Bult, P., van Gils, C. H., Hoogerbrugge, N., . . . Mann, R. M. (2018). Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk. Radiology, 286(2), 443-451. doi:10.1148/radiol.2017170458

Vrieling, C., Collette, L., Fourquet, A., Hoogenraad, W. J., Horiot, J. H., Jager, J. J., . . . Bartelink, H. (2000). The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol, 55(3), 219-232. 

Vugts, G., Maaskant-Braat, A. J., Voogd, A. C., van Riet, Y. E., Luiten, E. J., Rutgers, E. J., . . . Nieuwenhuijzen, G. A. (2015). Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer. Breast Cancer Res Treat, 153(3), 549-556. doi:10.1007/s10549-015-3571-4

Wulaningsih, W., Garmo, H., Ahlgren, J., Holmberg, L., Folkvaljon, Y., Wigertz, A., . . . Lambe, M. (2018). Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Res Treat, 172(1), 167-177. doi:10.1007/s10549-018-4890-z

Wyckoff, J., Greenberg, H., Sanderson, R., Wallach, P., & Balducci, L. (1994). Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc, 42(2), 150-152. 

Wyld, L., Garg, D. K., Kumar, I. D., Brown, H., & Reed, M. W. (2004). Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer, 90(8), 1486-1491. doi:10.1038/sj.bjc.6601742

Xing, M., Yan, F., Yu, S., & Shen, P. (2015). Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PLoS One, 10(7), e0133569. doi:10.1371/journal.pone.0133569

Xu, L., Zhang, Z., Xiang, Q., Liu, Q., Duan, X., Liu, Y., & Cui, Y. (2019). Extended adjuvant therapy with aromatase inhibitors for early breast cancer: A meta-analysis of randomized controlled trials. Clin Breast Cancer. doi:https://doi.org/10.1016/j.clbc.2019.03.005

Xue, F., & Michels, K. B. (2007). Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol, 8(12), 1088-1100. doi:10.1016/s1470-2045(07)70377-7

Yamnik, R. L., Digilova, A., Davis, D. C., Brodt, Z. N., Murphy, C. J., & Holz, M. K. (2009). S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem, 284(10), 6361-6369. doi:10.1074/jbc.M807532200

Yancik, R., Wesley, M. N., Ries, L. A., Havlik, R. J., Edwards, B. K., & Yates, J. W. (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama, 285(7), 885-892. 

Yardley, D. A., Coleman, R., Conte, P., Cortes, J., Brufsky, A., Shtivelband, M., . . . Harbeck, N. (2018). nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol, 29(8), 1763-1770. doi:10.1093/annonc/mdy201

Yarnold, J., Ashton, A., Bliss, J., Homewood, J., Harper, C., Hanson, J., . . . Owen, R. (2005). Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol, 75(1), 9-17. doi:10.1016/j.radonc.2005.01.005

Yellen, S. B., Cella, D. F., & Leslie, W. T. (1994). Age and clinical decision making in oncology patients. J Natl Cancer Inst, 86(23), 1766-1770. 

Yeoh, E. K., Denham, J. W., Davies, S. A., & Spittle, M. F. (1986). Primary breast cancer. Complications of axillary management. Acta Radiol Oncol, 25(2), 105-108. 

Yerushalmi, R., Tyldesley, S., Woods, R., Kennecke, H. F., Speers, C., & Gelmon, K. A. (2012). Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Ann Oncol, 23(4), 876-881. doi:10.1093/annonc/mdr326

Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11(2), 174-183. doi:10.1016/s1470-2045(09)70262-1

Yeung, R., Conroy, L., Long, K., Walrath, D., Li, H., Smith, W., . . . Phan, T. (2015). Cardiac dose reduction with deep inspiration breath hold for left-sided breast cancer radiotherapy patients with and without regional nodal irradiation. Radiat Oncol, 10, 200. doi:10.1186/s13014-015-0511-8

Yoshida, A., Takahashi, O., Okumura, Y., Arima, N., Nakatsukasa, K., Tanabe, M., . . . Ishitobi, M. (2016). Prognosis after mastectomy versus repeat lumpectomy in patients with ipsilateral breast cancer recurrence: A propensity score analysis. Eur J Surg Oncol, 42(4), 474-480. doi:10.1016/j.ejso.2016.01.011

Yu, J. H., Kim, M. J., Cho, H., Liu, H. J., Han, S. J., & Ahn, T. G. (2013). Breast diseases during pregnancy and lactation. Obstet Gynecol Sci, 56(3), 143-159. doi:10.5468/ogs.2013.56.3.143

Zachariah, B., Balducci, L., Venkattaramanabalaji, G. V., Casey, L., Greenberg, H. M., & DelRegato, J. A. (1997). Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys, 39(5), 1125-1129. 

Zackrisson, S., Lang, K., Rosso, A., Johnson, K., Dustler, M., Fornvik, D., . . . Andersson, I. (2018). One-view breast tomosynthesis versus two-view mammography in the Malmo Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study. Lancet Oncol, 19(11), 1493-1503. doi:10.1016/s1470-2045(18)30521-7

Zagouri, F., Sergentanis, T. N., Chrysikos, D., Dimitrakakis, C., Tsigginou, A., Zografos, C. G., . . . Papadimitriou, C. A. (2013). Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer, 13(1), 16-23. doi:10.1016/j.clbc.2012.09.014

Zavagno, G., De Salvo, G. L., Scalco, G., Bozza, F., Barutta, L., Del Bianco, P., . . . Nitti, D. (2008). A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg, 247(2), 207-213. doi:10.1097/SLA.0b013e31812e6a73

Zavos, A., & Valachis, A. (2016). Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol, 55(6), 664-670. doi:10.3109/0284186x.2016.1155738

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., . . . Berger, M. F. (2017). Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med, 23(6), 703-713. doi:10.1038/nm.4333

Zemlickis, D., Lishner, M., Degendorfer, P., Panzarella, T., Burke, B., Sutcliffe, S. B., & Koren, G. (1992). Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol, 166(3), 781-787. 

Zetterlund, L., Celebioglu, F., Axelsson, R., de Boniface, J., & Frisell, J. (2017). Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer. Breast Cancer Res Treat, 163(1), 93-101. doi:10.1007/s10549-017-4163-2

Zetterlund, L., Stemme, S., Arnrup, H., & de Boniface, J. (2014). Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg, 101(5), 488-494. doi:10.1002/bjs.9404

Zetterlund, L. H., Frisell, J., Zouzos, A., Axelsson, R., Hatschek, T., de Boniface, J., & Celebioglu, F. (2017). Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer. Breast Cancer Res Treat, 163(1), 103-110. doi:10.1007/s10549-017-4164-1

Zhang, L., Jin, K., Wang, X., Yang, Z., Wang, J., Ma, J., . . . Guo, X. (2019). The Impact of Radiotherapy on Reoperation Rates in Patients Undergoing Mastectomy and Breast Reconstruction. Ann Surg Oncol, 26(4), 961-968. doi:10.1245/s10434-018-07135-4

Zhang, L., Liu, C., Wang, W., Xu, X., & Chen, B. (2012). Is optimal timing of sentinel lymph node biopsy before neoadjuvant chemotherapy in patients with breast cancer? A literature review. Surg Oncol, 21(4), 252-256. doi:10.1016/j.suronc.2012.06.006

Zhang, Y., Ji, Y., Li, J., Lei, L., Wu, S., Zuo, W., . . . Liu, G. (2018). Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat, 168(3), 679-686. doi:10.1007/s10549-018-4660-y

Zong, Y., Wu, J., & Shen, K. (2017). Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget, 8(10), 17360-17372. doi:10.18632/oncotarget.14477

Återstående medellivslängd efter kön och ålder. Prognosår 2013 - 2110. Retrieved from www.statistikdatabasen.scb.se/goto/sv/ssd/BefProgLivslangd2013

Nästa kapitel
29 Vårdprogramgruppen